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Heart failure (HF) is often associated with inflammation and activation of the immune system. 
Moreover, the development to HF has been shown to be accompanied by autoimmune reactions since 
cardiac autoantibodies were identified in many studies. However, the role of T cells in load-induced 
HF had not been addressed previously. We hypothesized that an aortic constriction leading to 
hypertrophy and subsequently to HF can activate autoreactive T cells, which contribute to the 
progression of the disease. To examine autoimmune responses towards a cardiomyocyte-specific 
antigen, cMy-mOVA mice were used, which express ovalbumin (OVA) selectively on cardiomyocytes. 
In these mice, HF was induced by increasing the afterload by transverse aortic constriction (TAC). It 
was previously demonstrated in our group that cMy-mOVA mice did not show an accelerated 
impairment of heart function after TAC operation, although an activation of OVA-specific cytotoxic T 
lymphocytes (CTLs) was observed at a low level. To clarify the role of autoreactive T cells, TAC-
operated cMy-mOVA mice were challenged by transfer of OVA-specific CD4+ and CD8+ T cells. The 
adoptive transfer of CD8+ and/or CD4+ did not significantly accelerate progression to HF. However, 
double-transgenic cMy-mOVA/OT-II mice, in which the majority of T cells are OVA-specific CD4+ T cells, 
showed an accelerated progression towards HF. Since these mice did not develop OVA-specific 
autoantibodies, we could demonstrate that CD4+ T cells with specificity for a cardiomyocyte-specific 
autoantigen can promote the progression from hypertrophy to HF independent of autoantibodies.  
The immunological milieu within the myocard might not only affect the progression of HF but also the 
chances of repair by new regenerative therapies, e.g. the transplantation of stem cell-derived grafts. 
To clarify the probability of engraftment and reduce the risk of complications for the recipient after 
stem cell-derived graft transplantations, the immunogenicity of pluripotent stem cells (PSCs) and their 
differentiation products has to be considered. It is known that the mismatch of major 
histocompatibility complex (MHC) molecules lead to acute rejection of grafts but additionally, minor 
histocompatibility (miHC) antigens affect engraftment of organs even between MHC-matched 
individuals. Consequently, the role of miHC antigens in PSCs and their derivates need to be clarified 
since they cannot be matched in allogeneic transplantations. For this, OVA-expressing embryonic stem 
cells (ESCs) and induced pluripotent stem cells (iPSCs) were used to monitor immune responses 
against OVA as a model of a miHC antigen after injection into otherwise syngeneic mice. It was 
demonstrated that the expression of OVA led to a significantly reduced rate of engraftment of PSCs. 




can be sufficient to induce rejection of transplanted PSC-derived grafts suggesting that therapies using 
grafts derived from MHC-matched allogeneic PSCs will likely require immunosuppressive or 
immunomodulatory treatment.  
Since PSCs are at risk to give rise to teratomas if residuals of pluripotent cells remain in a graft after in 
vitro differentiation, the susceptibility of PSCs to natural killer (NK) cells was analyzed. Previous 
antibody inhibition studies indicated that the killing of murine PSCs by NK cells was mainly mediated 
by the activating NK cell receptor NKG2D. To clarify the role of NKG2D for killing of murine PSCs, 
NKG2D-deficient and wildtype NK cells were analyzed concerning their potential to kill several PSC 
lines including multipotent adult germline stem cells (maGSCs), ESCs and iPSCs. Naïve NKG2D-deficient 
NK cells failed to kill PSCs. Stimulation of NK cells by interleukin-2 (IL-2) increased the killing but could 
not completely compensate the NKG2D deficiency. Hence, it was demonstrated that NKG2D is an 
important activating receptor involved in killing of murine PSCs. 
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1.1 Heart failure – a disease of considerable clinical and socioeconomic relevance 
Besides cancer, heart failure (HF) is one of the most important health problems worldwide with rising 
incidence in western societies due to aging of the population. The pandemic of HF reflects the 
achievement in preventing premature death caused by other diseases but affects 1-2 % of the adult 
population in developed countries. In patients older than 70 years, HF is the major cause of disability 
and hospitalization with an increasing prevalence up to 10 % in the population (Mosterd and Hoes, 
2007). Current estimates assume that the number of deaths caused by HF will grow from todays  
17.3 million to 23.6 million per year by 2030 (Mozaffarian et al., 2014). While cancer is considered as 
a gain of function disease, HF is a degenerative type of disease since cells become progressively 
dysfunctional and consequently tissue function is declined (Campisi, 2005). In general, HF is not a 
single diagnosis, but is rather a syndrome of multiple etiologies, which the American Heart Association 
defined as ‘a complex clinical syndrome that results from any structural or functional impairment of 
ventricular filling or ejection of blood’ (Yancy et al., 2013). Hereby, HF can be caused by a wide number 
of conditions, including ischemic heart disease (IHD, also coronary artery disease CAD; including e.g. 
myocardial infarction (MI)), arterial hypertension, valvular heart disease, primary cardiomyopathy, 
diabetes mellitus or infections and inflammation (myocarditis) (Korczyk et al., 2012). These processes 
lead to deregulation and impairment of interstitial and cellular elements in the heart including 
fibroblasts, extracellular matrix and myocytes, resulting in chronic, maladaptive ventricular 
remodeling. Here, the pathological remodeling includes an increased myocardial volume and mass 
due to ventricular dilation and a net loss of myocytes (Borghi et al., 2015). Initially, these changes are 
able to compensate for the damages of the myocardium but are later responsible for further 
progression into HF. A hallmark of HF is impaired contractility and one measure of this is a reduced 




1.1.1 Therapy and molecular mechanisms of heart failure in humans 
Over the last decades, noninvasive and invasive techniques like echocardiography and cardiac 
catheterization were developed as most important diagnostic tools for patients with cardiovascular 
disease. However, despite large scientific efforts, the morbidity and mortality of HF remains high, since 
the molecular mechanisms leading to HF are still not clarified. Nevertheless, the identification of 
underlying targets is important for improving the efficacy of therapeutic strategies. The pathogenesis 
of chronic HF is often accompanied by inflammatory reactions. A cardiac stress response activates the 
innate immune system, which leads to expression of proinflammatory cytokines, including tumor 
necrosis factor alpha (TNFα), Interleukin (IL)-1 and IL-6, as well as to the activation of Toll-like 
receptors (TLR), that detect pathogen-associated molecular patterns (PAMPs) and damage-associated 
molecular patterns (DAMPs). All features have been observed in patients with HF (Mann, 2003; 
Topkara et al., 2011). During the last years, studies of several laboratories demonstrated that the 
activation of the immune system plays an important role in the progression of cardiac remodeling in 
HF. It was observed that in wound-healing after cardiac injury such as MI, the inflammatory response 
was crucial for the removal of the necrotic debris from the area of injury and helped to attract the 
cells involved in the formation of a scar (Blankesteijn and Altara, 2014). Besides this crucial 
contribution to initial tissue repair, a longstanding and strong inflammation can impair the heart 
function (Heymans et al., 2009). Hereby, inflammation has been described to be involved in the early 
development of cardiac hypertrophy as well as in later progression to HF (Ismahil et al., 2014; Koller 
et al., 2013; Purcell et al., 2001; Thaik et al., 1995; Yndestad et al., 2006). 
 
1.1.2 Evidence of autoimmunity 
The presence of autoimmune reactions accompanying the development to HF were monitored in 
several studies. In patients with myocarditis or dilated cardiomyopathy (DCM), several cardiac 
autoantibodies were identified, e.g. against α- and ß-isoforms of cardiac myosin heavy chain (MyHC) 
or cardiac receptors such as β1-adrenoreceptor (Magnusson et al., 1994). These anti-receptor 
antibodies were shown to either stimulate or block the receptor, thus affecting the cardiomyocyte 
contractility (Limas and Limas, 1991). Furthermore, it was shown that MI can lead to autoimmune 
reactions and the production of cardiac-specific antibodies of the immunoglobulin (Ig)G isotype 
(Bendjelid and Pugin, 2004). The presence of class-switched antibodies of the IgG isotype 




subgroups of T helper cells were discussed to contribute to cardiac fibrosis due to cytokine secretion, 
including Th17-polarized T cells (IL-13, IL-17) and regulatory T cells (Tregs) (TGF-β) (Wei, 2011).  
These observations highlight the importance of inflammation as a general molecular pathway of HF, 
offering potentially new options for therapy. Consequently, it is important to analyze the pathogenesis 
of the disease and to understand how inflammation or even autoimmunity could influence the success 
of new therapeutic options for HF, e.g. transplantations of stem cell-derived grafts into the heart.  
The mechanisms underlying autoimmunity and specifically cardiac autoimmunity have not been fully 
clarified. Autoimmunity displays a failure of effective tolerance towards self-antigens by the adaptive 
immune system, leading to inflammation and degeneration of tissues or whole organs by an 
immunopathological process (Abou-Raya and Abou-Raya, 2006). Hereby, genetic as well as 
environmental factors contribute to the induction of the disease (von Herrath et al., 2003). As genetic 
factors, human leukocyte antigen (HLA) genotype, polymorphisms of cytokines and their receptors, or 
defective apoptosis genes can influence the responses to commonly encountered antigens (Actor, 
2014). Additionally, variant antigen dose, infections, or exogenous influences causing tissue damage 
can lead to an altered immune response towards self-antigens (Ascherio and Munger, 2007; Fujinami, 
2001; Libbey and Fujinami, 2010). Mechanisms for the loss of tolerance against self-antigens include 
failure of autoreactive T cell deletion during development in the thymus, impairment of suppressor 
functions of Tregs, cross-reactivity between exogenous and self-antigens (molecular mimicry), 
increased B cell function based on polyclonal activation, e.g. by viral or bacterial components, 
enhanced or abnormal expression of MHC class II molecules, or release of self-antigens from so-called 
immunoprivileged sites. Consequently, various exogenous factors and/or genetic predispositions can 
lead to autoimmune reactions, which subsequently seem to play a role in secondary tissue damage, 







Figure 1 Potential mechanisms of autoimmunity induction after a primary myocardial damage, leading to the 
recognition of autoantigens by the immune system.  
Subsequent autoimmune reactions could additionally harm the heart tissue and thus accelerating the 
progression to HF. At this, several factors or predispositions might play a role in the generation of autoimmunity 




1.1.3 Cardiac immunity 
1.1.3.1 MHC and tolerance 
Besides various types of immune cells, which are responsible for the secretion of proinflammatory 
cytokines in autoimmunity, the primary cell types that are affected are B and T cells, recognizing self-
antigens. Recognition of antigens by T cells is enabled by the MHC molecules. This extremely 
polymorphic gene complex encoding these molecules is the HLA in humans and H2 complex in mice. 
MHC molecules can be divided into two main types, MHC class I and MHC class II molecules, which 
differ in their function and expression pattern. All nucleated cells are able to express MHC class I 
molecules on their cell surface, allowing the identification of infected cells in the organism since, e.g. 
viral peptides are presented via the MHC class I molecules on infected cells to T cell receptors (TCR) 
on cytotoxic CD8+ T cells. If the T cell was activated before, this directly leads to killing of the target 
cells. In contrast, MHC class II molecules are solely expressed on professional antigen presenting cells 
(APCs) such as dendritic cells (DCs), macrophages, B cells and endothelial cells. The function of MHC 
class II molecules is to present peptides to the TCR of CD4+ helper T cells, which are central mediators 




and humoral defense. Hereby, the engagement of the TCR by a peptide-MHC complex is necessary for 
T cell activation to direct an effective adaptive immune response against invading pathogens. It is 
critical to ensure that the reactivity of the immune response to self-antigens is avoided. For this, 
central tolerance is induced already in immature lymphocytes during development of naïve T cells in 
the thymus where the rearrangement of α and β TCR genes occurs and TCRs with random specificity 
are generated. T cells undergo two selection processes. In the first selection process, the positive 
selection, only T cells with a newly rearranged αβ TCR that recognize MHC class I or class II molecules 
e.g. expressed on thymic epithelial cells, further mature into CD8+ and CD4+ single positive cells 
respectively. In the negative selection process, T cells with high affinity to self-peptides presented by 
MHC class I or class II molecules are eliminated by apoptosis. Those T lymphocytes that survive, 
complete their maturation process and are released as naïve T cells into the circulation where further 
peripheral mechanisms of tolerance are able to suppress autoreactive T cells by induction of anergy 
(Figure 2). T cell reactivity generally requires two signals, an antigen-specific signal of the TCR 
recognizing peptide-loaded MHC molecules presented by APCs and a costimulatory signal from 
costimulatory molecules on the cell surface of professional APCs. CD28 is the best characterized 
costimulatory molecule on T cells, which interacts with CD80 and CD86 molecules on the cell surface 
of professional APCs. The absence of those costimulatory signals on the presenting cell leads to anergy 
of the T cell, meaning the T cell becomes functionally inactivated and is subsequently not capable of 
initiating proliferation or effector functions even if the antigen is encountered in the presence of full 
costimulation. Another mechanism of this peripheral tolerance induction can be caused by Tregs. Due 
to interactions including cytokine release, these cells can actively anergize lymphocytes in the 
periphery, which escaped the negative selection process in the thymus. Additionally, local secretion 
of immunosuppressive factors and presence of immunologically privileged sites (e.g. brain and eyes) 
can be seen as tolerance mechanisms due to the exclusion of antigen excess by a physical barrier. 
However disruption of the latter due to tissue damage can lead to release of hidden (cryptic) antigens, 





Figure 2 Tolerance induction of T lymphocytes in the thymus and periphery.  
Central tolerance comprises negative selection in the thymus, leading to apoptosis of autoreactive T cells. 
Peripheral tolerance includes induction of anergy due to absence of costimulatory signals, active suppression by 
Tregs via cytokine secretion or the interception of antigens in immunoprivileged sites. Antigen (Ag), L (ligand). 
Picture by Actor, 2014).  
 
B lymphocytes undergo central tolerance during their development in the bone marrow where the 
immature B cells undergo apoptosis upon interaction of IgM with multivalent self-molecules like MHC 
molecules expressed on stromal cells (clonal deletion). However, alternatively B cell can be rescued 
by receptor editing through further B cell receptor (BCR) gene rearrangements, replacing self-reactive 
B cell receptors. B cell anergy is induced by exposure to soluble circulating antigens, which lead to a 
downregulation of surface IgM expression and partial blockade of the intracellular signaling cascade. 
Generally, only B lymphocytes without self-reactivity migrate to the periphery albeit leakage of weakly 
self-reactive (sleeper) B cells can occur. These cells normally do not cause problems because they 




under certain conditions such as inflammation. In the periphery, response of B cells to antigens 
depends on its isotype type and signaling of coreceptors such as CD19 and CD21. T cell-dependent 
activation of B cells requires a TCR-MHC-II peptide binding complex and interaction of costimulatory 
signals like CD40L on T cells and the B cell surface receptor CD40 leading to B cell proliferation, 
immunoglobulin class switching and somatic hypermutation. Additional cytokines released by T cells 
bind to cytokine receptors of B lymphocytes and promote these processes.  
 
1.1.3.2 HF in animal models 
1.1.3.2.1 Animal models 
Animal models remain an invaluable implement to study cardiovascular diseases. Besides the 
advantage of reasonable similarities in biochemical pathways, pharmacological targets and organ 
function, mice are easy to keep, breed and relatively cheap in maintenance. The broad range of 
available invasive and non-invasive techniques including magnetic resonance imaging (MRI), 
hemodynamic measurements, electro- and echocardiography allow the evaluation of heart function, 
infarct size and specification of cardiac remodeling. Additionally, genetic engineering enables further 
examination of various cardiovascular diseases by mimicking its pathogenesis or addressing 
fundamental mechanism in transgenic or knockout strains. Consequently, mouse models could reveal 
future therapeutic strategies or molecular targets to treat HF. 
 
1.1.3.2.2 Murine overload models to induce HF 
Conventional methods to induce HF in mice include surgery to increase the load of the murine heart. 
These can be divided in volume or pressure overload models of HF that increase either the preload or 
the afterload, respectively. In contrast to an increased blood volume (preload), that can be caused by 
renal failure or valve insufficiency, an increased afterload displays a higher vascular resistance that 
can be obtained by hypertonus, vascular or valvular stenosis. The most common model of pressure 
overload is the transverse aortic constriction (TAC), which was first described by Rockman et al. (1991). 
Hereby, HF is induced by a partly constriction of the aorta, leading to an increased pressure gradient 
in the heart that can be quantified across the stricture by echocardiography. Subsequently, the heart 
becomes hypertrophic within 2 weeks, showing an increase of left ventricular (LV) mass of about  






In accordance with findings in human pathology, several animals studies in rats and mice revealed an 
influence of inflammation on the development of cardiac hypertrophy (Ismahil et al., 2014; Purcell et 
al., 2001; Thaik et al., 1995). The investigation of murine cardiac remodeling in a preload (aortocaval 
shunt) and afterload (TAC) model in C57BL/6 mice revealed an increase of leukocyte infiltration, 
fibrosis, and apoptosis in response to TAC (Toischer et al., 2010). Additionally, expression profiling 
data suggested an increased activity of T cells, B cells and natural killer (NK) cells in the afterload model 
in contrast to the preload model (aorto-caval shunt). Consequently, our research group focused on 
the examination of immune reactions after TAC operations in C57BL/6 mice. It was monitored that 
the proportion of myeloid cells and lymphocytes in the myocardium was increased after TAC as 
determined by immunohistochemistry (IHC) and flow cytometry (Sasse et al., unpublished data) 
Furthermore, it was shown that NK cells, T helper and cytotoxic T cells were systemically activated, 
leading to a severe inflammation in single animals (Sasse et al., unpublished data). By others, it was 
shown that humoral autoimmune reactions occurred in HF models, e.g. antibodies against troponin I, 
a cardiac-specific antigen, were found in mice (Kaya et al., 2008). Additionally, cardiomyocyte-specific 
autoantibodies were identified in a rat model of aortic constriction (Liu et al., 2002) and in mouse and 
rabbit models (Kaya et al., 2012). These findings indicate a link of autoantibodies to HF and suggest 
that also activated CD4+ T cells with specificity for cardiac antigens might play a role in ventricular 
remodeling and the progression from cardiac hypertrophy to HF. Nevertheless, these autoreactive  
T cells had not been directly identified in these animal models, yet. Analysis of immunodeficient mice 
showed that these are not protected from the progression to HF after TAC surgery (Sasse et al., 
unpublished data). It was recently shown that OT-II mice, which only bear TCR-transgenic T cells 
Figure 3 Exemplary pictures of (A) sham- and 
(B) TAC-operated hearts of C57BL/6 mice 16 
weeks after the operation.  
TAC operation led to cardiac remodeling and 
hypertrophy of the heart. Scale bars indicate 1 





specific for ovalbumin (OVA), which is not present in the murine organism under normal conditions, 
failed to develop HF and adverse remodeling after TAC (Laroumanie et al., 2014). This is a further hint 
that antigen-specific immune responses in the heart could be a critical for the progression to HF. We 
further analyzed this process in our research group. CMy-mOVA mice that express OVA selectively in 
cardiomyocytes are a suitable model to study the influence of antigen-specific immune reactions and 
autoimmunity on the outcome of HF. These mice express OVA under the control of the mouse cardiac 
alpha myosin heavy chain (MyHC) promoter on the cell surface of cardiomyocytes (Figure 4). They 
were first described by Grabie et al. (2003a), who showed that the endogenous adaptive immune 




To test if these mice develop autoimmunity against OVA in HF, they underwent TAC surgery. After 
this, neither OVA-specific IgG autoantibodies arose nor was the proliferation or cytokine expression 
pattern of CD4+ T cells altered compared to sham-operated mice (Röhrborn et al., unpublished data). 
In contrast, a low but significant activation of OVA-specific CD8+ T cells was found 10 weeks after TAC, 
but this did not significantly impair heart function. However, single animals displayed a higher activity 
of OVA-specific CTLs. These findings suggested that clinically relevant autoimmunity against OVA as 
cardiac antigen is not frequent after TAC in young and otherwise healthy mice. However, cytotoxic  
T cells were activated at low level and consequently, in this thesis, the role of T cells in animals, which 
are at higher risk to develop autoimmunity was further investigated. Therefore, we challenged the 
cMy-mOVA mice with adoptive transfer of OVA-specific CD4+ and CD8+ T cells and aimed to generate 
double-transgenic cMy-mOVA/OT-I and cMy-mOVA/OT-II mice, which were expected to have 
predominantly OVA-specific CD4+ or CD8+ T cells. The influence of these OVA-specific T cells on the 
progression to HF and on the immunological milieu in the myocardium of cMy-mOVA mice was 
Figure 4 CMy-mOVA transgene construct.  
OVA 258–265 and OVA 323–339 epitopes 
are recognized by OT-I and OT-II TCR-
transgenic T cells, respectively. BGHpA, 
bovine growth hormone, polyadenylation 
signal; TM, transmembrane domain; frag, 





examined. The heart function was assessed by echocardiography and immunological test were 
performed to determine immune responses against OVA and the infiltration of immune cells into the 
myocardium and pathologic features like fibrosis were evaluated. 
 
1.1.3.3 Importance for stem cell therapy 
The immunological characterization of the failing myocard is highly important for the development of 
new therapeutic strategies such as the transplantation of cardiomyocytes derived from pluripotent 
stem cells (PSCs). These transplantations are an upcoming therapeutic concept for HF. Although being 
a promising therapeutic approach, its success in pre-clinical models is currently limited due to loss of 
implanted cells and poor integration (Laflamme and Murry, 2011). Most of the integrated cells either 
spontaneously die or are eliminated by the immune system of the recipient. These problems are 
presumably aggravated by a proinflammatory milieu in the target tissue. Thus, the immunological 
situation in the target tissue of a stem cell-derived transplant has to be considered in the development 
of new transplantation therapies. Moreover, although induced pluripotent stem cell (iPSC) technology 
principally could allow the generation of autologous grafts, most researchers and physicians in the 
field of regenerative medicine currently assume that only allogeneic transplantations will be feasible 




1.2 Stem cell therapy 
The possibility of using PSCs to replace damaged cells or tissue is very appealing and has been 
suggested for various diseases including chronic HF. The replacement of diseased organs by donor 
organs requires lifelong immunosuppressive treatment. Moreover, more organs are required than are 
available. Nonetheless, the frequency of age-related diseases is rising due to the increasing age of 
populations in western countries. Thus, the development of alternative treatments including 
transplantation of stem cells or stem cell-derived grafts is required. However, these regenerative 
therapies will also likely encounter immunological hurdles. The use of allogeneic cells could lead to 
rapid immune rejection if the MHC molecules of donor and recipient are mismatched. If MHC 
molecules are matched, minor histocompatibility (miHC) antigens could still lead to graft rejection by 
the immune system of the recipient. Another hurdle is the ability of PSCs to indefinitely proliferate 
and to give rise to teratomas if residuals of pluripotent cells remain in a graft after in vitro 
differentiation. Here, the immune system could reduce tumor risk, if specifically pluripotent cells could 
be targeted.  
 
1.2.1 Stem cell types and their role for transplantation therapy 
Embryonic stem cells (ESCs) were the first isolated and cultured PSCs, obtained from mouse embryos 
in 1981 by Evans and Kaufman, and  Martin, and later from human embryos by Thomson et al. (1998). 
ESCs are cells derived from the inner cell mass (ICM) of the early blastocyst. They have the capacity of 
self-renewal and to differentiate into any cell type of the three germ layers (Bradley et al., 1984). 
However, because of ethical concerns about their generation and the limitation to be used for the 
generation of allogenic grafts only, efforts to generate pluripotent cells that overcome these 
limitations were pushed. The strategies for the development of autologous pluripotent stem cells 
included somatic cell nuclear transfer (SCNT) and the generation of iPSCs. However, the generations 
of PSCs by SCNT, in which a patient-specific nucleus is transferred into an enucleated oocyte, involves 
again usage of ethical debated biological materials (Rao and Condic, 2008). Therefore, the method of 
reprogramming patient-specific somatic cells into PSCs by transduction of specific transcription factors 
was rapidly further investigated and developed since their first description by Takahashi and 
Yamanaka (2006). Subsequently, iPSCs have been generated from rat (Buehr et al., 2008), rabbit 
(Honda et al., 2010), pig (Esteban et al., 2009), dog (Koh et al., 2010), monkey (Liu et al., 2008) and 




transcription factors Oct4, Klf4, Sox2 and c-Myc. Human iPSCs were generated by introducing these 
factors (Takahashi et al., 2007) or OCT4, SOX2, NANOG, and LIN28 (Yu et al., 2007) into somatic cells. 
IPSCs were generated from several cell types including keratinocytes, hepatocytes, hematopoietic 
cells, pancreatic cells and also from patients, including those with Parkinson’s disease (PD), down 
syndrome (DS) and Huntington disease (HD) (Park et al., 2008; Takahashi and Yamanaka, 2006). The 
therapeutic potential of iPSCs was shown in several animals studies, in which murine iPSCs were 
successful differentiated into neural, cardiovascular, hematopoietic or hepatic progenitor cells (Cantz 
et al., 2008; Kuzmenkin et al., 2009; Narazaki et al., 2008; Schenke-Layland et al., 2008; Wernig et al., 
2008). Especially the differentiation of PSCs into functional cardiomyocytes promoted therapeutic 
studies treating the diseased myocardium (Caspi et al., 2007; Laflamme et al., 2007; Qian et al., 2012; 
Shiba et al., 2012; Singla et al., 2006; Song et al., 2012; Xue et al., 2005). Due to these innovations, 
stem cells are seen not only as regenerative source for patient-specific cell therapies but could also 
replace animal experiments in toxicity tests and drug development. Nonetheless, despite the 
promising results, PSC technology has to overcome various obstacles. 
 
1.2.1.1 Limitations 
The usage of viral vectors such as lentivirus and retrovirus was reported to cause tumors and genomic 
instabilities due to the integration of the transcription factors into the genome (Takahashi and 
Yamanaka, 2006). Therefore, various non-integration techniques including the use of plasmids, small 
molecules, mRNA, miRNA, recombinant proteins or adenovirus vectors were examined to improve the 
reprogramming method (Anokye-Danso et al., 2011; Fusaki et al., 2009; Okita et al., 2008; Rohani et 
al., 2016; Soldner et al., 2009; Yakubov et al., 2010; Yusa et al., 2009). Additionally, analysis of 
differentiation, gene expression and epigenetic modulation revealed an frequently insufficient 
reprogramming of iPSCs (Ghosh et al., 2010; Hu et al., 2010; Marchetto et al., 2009; Pick et al., 2009), 
which has to be considered for future therapeutic applications. These differences in the PSC profile 
could sustain after in vitro differentiation and might lead to unexpected immune responses in the 
recipient, eventually destroying the graft and harming the recipient. Moreover, the general 




1.2.2 Stem cell immunogenicity 
1.2.2.1 Expression of histocompatibility antigens 
Histocompatibility antigens can be divided into MHC molecules, miHC antigens and ABO blood group 
antigens (Roopenian et al., 2002, Watkins, 2001). Among these variable antigens, the highly 
polymorphic MHC molecules are the strongest indicator for inducing allograft rejections after 
transplantation, if mismatched between donor and recipient (Lechler et al., 2005). MHC molecules 
present processed antigens to circulating T cells which normally respond only to foreign antigens, due 
to tolerance induction in the thymus or periphery. MHC class I molecules, expressed on nearly all 
nucleated cells, present primarily cytosolic proteins to CD8+ T cells, whereas MHC class II molecules, 
located on the surface of professional APCs, show exogenous antigens to CD4+ T cells. The 
allorecognition pathways can be divided into the direct and indirect pathway, which are mainly 
mediated by professional APCs and T cells (Figure 5). During direct allorecognition, T cells recognize 
intact allogeneic MHC molecules on donor APCs such as DCs that migrated from the graft to lymph 
nodes of the recipient. T cell activation results in acute cytotoxic responses leading to graft rejection 
(Morelli and Thomson, 2003). In contrast, the indirect allorecognition pathway comprises the 
recognition of processed alloantigens by T cells in the context of recipient MHC class II molecules, 
causing chronic rejection by promoting the production of alloantibodies and allospecific T cells 




Figure 5 Mechanism of allorecognition. 
During direct allorecognition (left), T cells 
recognize foreign MHC molecules on 
donor APCs, whereas the indirect 
allorecognition (right) involves the 
degradation and processing of donor MHC 
molecules or other allogenes to peptides 
which are taken up by recipient APCs and 





Consequently, it is preferred to match MHC alleles prior to organ transplantation to reduce the 
immune response against allografts. However, these processes cannot only be elicited by foreign MHC 
molecules, but by any other polymorphic antigens, collectively known as miHC antigens. Generally, 
one third of newly synthesized proteins is immediately degraded by the proteasome, producing 
peptides that can potentially elicit CD4+ and CD8+ T cell alloresponses, if the proteins display 
polymorphism between individuals in a transplantation setting, even if MHC loci were matched 
between donor and recipient (Roopenian et al., 2002; Wallny and Rammensee, 1990). Those reactions 
were shown after transplantations between HLA-identical siblings in which the recipients developed 
graft versus host disease (GVHD), graft versus leukemia (GVL) or T cell-mediated graft failure (Bleakley 
and Riddell, 2004; Ferrara et al., 2009; Goulmy et al., 1976; Opelz and Collaborative Transplant Study, 
2005). Also, if patient-specific iPSC would be used for transplantation, it is still possible that miHC 
antigens are ectopically expressed due reprogramming or in vitro culture (Dhodapkar et al., 2010; 
Zhao et al., 2011). Nevertheless, to which extent these miHC antigens would affect immune responses 
after transplantations of stem cell derived grafts, has to be clarified.  
To evaluate the antigenic characteristics of PSCs, expression of MHC molecules on human and murine 
PSCs were examined during the last years. Generally, it was shown that human PSCs express only low 
levels of MHC class I molecules but no MHC class II molecules (Draper et al., 2002; Drukker et al., 2002; 
Jurisicova et al., 1996). On murine PSCs, no MHC class I or class II molecules were detected via flow 
cytometry (Dressel et al., 2008, 2009; Magliocca et al., 2006; Tian et al., 1997). Nevertheless, minor 
amounts of MHC class I molecules must to be expressed since murine ESCs were shown to become 
targets of CTLs after pulsing with appropriate peptides (Dressel et al., 2009).  Some PSCs were reported 
to upregulate MHC class I molecules after the treatment with the proinflammatory cytokine  
interferon γ (IFNγ) but MHC class II molecules were not detected (Bonde and Zavazava, 2006; Drukker 
et al., 2002). However, other murine studies showed that MHC class I molecules on PSCs were not 
affected by INFγ treatment (Abdullah et al., 2007; Monecke, 2013; Nussbaum et al., 2007; Tian et al., 
1997). With differentiation, levels of MHC class I molecules increased (Drukker et al., 2002; Nussbaum 
et al., 2007) and MHC class II expression was ascertained after DC and hematopoietic differentiation 
(Senju et al., 2007; Slukvin et al., 2006; Zhan et al., 2004).  
Concerning the ABO antigen expression, it was demonstrated that human ESCs and differentiated 
cardiomyocyte-like cells express these antigens, what has to be considered prior to clinical translation 




Expression of miHC antigens on PSCs was not directly investigated to date, albeit OCT4-specific T cells 
were found in humans, which is a key factor for pluripotency in stem cells (Dhodapkar et al., 2010). 
Nonetheless, whether the expression of miHC antigens on PSCs alter their immunogenicity has to be 
analyzed, which will be done in this thesis by using OVA as model antigen expressed in PSCs. 
 
1.2.2.2 Susceptibility to T and NK cell killing 
Besides MHC-TCR interaction, costimulatory signals are important for T cell-mediated immune 
responses. CD80 and CD86, ligands for the activation receptor CD28 on T cells were not expressed on 
human ESCs (Drukker et al., 2002; Lechler et al., 2005) but were shown after differentiation into 
hematopoietic cells or DCs (Senju et al., 2007; Slukvin et al., 2006; Zhan et al., 2004). Adhesion 
molecules such as the intercellular adhesion molecule 1 (ICAM-1) and ICAM-3, or B7 molecules (Suh 
et al., 2003) might have additional important functions for PSC immunogenicity. ICAM-1 was reported 
to be important for the killing of murine ESCs (Frenzel et al., 2009). 
However, ligands negatively regulating T cells such as Fas ligand (FasL), which recognizes the death 
receptor Fas on lymphocytes and leads to apoptosis, was shown only on rat ES-like cells but not on 
human PSCs (Drukker, 2006; Fändrich et al., 2002). Additionally, expression of Serpin-6, an inhibitor 
of cytotoxic T cells was found on murine ESCs (Abdullah et al., 2007). However, our group could not 
confirm these results due to missing surface expression of Serpin-6 on several murine PSC lines and 
small amount of detected mRNA (Dressel et al., 2010). The protective protein Cathepsin B, which 
inactivates granzyme B (GrB), was detected on various murine PSCs, but showed no functional 
correlation with resistance to CTLs (Dressel et al., 2010). Additionally, Arginase 1 (Arg1) and 
Indoleamine 2, 3-dioxygenase (IDO), enzymes that degrade necessary amino acids from the 
microenvironment, thereby inhibiting T cells activation and proliferation were reported to be 
expressed on PSCs in few studies (Plumas et al., 2005; Su et al., 2014; Yachimovich-Cohen et al., 2010). 
However, they could not be confirmed to be expressed on murine PSCs by prior studies in our group 
(Monecke, 2013). Furthermore, it was reported that murine ESCs evade an immune response by 
secretion of transforming growth factor beta (TGFβ), which generally inhibits the activation of naïve  





Our group showed that PSCs were able to actively suppress T cell activation in vitro, mediated by cell-
cell contact of PSCs and T cells, but the cellular mechanism could not be clarified (Monecke, 2013). 
However, it was shown that the rejection of murine ESCs is dependent on the immune competence 
of the recipient and the immunogenetic setting of the transplantation and includes several immune 
effector mechanisms such as T cells and the complement system (Dressel et al., 2008; Koch et al., 
2008; Pearl et al., 2011). Moreover, T cell-mediated responses against murine ESCs were 
demonstrated in several in vivo studies (Boyd and Wood, 2009; Robertson et al., 2007; Wu et al., 2008) 
and despite the low expression of MHC class I molecules, it was shown that CTLs can kill PSCs in a 
peptide-dependent manner (Dressel et al., 2009). However, murine PSCs fail to process endogenous 
antigens and require pulsing with exogenous peptides to be recognized by CTLs (Monecke, 2013). 
NK cell activation against target cells is regulated by signaling of inhibitory and activating receptors on 
the surface of the cells (Figure 6) (Koch et al., 2013; Raulet, 2006). MHC class I molecules serve as 
ligands for Ly49 receptors on murine and for killer immunoglobulin-like receptors (KIRs) on human NK 
cells (Pegram et al., 2011). The majority of these receptors are inhibitory and signal through 
immunoreceptor tyrosine-based inhibitory motif (ITIM), however also activating KIRs and Ly49 
receptors are known. Further NK cell receptors include the activating receptor NKG2D, which interacts 
with MICA, MICB and ULBPs (1-6) ligands on human cells, and with RAE1, MULT1 and H60 ligands on 
murine cells. Other activating receptors are DNAM-1 to which CD122 and CD155 ligands can bind and 
the natural cytotoxicity receptors (NCRs), including NKp30, NKp44 and NKp46, for which a number of 
various ligands were described (Koch et al., 2013). Generally, NK cell receptors like MICA and MICB 
are not expressed by normal cells but become upregulated due to cellular or genotoxic stress in 








Despite several studies in which it was claimed that ESCs are resistant to NK cells (Drukker, 2006; 
Nussbaum et al., 2007; Swijnenburg et al., 2005), it was shown that various PSC lines, including murine 
ESCs, iPSCs and maGSCs can become targets of NK cells due to high expression of ligands for activating 
NK cell receptors, such as NKG2D and DNAM-1, and low expression of ligands for inhibitory NK 
receptors, such as MHC class I molecules (Dressel et al., 2008, 2010; Frenzel et al., 2009; Suárez-
Alvarez et al., 2010). This includes expression of low amounts of ligands of the activating NK receptor 
NKp46 and the NKG2D ligands MICA and MICB detected on human ESCs and iPSCs (Chen et al., 2015; 
Suárez-Alvarez et al., 2010). Murine and human PSCs were shown to be highly susceptible to killing by 
IL-2-activated allogeneic and autologous NK cells (Dressel et al., 2008, 2010; Elsner et al., 2010; Kruse, 
Hamann et al., 2015). At this, killing of human PSCs was partly dependent on the activating NK receptor 
DNAM-1, whereas in the murine situation NKG2D seemed to play a major role.  
In summary, the recent results showed that PSCs are more immunogenic than initially proposed (Koch 
et al., 2008; Li et al., 2004b; Magliocca et al., 2006). Nevertheless, extensive investigations about the 
impact of miHC antigen expression on the stem cell immunogenicity are still lacking. Therefore, in vivo 
analysis of the previously in vitro examined OVA-expressing stem cells (Monecke, 2013) were 
performed to determine the immunogenic potential of those miHC antigen expressing stem cells 
compared to wildtype stem cells.
Figure 6 The activation of NK cells 
depends on a balance between 
inhibitory and activating receptor 
signaling. 
The lack of MHC class I molecules can 
trigger the cytotoxic activity of NK 
cells, which is described as missing-
self concept (Kärre, 2008). 
Additionally, upregulation of 
activating receptors on diseased or 
stress cells can shift the balance 
toward NK cell activation. Picture 
modified from Vivier et al. (2012). 
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2 Aims of this thesis 
The major objectives of this thesis were to examine (1) T cell immune reactions against a 
cardiomyocyte-specific antigen during the progression to heart failure (HF) and (2) T cell immune 
reactions against an antigen of stem cells or stem cell-derived grafts that might affect transplantation 
of those grafts. Knowledge of the immunological milieu in the myocardium is important for future 
medical therapies including tissue transplantation or control of autoimmunity to counteract tissue or 
graft damage by suitable treatments.  
Occurrence of autoimmunity during heart failure 
In the first part of the thesis, the development of autoimmunity in a model of increased afterload 
leading to HF in mice at risk for autoimmune responses was examined. Important questions to answer 
were whether autoimmunity can be triggered by an increased afterload of the heart and additional 
challenge by autoreactive T cells. Differences in the progression to HF or in the immune response after 
transfer of autoreactive T cells or endogenous autoreactive T cells should be clarified.  
Influence of minor histocompatibility antigen expression on stem cell immunity 
Due to the expression of OVA as endogenously expressed antigen in stem cells, the effect of a single 
miHC antigen on engraftment and stem cell immunogenicity was analyzed. For this, teratoma 
formation in immunodeficient and immunocompetent syngeneic recipients was accessed, T and B cell 
activation against OVA monitored, and their infiltration into stem cell-derived teratomas determined. 
Clarification of importance of NKG2D for NK cell killing of pluripotent stem cells 
In addition to T cells also NK cells contribute to the rejection of PSCs. Inhibition experiments in our 
research group had identified NKG2D as the most relevant NK cell receptor for recognition of murine 
PSCs, but DNAM-1 as most important for killing of human iPSCs. Therefore, we wanted to examine 
the relevance of NKG2D for killing of murine PSCs by NK cells by comparing NKG2D-deficient and 
wildtype NK cells. 
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3 Materials and Methods  
3.1 Materials 
3.1.1 Biological material 
3.1.1.1 Cell lines 
 
Table 1 Cell lines. 








ESC BTL1 129/Sv 
mouse 
blastocyst-derived 
embryonic stem cell 
W. Engel; Human 
Genetics, UMC 
Göttingen. 
ESC MPI-II 129/Sv 
mouse 
blastocyst-derived 
embryonic stem cell 
A. Mansouri; MPI for 
Biophysical Chemistry, 
Göttingen 
ESC BTL1 OVA 
(clones #1, #4, 






ESC MPI-II OVA 






iPSC (129/Sv) 129/Sv 
mouse 
iPSCs; clone 11.1; derived 
from MEFs 
(Guan et al., 2006) 
iPSC 129/Sv OVA 







maGSC (129/Sv) 129/Sv 
mouse 
multipotent adult 
germline stem cell 
(Guan et al., 2006) 
maGSC (C57BL/6) C57BL/6 
mouse 
multipotent adult 
germline stem cell 










 RMA eGFP  C57BL/6 
mouse 
T cell lymphoma cell line; 
hEF1α/CAG-P-eGFP-NeoR 
(Monecke, 2013) 
RMA eGFP-OVA C57BL/6 
mouse 






Lymphoma cell line  
 
OVA-expressing stem cell lines were previously constructed by electrophoretic transfection of an 
expression construct for OVA-eGFP under the control of the ubiquitously active hEF1α or CAG 
promoter and selection for Neomycin resistance (Monecke, 2013). 
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3.1.1.2 Laboratory animals 
All animal experiments had been approved by the local government and were in accordance with 
institutional guidelines for the welfare of animals. Laboratory animals were bred in the central animal 
facility of the University Medical Center (UMC) Göttingen, where they were kept under specific 
pathogen-free conditions in individually-ventilated cages (IVC) in a 12 hrs light-dark cycle. Female (f) 
and male (m) mice between 8 and 20 weeks of age were used for experiments.  
 
Table 2 Laboratory animals 
Strain  Organism  Description  Reference  
129/Sv mouse MHC haplotype: H2b  
BUF rat MHC haplotype: RT1b  
cMy-mOVA  mouse mice are homozygous for the α-
MyHC-P-mOVA transgene  
(Grabie et al., 2003a)  
cMy-mOVA/OT-I mouse α-MyHC-P-mOVA; transgenic for a 
TCR recognizing SIINFEKL/H2Kb 
 




LOU/c rat MHC haplotype: RT1u  
NKG2D-/- mouse Introduced mutation in exon 2 of 
NKG2D (Klrk1) locus 
(Zafirova et al., 2009) 
OT-I mouse transgenic for a TCR recognizing 
SIINFEKL/H2Kb 
(Hogquist et al., 1994) 
OT-II mouse transgenic for a TCR recognizing 
ISQAVHAAHAEINEAGR/ H2b  
(Barnden et al., 1998) 
RAG2-/- mouse Immunodeficiency affecting B and 
T cells 
(Shinkai et al., 1992) 
RAG2-/-c-/- mouse severe combined 
immunodeficiency affecting B, T 
and NK cells 
(Mombaerts et al., 1992) 
SCID  mouse severe combined 
immunodeficiency affecting B and 
T cells 
(Pla and Mahouy, 1991) 
SCID/beige mouse severe combined 
immunodeficiency affecting B, T 
and NK cells 










Antibodies were used according to manufacturer's instructions.  
 
Table 3 Primary murine antibodies.  
Antigen  Isotype Clone Label Supplier 
CD115 rat IgG2a TX56 Alexa 488 BioLegend 
CD11b rat IgG2b M1/70 PE/Cy5 BioLegend 
CD11c hamster IgG N418 PE BioLegend 
CD144 rat IgG1 BV13 APC BioLegend 
CD19 rat IgG2b PeCa1 FITC BioLegend 
CD25 rat IgG1 PC61.5.3 FITC BioLegend 
CD3  mouse IgG2b 17A2 FITC  BioLegend 
CD3 mouse IgG2b 17A2 PE BioLegend 
CD31 rat IgG2a 390 PE BioLegend 
CD314 (NKG2D)  mouse IgG1 149810  PE  R&D Systems  
CD4 rat IgG2a RM4-5 PE/Cy5 BioLegend 
CD45 rat IgG2b 30-F11 FITC, PE, APC BioLegend  
CD45.1 mouse IgG2a A20 FITC BioLegend  
CD45.2 mouse IgG2a 104 FITC BioLegend  
CD45R rat IgG2a RA2-6B2 unconjugated BioLegend 
CD45R rat IgG2a RA2-6B2 PE BioLegend 
CD49b (DX5) rat IgM DX5 PE BioLegend  
CD69 hamster IgG H1.2F3 PE BioLegend 
CD8a  rat IgG2a  53-6.7 PE/Cy5 BioLegend 
F4/80 rat IgG2b A3-1 unconjugated BioLegend 
F4/80 rat IgG2a  BM8 PE BioLegend 
FoxP3 mouse IgG1 159D PE BioLegend  
H60 rat IgG2a 205326 unconjugated RD 
I-Ab MHC II mouse IgG2a AF6-120.1 FITC BioLegend 
IFNγ rat IgG2b JES5-16E3 PE BioLegend 
IL-10 rat IgG1 MP5-20F3 PE BioLegend 
IL-17A rat IgG1 MP6-XT22 PE BioLegend 
IL-17F rat IgG1 TC11-18H10.1 PE BioLegend 
IL-2 mouse IgG1 13/45/31-2 ohne Dianova 
IL-4 rat IgG2b JES6-5H4 PE BioLegend 
IL-6 rat IgG1 11B11 PE BioLegend 
Ki-67 rat IgG2a TEC3 unconjugated DAKO 
Ly6C rat IgG2b HK1.4 PE BioLegend 
Ly6G rat IgG2b RB6-8C5 PE BioLegend 
Mult-1 rat IgG2a 237104 unconjugated RD 
NKp46 rat IgG2a 29A1.4 unconjugated BioLegend 
NKp46 rat IgG2a 29A1.4 PE BioLegend 
Oct3/4 mouse IgG1 40-Oct3 unconjugated BioLegend  
OVA ascites mouse IgG1 OVA-14 unconjugated Sigma 
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RAE-1 (pan) rat IgG2a 186107 unconjugated RD 
TCR Vβ 5.1,5.2 mouse IgG1 MR9-4 FITC BD 
TGFß1 mouse IgG1 9D3.1C8 PE BioLegend 
TNFα rat IgG1 XMG1.2 PE BioLegend 
γδ TCR hamster IgG GL3 PE BioLegend 
 
Table 4 Secondary antibodies and ELISA antibodies 
Antigen  Isotype Clone Label Supplier 
anti-mouse APC  goat IgG Poly4053   BioLegend  
anti-mouse Cy3  donkey IgG 
F(ab')2-fragment 
  Jackson 
ImmunoResearch  
anti-mouse FITC  goat  IgG Poly4053  FITC BioLegend  
anti-mouse IgA  rat IgG1  C10-1   BD  
anti-mouse IgE  rat IgG1  R35-72   BD  
anti-mouse IgG  goat IgG1  M35006  TC BioLegend 
anti-mouse IgG1  rat IgG1  A85-1   BD  
anti-mouse IgG2a  rat IgG1  R11-89   BD  
anti-mouse IgG2b  rat IgG2a  R12-3   BD  
anti-mouse IgG3  rat IgG1  R2-38   BD  
anti-mouse IgM  rat IgG2a  II-41   BD  
 
Table 5 Isotype controls 
Isotype Label  Supplier  
hamster IgG PE BioLegend 
mouse IgG1 FITC BioLegend 
mouse IgG1  PE Immunotools  
mouse IgG2a  FITC  Pharmingen 
mouse IgG2b  PE BioLegend 
mouse IgG2b FITC BioLegend 
mouse IgM  FITC BioLegend 
rat IgG1 FITC BioLegend 
rat IgG1 PE BioLegend 
rat IgG1 APC BioLegend 
rat IgG2a FITC BioLegend 
rat IgG2a PE BioLegend 
rat IgG2a PE/Cy5 BioLegend 
rat IgG2a Alexa 488 BioLegend 
rat IgG2b FITC BioLegend 
rat IgG2b PE BioLegend 
rat IgG2b APC BioLegend 
rat IgM  FITC BioLegend 
rat IgM PE BioLegend 
rat IgM PE/Cy5 BioLegend 




Table 6 Enzymes 
Enzyme  Supplier  
DNase I  NEB  
Liberase Roche 
M-MLV Reverse Transcriptase  Promega  
Proteinase K  Merck  
RNAse A  Roche Diagnostics  
RNAsin®  Promega  
Taq DNA Polymerase  NEB  
 
3.1.2 Chemicals and Reagents 
Table 7 Chemicals and reagents 
Chemical/Reagent  Supplier 
2,2’-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid (ABTS)  AppliChem  
2-β-Mercaptoethanol  SIGMA-Aldrich®  
3,3’-diaminobenzidine (DAB)  Carl Roth  
ABsolute Blue qPCR SYBR Green low Rox Mix  Thermo Scientific  
ABTS® ELISA HRP Substrate  KPL, Sera Care  
Acetic acid  Merck  
Ammonium chloride (NH4Cl)  Merck  
Bovine Serum Albumin (BSA) 100x  Promega  
Carboxyflourescein diacetate succinimidyl ester (CFSE)  Life Technologies  
Chloroform  Merck  
Dimethyl sulfoxide (DMSO)  Merck  
Direct Red 80 Sigma 
DL-Dithiothreitol (DTT)  Promega  
dNTPs  NEB  
Eosin Y  Merck Millipore  
ESGRO® Leukemia Inhibory Facator (LIF)  Merck Millipore  
Ethanol (analytical grade)  UMG Apotheke  
Ethanol (EtOH)  UMG Apotheke  
Ethidium bromide  HyClon  
Ethylenediaminetetraacetic acid (EDTA)  Carl Roth  
FACSflow  BD Biosciences  
FACS™ Lysis solution  BD Biosciences  
Fetal calf serum (FCS)  Biochrom  
Forene (Isofluran) Abbvie 
Geltrex (Growth Factor Reduced)  Life Technologies  
GeneRuler 1 kb DNA ladder Thermo Scientific  
Geneticin (G418 Sulfate)  Biochrom  
GIBCO® Penicillin/Streptomycin  Merck  
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Heparin sodium  Rotexmedica  
Hydrochloric acid (HCl) Merck  
Hydrogen peroxide (H2O2)  Merck  
Isoamylalcohol  Merck  
Isopropanol  Merck  
Magnesium chloride (MgCl2)  Merck  
Mayer’s hemalum solution  Merck Millipore  
Methanol  Merck  
Mitomycin C  AppliChem  
MLV-RT Puffer  Promega  
M-MLV Puffer  Promega  
Non-essential amino acids  Merk Millipore  
Novaminsulfon (Metamizol) Zentiva 
Ovalbumin (OVA) Sigma 
Paraffin  Carl Roth  
PCR-Puffer 10x  NEB  
Picric acid Morphisto 
Potassium chloride (KCl)  Carl Roth  
Potassium phosphate (KH2PO4)  Merck  
Pre-stained protein marker, broad range  NEB  
Propidium iodide (PI)  AppliChem  
Random primer  Promega  
Recombinant mouse interleukin-2 (IL-2)  R & D Systems  
RNasin® Plus Ribonuclease Inhibitor  Promega  
Roswell Park Memorial Institute medium (RPMI)  Gibco  
Roti®-Histokitt  Carl Roth  
Roti®-Phenol  Carl Roth  
Scintillator Optiphase HiSafe 3  PerkinElmer  
SIINFEKL (Ovalbumin amino acid (aa) 257–264)  Bachem AG  
Sodium carbonate (Na2CO3 / NaHCO3)  Merck  
Sodium chloride (NaCl)  Carl Roth  
Sodium chromate (Na251CrO4)  Hartmann Analytic  
Sodium hydroxide (NaOH) Carl Roth 
Sodium phosphate (Na2HPO4 / NaH2PO4)  Carl Roth  
Streptavidin-horseradish peroxidase (HRP)  BioLegend  
Sucrose  Carl Roth  
TiterMax®  TiterMax  
Tris  Carl Roth  
Triton X-100  AppliChem  
TRIzol® Reagent  Invitrogen™  
Trypan blue  SIGMA-Aldrich®  
Trypsin  Biochrom  
UltraPure™ Agarose  Invitrogen  
VLE Dulbecco’s Modified Eagle’s medium (DMEM)  Gibco  
Xylol Carl Roth  
 




Table 8 Disposables 
Label  Supplier  
96 - well plates for qPCR  Applied Biosystems  
96 - well Wallac plates  PerkinElmer  
Cell culture 96- and 24-well plates  Sarstedt  
Cell culture flasks T25  Sarstedt  
Cell culture plates (5 ml, 10 ml, 25 ml)  Greiner  
Cell culture plates (6, 12, 24 well)  Greiner/Thermo Scientific  
Cell culture plates 96 well round bottom  Sarstedt  
Cell strainer  Falcon  
Conical tubes (13 ml, 15 ml, 50 ml)  Greiner/Sarstedt  
Cover slips glass  Roth  
Cover slips plastic  Sarstedt  
Cryo tubes  Greiner  
FACS tubes  BD/Sarstedt  
MACS LS columns  MACS Miltenyi Biotec  
Microscope slides  Menzel  
Multipette® plus Combitips  Eppendorf  
Needles 21 G x 1 1/2", 22 G x 1 1/4", 26 G x 1/2", 30 G x 1/2"  B. Braun Melsungen AG  
Nunc MaxiSorp microtiter plates Thermo Scientific 
Parafilm  Pechiney Plastic Packaging  
Pasteur pipettes  Wilhelm Ulbrich Mainz  
Pipette Tips (10 μl, 20 μl, 200 μl, 1000 μl)  Greiner/Sarstedt  
Reaction Tubes (0.2 ml, 1 ml, 2 ml)  Greiner/Sarstedt  
Sterile filters (pore size 0.2 μm, 0.45 μm)  Greiner  
Sterile pipettes (1 ml, 2 ml, 5 ml, 10 ml, 25 ml)  Greiner  
Superfrost Plus glass slides  Thermo  
Syringes (1 ml, 2ml, 5ml, 10 ml, 20ml)  Becton Dickinson  
Top Seal for qPCR plates  Applied Biosystems  
Top seal for Wallac plates  PerkinElmer  
U-100 Insulin syringes 0.5 ml BD Micro-Fine™ BD 











Table 9 Devices 
Description  Label  Supplier  
Agarose gel trays and 
chambers  
Perfect Blue™ Gel System  Peglab  
Aqua bidest. Supply  arium® pro  Sartorius  
Autoclave  High pressure steam sterilisator FVS  Integra Biosciences  
Biological Safety Cabinet  HERASave®  Thermo Fisher Scientific  
Centrifuge Multifuge 3 S-R Heraeus  
Centrifuge Mini Centrifuge MCF-2360  Heraeus  
Centrifuge 3K30  LMS Consult  
Centrifuge RC 3B Plus  Sigma  
Centrifuge Mini Centrifuge MCF-2360  Sorvall  
Counting chamber  Neubauer improved  Krannich  
Dispenser  Multipette® plus  Eppendorf  
Echocardiography digital 
imaging platform 
Vevo2100   VisualSonics, Toronto, 
Canada 
ELISA reader PowerWave 340 microplate 
spectrophotometer 
BioTek 
Flow Cytometer  FACS Calibur  Becton Dickinson  
Freezer HERA freeze -80°C  Heraeus  
Freezer Liebherr Comfort -20°C  Liebherr GmbH  
Freezer VIP plus -150°C  SANYO Electric Co., Japan  
Homogenizer  Tenbroeck  schuett-biotec  
Imaging devices  Chemilux Blot Detection Imager  Intas 
Imaging devices  UV workbench GelImager  Intas 
Incubator shaker  Unitron-plus  Infors  
Incubators  HERACell 150  Heraeus  
Liquid Scintillation Counters  MicroBeta2 Plate Counter  PerkinElmer  
MACS separator  VarioMACS™ Separator  MACS Miltenyi Biotec  
Magnetic stirrer/heater  RH basic 2  IKA  
Microscope Axiovert 35  Zeiss  
Microscope LSM 510 Axioplan 2  Zeiss  
Microtome Leica RM2255 Leica Biosystems 
Microwave  HF12M 900W  Siemens  
pH-Meter  inoLab® pH Level 1  WTW  
Pipettes  Research® & Reference®  Eppendorf  
Pipettor  IBS PIPETBOY acu  Integra Bioscience  
Power supply  EPS-301/-3501 XL  GE Heathcare  
Scales  ACCULAB Vicon  Sartorius  
Scales  BP 61  Sartorius  
Slide scanner dotSlide – Virtual slide system Olympus Life Science 
Spectrophotometer  NanoDrop™ ND-1000  Thermo Fisher Scientific  
Thermal Cycler  ABI 7500 Real-Time PCR System  Applied Biosystems  
Thermal Cycler  MasterCycler epgradient  Eppendorf  
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Thermal Cycler  TPersonal 48  Biometra  
Thermoblock  Thermomixer comfort  Eppendorf  
Thermoblock  Stuart Block Heater SBH130  Bibby Scientific  
Vortexer  MS1 Minishaker  IKA  
Water bath  Medingen W6  Labortechnik Medingen  
 
3.1.5 Commercial kits 
Table 10 Commercial kits 
Label Supplier 
ABsolute™ Blue QPCR SYBR® Green Low ROX Mix  Thermo Fisher  
Cytofix/CytopermTM Kit BD 
GeneJET Genomic DNA Purification Kit Thermo Scientific 
Mouse CD4+ T cell isolation kit (MACS) Miltenyi Biotec 
Mouse CD8a+ T cell isolation kit (MACS) Miltenyi Biotec 
Mouse NK cell isolation kit (MACS) Miltenyi Biotec 
 
3.1.6 Buffers and Solutions 
The composition of used buffers and solutions is specified in the corresponding method section. 
Solutions were autoclaved at 125 °C for 30 min or filtrated with a 0.2 μm sterile filter for sterilization. 
A consistently used buffer was PBS with the following composition:  
 
 
PBS 137 mM NaCl 
 2.7 mM KCL 
 10 µM Na2HPO4 
 2.0 mM KH2PO4 
 dissolved in dH2O, pH 7.4 
 
3.1.7 Oligonucleotides 
All primers were synthesized by biomers.net GmbH. The qPCR primers were designed using IDT's 
PrimerQuest that incorporates Primer3 software developed by the Whitehead Institute for Biomedical 
Research. The specificity of the primers was verified with the nucleotide BLAST web tool from NCBI. 
The primers were designed to target all transcript variants if several isoforms exist and to span exon-
exon junctions if feasible. 
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Table 11 Synthetic oligonucleotides used for qPCR. Mus musculus. Dissociation temperature [°C], P.E.: Primer 
efficiencies, *(Monecke, 2013)  










Gapdh F TGTGTCCGTCGTGGATCTGA RTPrimerDB ID: 
7880 
85 2.0 * 
R TTGCTGTTGAAGTCGCAGGAG 
Hprt F GTCCTGTGGCCATCTGCCTA NM_013556.2 78 1.9 * 
R GGGACGCAGCAACTGACATT 
Ubc F AGGTCAAACAGGAAGACAGACGTA RTPrimerDB ID: 42  79 1.8 * 







 Ova F AGAGGTGGTAGGGTCAGCAGAGG NM_205152.1  82 1.9 * 
R TGGTTGCGATGTGCTTGATACAGAAG 











Nanog F GCTGATTTGGTTGGTGTCTTGCTC NM_028016.3 80 1.9  
R TGTGATGGCGAGGGAAGGGATTT 
















Cyp3a11 F ACAAGCAGGGATGGACCTGG NM_007818.3 82 2.0  
R TGTGACAGCAAGGAGAGGCG 
Hormad1 F TGTTTGTCACCTACACTCAGG NM_026489.2 80 2.0  
R GTAAGGAAGAAGAAACTATGC 
Zg16 F TGATCTTCGTGACGGACAAG NM_026918.2 81 2.0  
R CCAGATCGCCCACTAATGAA 
Ido F CCACACTGAGCACGGACGG NM_008324.1  84 2.0 * 
R TGCGGGGCAGCACCTTTCG 








α-Mhc F GCAGGAGCTGATTGAGACCA NM_010856.4 85   
R CTGTCTGGAGTTGGGTCAGG   
Th F GTCTCAGAGCAGGATACCAAGC NM_009377 89   
R CTCTCCTCGAATACCACAGCC   
Syn F CAGTTCCGGGTGGTCAAGG NM_009305 86   
R ACTCTCCGTCTTGTTGGCAC   
Ctnt F AGAGGACACCAAACCCAAGC NM_001130176.1 85   
R CCTGTGGATGTCATCAAAGTCC   
Alb F GGCGACTATCTCCAGCAAACT NM_009654.3 83   
R TCATACAAGAACGTGCCCAGG   
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3.1.8 Software and Databases 
Table 12 Software and databases 
Product Company 
cellSens dimension Olympus Life Science 
7000 System SDS Software  Applied Biosystems  
CellQuest Pro  BD Biosciences  
FlowJo  Tree Star, Inc., USA  
MFE primer-2.0 GitHub Inc.  
MicroBeta Workstation  PerkinElmer  
Microsoft Office Professional Plus 2013  Microsoft  
NCBI database  National Center for Biotechnology Information (NCBI)  
Oligo Analyzer  Integrated DNA Technologies (IDT)  
Primer Quest  Integrated DNA Technologies (IDT)  
qPCR primer database  RTprimerDB.org  
WinStat  R. Fitch Software  
Zotero Standalone for Windows Roy Rosenzweig Center for History and New Media 
 




3.2.1 Biomolecular methods 
3.2.1.1 Isolation of nucleic acids 
3.2.1.1.1 Genomic DNA preparation 
DNA was prepared from cell pellets (1 x 106 to 5 x 106 cells) using the GeneJET Genomic DNA 
Purification Kit according to manufacturer’s instructions. DNA was dissolved in dH20 and stored at  
4 °C. The quantity of DNA was determined using the Nanodrop 2000. Thereby, the ratio of 260 nm to 
280 nm values was an important criterion for sample purity (pure DNA: ratio ≥ 1.8). 
 
3.2.1.1.2 RNA preparation 
RNA was isolated from 1 x 106 to 5 x 106 cells or 100 mg tissue using TRIzol® reagent according to the 
manufacturer's protocol. To eliminate trace amounts of DNA, RNA samples were digested with  
DNAse I for 30 min at 37 °C using the following reagents: 
 
5 % 1 M Tris-HCl pH 7.5  
1 % MgCl2  
1 % DNAse I (10 U/μl) 
0.5 % RNAse Inhibitor (40 U/μl)  
50 % total RNA eluate  
add to 50 μl dH2O 
 
After a phenol chlorophorm extraction and alcohol precipitation (Ch. 3.2.1.2.2), the RNA was dissolved 
in an appropriate amount of RNase-free dH2O and stored at -80 °C. The quality of RNA was assured by 
visualization of the integrity of 18S and 28S RNA loaded on a 1 % agarose gel, while the quantity was 
determined using the Nanodrop 2000 at a wavelength of 260 nm.  
 
3.2.1.2 Purification of nucleic acids 
3.2.1.2.1 Purification of nucleic acids via alcohol precipitation 
Nucleic acids were precipitated from aqueous solution by adding 1/10 volume of 3 M sodium acetate 
(pH 4.8; 0.3 M final) and one volume isopropanol or 2.5 volumes pure ethanol, respectively. 
Alternatively, 1/3 volume of 7.5 M (2.5 M final) ammonium acetate was used instead of sodium 
acetate to avoid coprecipitation of short oligonucleotides. Samples were centrifuged (15000 rpm;  
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4 °C; 30 min) and the resulting DNA pellet was washed with 70 % ethanol before solubilization in an 
appropriate volume of dH2O. DNA was stored at -20 °C. 
 
3.2.1.2.2 Precipitation of nucleic acids via phenol-chloroform extraction 
Proteins and other contaminants were removed from nucleic acid solutions using phenol chloroform 
extraction. For this, an equal volume of phenol-chloroform-isoamylalcohol (25:24:1) was added and 
after thoroughly mixing the solution was centrifuged to gain phase separation. The DNA-containing 
aqueous phase was transferred into a new reaction tube. The procedure was repeated with 1 volume 
of chloroform to remove remaining phenol. The nucleic acids were subsequently precipitated by 
alcohol precipitation. 
 
3.2.1.3 Amplification of nucleic acids 
3.2.1.3.1 Polymerase chain reaction 
The polymerase chain reaction (PCR) is a common used in vitro technique to amplify a specific DNA 
segment. Main features are the three distinct temperature steps allowing denaturation of double-
stranded DNA, primer annealing and elongation by a DNA polymerase. For analytical purposes, Taq 




The PCR cycler program was adapted with regard to temperature and time for denaturation, annealing 
and elongation steps. The denaturation and elongation times are associated with the polymerase 
specifications and were set according to manufacturer’s instructions, whereas annealing 
temperatures were set according to the specific melting temperatures of the primers that were used.  
2.5 μl  10 x Taq PCR buffer  
0.5 μl  dNTP-Mix (10 mM)  
5 pmol  sense primer  
5 pmol  antisense primer  
100 ng  template DNA  
5 U  Taq polymerase  
add to 25 μl  dH2O  
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3.2.1.3.2 cDNA synthesis 
RNA samples need to be completely transcribed into complementary DNA (cDNA) for qPCR. Thus, 
random hexamers, which are short oligodeoxyribonucleotides of random sequence [d(N)6] that anneal 
to random complementary sites on the target RNA, and the M-MLV reverse transcriptase were used. 
A mixture of 2 μg RNA and 2 μl random hexamer primers was filled with dH2O to a final volume of  
15 μl and was incubated at 70 °C for 10 min to break up secondary structures of the RNA. The sample 
was chilled down on ice to prevent reforming of these structures and subsequently, the following 
master mix was added: 
 
5 μl  5X reverse transcriptase buffer  
2 μl  dNTP mix (10 mM)  
1 μl  DTT (0.1 M)  
1 μl  RNasin plus RNase inhibitor (40 U/μl)  
1 μl  MMLV-reverse transcriptase (200 U/μl)  
 
The reverse transcription reaction was incubated at 37 °C for 1 h for cDNA synthesis and afterwards 
stored at -20 °C. 
 
3.2.1.3.3 Quantitative real-time PCR 
Quantitative real-time PCR (qPCR) was performed to determine the relative amount of specific mRNA 
transcripts of a gene of interest using the ABI 7500 Real-Time PCR system and the ABsolute™ Blue 
QPCR SYBR® green mix. The cDNA was diluted 1:40 with dH2O prior to the reaction, which was set up 
as follows:  
 
10 μl  ABsolute™ Blue QPCR SYBR® Green Mix  
5 pmol  sense primer  
5 pmol  antisense primer  
1 μl  1:40 template cDNA  
add to 20 μl  dH2O  
 
Tested genes were analyzed in triplicates to obtain more valid results. Reactions were set up in 96 well 
plates, which were centrifuged briefly before amplification applying the following PCR program:
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PCR step Temperature Time Repeat 
Enzyme activation  50 °C  2 min   
Initial denaturation  95 °C  10 min   
Denaturation  95 °C  15 sec  }   40 cycles Annealing/ elongation 60 °C  60 sec 
Dissociation stage  60-90 °C  +1 °C per min   
 
Since SYBR green dye intercalates non-specifically into DNA, unintended products like primer dimers 
or contaminations could cause a false positive fluorescence signals. Therefore, a stepwise increase of 
temperature during the dissociation step was included to verify the specificity of the arising products 
by comparing temperature peaks of the dissociations curves to the known melting temperatures of 
the intended products. The emerging qPCR data (cycle threshold (Ct)-values) was normalized to a 
reference gene, i.e. housekepper gene, leading to the ΔCt-values. Ct-values over 35 were considered 
as unspecific due to the late amplification and were excluded from analysis. Gene expression in 
reference cell lines was set 1 to calculate relative expression of target tissues (<1: lower expression 
than reference; > 1: higher expression than reference). The relative quantity of expression was 
calculated as 2-ΔΔCt to the control (Livak and Schmittgen, 2001) or with the specific primer pair 
efficiency. The primer pair efficiencies were inferred from the following formula: Efficiency = 10-1/slope. 
Hereby, the slope was calculated from a linear regression based on the obtained Ct-values, when a 
dilution series of pooled cDNA samples were used as template for each specific primer pair.  
 
3.2.1.3.3.1 Housekeeper 
The most stable housekeeping gene for the used cell lines and tissues had to be determined. For this, 
The three different housekeeping genes Hprt, Gapdh and Ubc were compared in several teratomas to 
calculate their gene expression stability. The formulas for housekeeper calculation were described in 
(Vandesompele et al., 2002). Hprt was the most stable housekeeper gene (gene stability measure M 
= -3.1 x 10-3), followed by Gapdh (M = 0.014) and Ubc (M = 0.016). Consequently Hprt was used as 
main housekeeper gene for normalization of gene expression and only in experiments in which Gapdh 
was additionally analyzed, the geometric mean of Hprt and Gapdh was used for normalization 
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3.2.1.4 Agarose gel electrophoresis 
DNA or RNA fragments were identified and separated by using the Perfect Blue™ Gel System. The 
agarose concentration varied between 0.7 % up to 2 % (w/v) according to the size of the fragments. 
TAE buffer was used as running buffer and for agarose solutions (dissolved at 100 °C). In addition, 
ethidium bromide was added in concentrations of 0.1 % (v/v) to identify DNA fragments when exposed 
to UV light. The DNA samples were supplemented with 6 x DNA loading dye to facilitate the loading 
procedure and for visualization of the progression during the run. The DNA molecular weight standard 
GeneRuler 1 kb DNA ladder was loaded on the gel to determine the size of amplified products. An 
electric field of 90 to 120 V and 220 mA was applied for 10 to 15 min for RNA and 30 to 60 min for 
DNA according to the fragment length. The running time for RNA samples should not exceed 15 min 
to avoid RNA degradation.  
 
6 x loading dye 34 % (w/v) sucrose 
 0.02 % (w/v)  cresol red dye  
 dissolved in  dH2O 
1 x TAE buffer 40 mM Tris-acetate pH 8.0 
 1 mM EDTA 
 dissolved in dH2O 
 
 
3.2.2 Cell culture methods 
3.2.2.1 Culture of cells 
Cell lines were cultured in a 5 % CO2 humidified atmosphere at 37 °C. All cell culturing was done under 
sterile conditions in laminar flow cabinets and with sterile equipment. If not indicated otherwise, basal 
medium (DMEM + Glutamax with 10 % (v/v) FCS) was used for cell culture. The sterility of medium 
additives was assured by manufacturers or achieved by autoclaving or sterile filtration through a  
0.2 μm filter unit, if necessary. Before usage, FCS was heated to 56 °C for 30 min for inactivation of 
complement factors. Centrifugation of eukaryotic cells was performed at 1200 rpm and RT for 5 min, 
unless otherwise stated.  
 
3.2.2.1.1 Stem cell culture 
Stem cells were cultured on a monolayer of inactivated mouse embryonic fibroblasts (MEFs) or on 
Geltrex coated cell culture plates (333 µg/T25 flask), prepared after manufacturer’s instructions. The 
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cells were splitted upon 80 % confluence by washing once with PBS and subsequent incubation with 
stem cell trypsin for several minutes at 37 °C until dissociation of stem cell colonies occurred. A single 
cell suspension was prepared by diluting cells in 10 volumes of stem cell medium and gently pipetting 
up and down. About 1/10 volume of this cells suspension was transferred into a new cell culture flask 
prepared with MEFs or Geltrex for further culture. Geltrex-coated flasks had to be incubated at 37 °C 
for at least 30 min before usage, MEF coated flasks for 1 day in advance of stem cell passaging. 
Centrifugation of stem cells was always performed at 1000 rpm for 5 min. Stem cells were tested for 
fungal, bacterial and mycoplasma infection via PCR prior to experiments. 
 
Stem cell medium DMEM + Glutamax 
 + 10 % (v/v) FCS 
 + 1 % (v/v) 100 x NEAA  
 + 50 μM 2-mercaptoethanol  
 + 1000 U/ml LIF  
 
Stem cell trypsin 0.1 % (w/v) Glucose 
 0.3 % (w/v)  Tris-HCl  
 0.25 % (w/v)  Trypsin  
 0.02 % (w/v)  EDTA  
 dissolved in PBS 
 
 
3.2.2.1.1.1 Preparation of MEFs 
For generation of MEFs, an uterus of a pregnant mouse was dissected on day 13.5 and transferred 
into a cell culture dish with pre-warmed PBS. The embryos were removed and heads, extremities, tail 
and organs were discarded. Remaining parts were minced using forceps and incubated in an 
Erlenmeyer flask with sterile ballotinis and 5 ml MEF trypsin (0.25 % (w/v) Trypsin; 0.02 % (w/v) EDTA; 
dissolved in PBS) on a magnetic stirrer for 20 min at 37 °C. After washing with 10 ml medium and 
centrifugation for 5 min at 1000 rpm, the pellet was resuspended in 25 ml MEF medium and plated 
on a 15 cm cell culture dish. Following 3 days of culture, cells were frozen (-150 °C) or directly used for 
expansion and inactivation. For this, MEFs were expanded up to passage 4 in 15 cm cell culture dishes 
and upon confluence were inactivated with Mitomycin C (stock solution: 1 mg/ml PBS). After 2.5 hrs 
incubation with 10 ml inactivation medium (1 % (v/v) Mitomycin C stock solution in MEF medium), 
MEFs were washed twice with PBS and harvested by trypsinization. The cells were frozen in aliquots 
à 2 x 106 cells or directly plated for later usage on cell culture flasks treated with 0.1 % (w/v) gelatine 
for 15 min at RT. 
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3.2.2.1.2 Tumor cell culture 
Suspension tumor cells were cultured in MEF medium and maintained in the exponential growth 
phase by regular cell passaging twice a week. For this, approximately 1/10 volume of the cell 
suspension was transferred into a new cell culture dish for further cell culture. Remaining cells were 
used for analysis or were discarded. 
 
3.2.2.1.3 Effector cell culture 
3.2.2.1.3.1 MACS separation 
The magnetic-activated cell sorting (MACS) method allows the separation of various cell populations 
depending on their surface antigens by magnetic particles (magnetic MicroBeads) and a magnetic 
field. For isolation of NK cells, murine spleens were homogenized by a TenBrook homogenizer and 
isolated by MACS technology using a mouse NK cell isolation kit. TCR-transgenic T cells were isolated 
from homogenized lymph nodes using the mouse CD4+ T cell isolation kit or the CD8a+ T cell isolation 
kit, respectively. Cell isolation was accomplished by negative selection according to manufacturer’s 
instructions. The cell solutions with the biotin-antibody cocktail and MicroBeads were transferred on 
MACS LS columns placed in a strong magnetic field of a MACS separator, catching magnetically labeled 
non-target cells on the column, whereas unlabeled NK or T cells pass through and were collected. 
Purity of obtained cells was determined by flow cytometry. 
 
3.2.2.1.3.2 NK cell culture 
NK cells were isolated by MACS separation (Ch. 3.2.2.1.3.1) and cultured in stimulation medium for  
4 days in 6 well plates. The cell density ranged from 106 to 107 cells/ml. 
 
NK cell stimulation medium DMEM + Glutamax 
 + 10 % (v/v) FCS 
 + 50 μM 2-mercaptoethanol 
 + 10 ng/ml mIL-2 
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3.2.2.1.3.3 Splenocyte cell culture 
For restimulation of splenocytes, spleens were extracted from animals and homogenized using a 
Tenbrook homogenizer. Cells were centrifuged and pellets were treated with 2 ml erythrocyte lysis 
buffer for 3 min. After an additional washing step, cell pellets were resuspended in DMEM 
supplemented with stimulation reagents and plated in 96 well plates for 4 days at 37 °C.  
 
Restimulation medium for splenocytes DMEM + Glutamax 
 + 10 % (v/v) FCS 
 + 50 μM 2-mercaptoethanol 
 + 10 ng/ml mIL-2 
 + 1 μM OVA 
 + 20 % Con A supernatant 
 
To monitor the proliferation of splenocytes during the culturing, cells were previously stained with 
CFSE (Ch. 3.2.2.4). Unstained cells as well as portions of unstimulated cells were always cultured as 
reference cells, e.g. for flow cytometry. Cells were cultured in restimulation medium supplemented 
with OVA protein to final concentrations of 250 µM for stimulation of CD4+ T cell from OT-II mice and 
1 µM for CD8+ T cells from OT-I mice. 
 
Erythrocyte lysis buffer 155 mM NH4Cl  
 10 mM KHCO3  
 0.1 mM EDTA  
 dissolved in dH2O, pH 7.2  
 
 
3.2.2.2 Freezing and thawing cells 
Cells were harvested from cell culture dishes depending on their specific growth conditions. After 
centrifugation, the cell pellets were resuspended in an adequate volume of cell-specific medium to 
reach a cell density around 1 x 106 cells/ml, of which 500 µl were transferred into a cryo conservation 
tube. After addition of an equal volume of 2 x freezing medium (60 % (v/v) cell-specific culture 
medium; 20 % (v/v) DMSO; 20 % (v/v) FCS), cryo tubes were slowly frozen in a closed styrofoam box 
at -80 °C for 24 hrs. For long-term storage tubes were transferred to -150 °C. For thawing, cryo tubes 
with frozen cells were incubated briefly in a water bath at 37 °C, diluted in washing medium and 
centrifuged for 5 min. Subsequently, cells were resuspended in their specific growth medium and 
plated in an appropriate cell culture dish. 
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3.2.2.3 Counting of cells 
For cell counting, a Neubauer counting chamber and a Zeiss inverted microscope were used. After 
thorough resuspension of cells in an appropriate volume, either the suspension was directly used for 
counting or cells were mixed with 1 % acetic acid to eliminate remaining erythrocytes in the solution 
(used for splenocyte cell suspensions). Alternatively, cells could be mixed with trypan blue counting 
solution (0.4 % (w/v) trypan blue in PBS, pH 7.2), which selectively colors dead cells blue. The latter 
counting method is called trypan blue exclusion method, since living cells are excluded from staining. 
Counting was performed according to manufacturer’s instructions of the Neubauer chamber by 
loading 10 μl of any cell suspension on the loading groove (0.1 mm depth) between the chamber and 
the cover slip. 
 
3.2.2.4 CFSE staining of cells 
CFSE-stainings were performed to either monitor the proliferation capacity of in vitro restimulated 
splenocytes or to track stained cells after adoptive transfer into mice. Isolated splenocytes or TCR-
transgenic T cells were incubated with CFSE according to manufacturer’s instructions for 10 min in a 
water bath at 37 °C. Subsequently, cells were washed three times with basal medium followed by 
centrifugation at 1.200 rpm for 5 min. 
 
3.2.3 Immunological methods 
3.2.3.1 Flow cytometry 
Flow cytometry is a laser-based, biophysical technology which allows rapid cell counting and detection 
of different characteristics of a single cell suspension. Endogenous fluorescence signals such as GFP or 
fluorescent dye-coupled antibodies, as well as cell size and granularity can be detected. Flow 
cytometry was performed with a FACSCalibur flow cytometer and CellQuest data acquisition software. 
Analysis was performed using FlowJo software. For measuring, single cells were collected from 
suspension cell culture or by trypsinization for adherent cells and washed with PBS. Approximately  
1 x 106 cells per FACS tube were incubated with fluorescence-conjugated antibodies for 30 min at 4 °C 
in 100 µl PBS to stain for different cell surface molecules. If unconjugated antibodies were used, an 
additional incubation with a fluorescence-conjugated secondary antibody was performed. Antibodies 
were used in dilutions according to manufacturer’s instructions. After washing with PBS, cells were 
resuspended in an appropriate volume of PBS for measurement. Isotype controls were included for 
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each experiment and fluorescent compensation of different fluorescent dye-conjugated antibodies 
was done with single-stained cell populations and unstained cells, respectively. In some cases, 
propidium iodide (PI) was added to the sample (10 μM final) in order to assess the viability of the cells. 
 
3.2.3.1.1 Intracellular cytokine measurements 
For intracellular cytokine measurements (ICM) via flow cytometry, splenocytes were stained with  
CD3-FITC and CD4-TC antibodies followed by a washing step with PBS. The cell pellets were then mixed 
with 2 ml of BD Fix/Perm solution and incubated for 20 min at 4 °C. After two washing steps with each 
2 ml of BD Perm/Wash solution, cells were stained with PE-coupled antibodies for intracellular 
cytokines for 30 min at 4 °C. Subsequently, cells were washed once with BD Perm/Wash, followed by 
washing with PBS before analysis via the flow cytometer. 
 
3.2.3.2 51Chromium release assay 
The 51Chromium (51Cr) release assay is an in vitro method for quantification of cellular cytotoxicity, 
assessing the susceptibility of different target cells to cytotoxic immune effector cells. If killed,  
51Cr-labeled target cells release the radioactive radionuclide, which can be measured in a liquid 
scintillation counter (LSC). For labeling of the targets, single cell suspensions of 1 x 106 or 5 x 105 cells 
were incubated with 200 μl DMEM containing 100 μl FCS and 50 μCi Na251CrO4 for 1 h at 37 °C. Effector 
cells, i.e. NK cells or splenocytes, were plated in triplicates in serial dilutions on round-bottomed  
96 well microtiter plates to achieve different effector to target (E:T) ratios. Labeled target cells were 
washed three times with PBS and added in numbers of 1 x 104 or 5 x 103 cells, respectively in DMEM 
+ 10 % FCS into the plates with a final volume of 200 µl per well. Spontaneous release was determined 
by incubation of target cells in the absence of effector cells. The microtiter plates were centrifuged 
for 5 min at 600 rpm and incubated at 37 °C for 4 hrs. After incubation, the plates were centrifuged 
again and 50 µl of supernatant was transferred into Wallac plates. To break up the remaining cells and 
set all 51Cr isotopes free, 10 µl 10 % Triton-X was added, mixed thoroughly and 50 µl of this sediment 
part was transferred into separate Wallac plates. All probes were mixed with 200 μl Scintillator and 
sealed before measurement in the MicroBeta2 Plate Counter. E:T ratios were adjusted depending on 
the percentage of the effector population measured via flow cytometric analysis. The percentage of 
specific lysis was calculated by subtracting the spontaneous 51Cr release (51Cr release in absence of 
effector cells) shown in particular in the following formula:  




[%] lysis = 
         4 x cpm supernatant x 100               X 
3 x cpm sediment + 1 x cpm supernatant 
 
3.2.3.3 ELISA 
Enzyme-linked immunosorbent assay (ELISA) is an analytic biochemical assay which can be used for 
detecting and quantifying substances like peptides or antibodies. With this method, the presence of 
OVA-specific antibodies in the sera of mice that previously received stem cell injections was analyzed 
in this study. ELISAs were performed in 96-well Nunc MaxiSorpTM microtiter plates and analyzed with 
a BioTek PowerWave 340 microplate spectrophotometer. At first, 96-well plates were coated 
overnight with 1 μg OVA per well diluted in 50 μl carbonate buffer at 4 °C, followed by an incubation 
with 150 μl of 1 % (w/v) gelatine dissolved in PBS for 1 hr at 37 °C to ensure the blocking of unspecific 
binding sites. After the dilution of sera with PBS/Tween, 50 µl of these were incubated in the prepared 
96-well plates for 2 hrs at 37 °C. The plates were then washed three times with H2O and 50 μl 
peroxidase conjugated goat anti-mouse IgG (1:5000 in PBS/Tween) antibody solution per well was 
added to the plates. In order to differentiate between Ig isotypes in the sera, isotype-specific 
secondary antibodies were additionally used, which were detected with a peroxidase-conjugated goat 
anti-rat antibody. The plates were again incubated at 37 °C for 1 hr and washed 5 times with H2O 
before 100 μl substrate solution per well was added. After 5 min, the maximum absorbance at  
405 nm was detected in the ELISA reader. 
 
Carbonate buffer 85 ml Na2CO3 (0.2 M) 
 40 ml NaHCO3 (0.2 M)  
 375 ml dH2O  
   
PBS/Tween  PBS 
 0.05 % (v/v) Tween 
   
Substrate buffer 0.1 M C2H3NaO2  
 0.05 M NaH2PO4 pH 4.0  
   
Substrate solution 10 ml substrate buffer  
 500μl ABTS (40mM) 
 10μl H2O2 (30 %) 
 
 




3.2.4.1 Tissue cross-sections  
Previously fixed teratoma and heart tissue were dehydrated in a series of ethanol solutions of 
increasing concentrations until 100 % (50 %, 70 %, 80 %, 2 x 96 %, 2 x 100 % for 75 min each), since 
paraffin is immiscible with water. Then, the ethanol was replaced with xylol (2 x 75 min), which was 
exchanged by liquid paraffin wax (56 - 58 °C) and the samples were subsequently embedded into 
paraffin blocks. Thin slices of 2.5 µl (teratoma) to 5 μm (heart) from pre-chilled blocks were generated 
using a microtome and transferred to glass slides. These were dried overnight at 37 °C and stored at 
RT for subsequent analysis. 
 
3.2.4.2 Hematoxylin and eosin staining 
For histopathological examination, paraffin sections were stained with Hematoxylin and eosin (H&E) 
to get a broad overview of different cell types within the sample by differentiating between cytoplasm 
and cell nuclei. Hematoxylin (hematein) is considered as a basic dye, which stain acidic or basophilic 
structures a purplish blue (e.g. DNA, RNA), whereas eosin, as an acidic dye, stains basic or acidophilic 
structures red or pink (e.g. cytoplasmic proteins). Dried tissue sections were deparaffinized with xylol 
(2 x 7 min), rehydrated in a descending alcohol series (100 %, 96 %, 75 % and 60 % ethanol for 5 min 
each) and washed with dH2O for 5 min. The samples were then incubated in Mayer’s hemalum 
solution for 5 min, rinsed with H2O for 10 min and incubated in eosin solution (1 % Eosin, 200 µl acetic 
acid, dH2O up to 100 ml) for additional 5 min. Subsequently, samples were briefly washed with dH2O 
followed by incubation in an ascending series of alcohol (60 %, 75 %, 96 %, 100 %) and isopropanol  
(5 min). Sections were transferred to xylol (2 x 5 min) prior to embedding using Roti®-Histokitt. For 
staining of specific proteins, additional immunohistochemistry was performed. 
 
3.2.4.3 Sirius Red staining  
For collagen stainings of myocardia, tissue sections were stained for 1 hr at RT in Sirius Red solution, 
i.e. 0.1 % Direct Red 80 in saturated aqueous picric acid adjusted to pH 2.0 with sodium hydroxide. 
After tipping in 0.5 % acetic acid solution for four times, slides were incubated in ethanol (1 x 5 min), 
isopropanol (1 x 5 min) and xylol (2 x 10 min). Subsequently, slides were embedded using Roti®-
Histokitt, scanned with a dotSlide and analyzed with the cellSens dimensions software. 




For Immunohistochemistry (IHC), paraffin sections were stained with specific antibodies to detect 
proteins of interest. All antibodies were diluted according to the manufacturer’s instructions and were 
incubated in a humidified atmosphere on the slides to prevent dehydration of the tissue samples. 
First, tissue sections were processed as for H&E staining (Ch. 3.2.4.2) but after rehydration, sections 
were boiled in citrate buffer (3 x 5 min; 10 mM, pH 6.0) for antigen retrieval. After cooling down to 
RT, samples were incubated with IHC blocking solution (4 % BSA in PBS) for 1 hr at RT. The primary 
antibody was diluted in PBS with 1 % BSA and incubated overnight at 4 °C. To block endogenous 
peroxidases, tissue sections were incubated in 3 % H2O2 (30 %) in PBS at RT for 10 min and slides were 
subsequently washed with PBS (3 x 5 min) before incubation with the secondary biotin-conjugated 
antibody for 1 hr at RT. After additional washings with PBS (3 x 5 min), samples were incubated with 
HRP-streptavidin for 1 hr at RT and stained with a DAB substrate solution (0.05 % DAB, 0.015 % H2O2, 
dissolved in PBS). For a hematoxylin counterstaining, the samples were incubated in hematoxylin  
(3 min), rinsed with H2O (5 min) and dehydrated before the tissue slides were mounted with Roti®-
Histokitt for imaging. Stained slides were scanned with a dotSlide and further analyzed using the 
cellSens dimensions software. 
 
3.2.5 Animal experiments 
3.2.5.1 Animal monitoring 
Animals were monitored for the complete duration of experiments. Every second day, weight of 
operated mice was controlled. The loss of more than 20 % weight in 48 hrs or an altered outer 
appearance let to preterm ending of the experiment. Mice with inoculated stem cells were examined 
for tumor growth every third day and the mice were sacrificed when a tumor volume of 1 cm3 was 
reached or any signs of pain or discomfort were recorded. 
 
3.2.5.2 Teratoma assays 
To analyze the tumorigenicity and immunogenicity of stem cell lines, cells were inoculated in 
syngeneic immunocompetent mice. For this, stem cells were harvested, counted and washed with 
PBS. Each mouse received amounts of 1.5 x 106 to 3 x 106 cells, resuspended in 100 µl PBS via 
subcutaneously (s.c.) injections into the flank. Tumor growth was monitored for up to 90 days and 
regularly controlled by palpation.  
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3.2.5.3 Adoptive transfer of TCR-transgenic T cells 
TCR-transgenic T cells were isolated from OT-I and OT-II mice via MACS technology. After CFSE-
staining, 1.5 x 106 to 12 x 106 T cells, depending on the experimental setup, were dissolved in 
approximately 100 µl PBS. Mice were fixed in a special self-made 50 ml falcon with breathing holes 
and notch for the tail. Before intravenous (i.v.) injection, mice tails were stuck into warm water which 
lead to dilation of blood vessels and as a consequence to a better visualization of the tail veins. Cells 
were injected into a lateral vein of the mouse tail. 
 
3.2.5.4 Transverse aortic constriction and echocardiography 
TAC surgery was performed by CRC 1002 service project using a minimally invasive operation 
procedure previously described in Toischer et al. (2010). For this, 8 to 12 weeks old mice were 
anesthetized via intraperitoneal injections of medetomidin (0.5 mg/kg), midazolam (5 mg/kg), and 
fentanyl (0.05 mg/kg). Pressure overload was induced by transversal aortic constriction using a  
26 gauge needle. Hereby, the diameter of the aorta was typically reduced by approximately 50 % to 
create a 50 to 60 mmHg systolic pressure gradient between the left ventricle (LV) and aortic pressure. 
However the gradient might vary depending on hemodynamic conditions and the severity of the aortic 
ligation. In sham operations, the transversal aorta was displayed but not restricted. Anesthesia was 
reversed by s.c. injections of atipamezol (2.5 mg/kg) and flumazenil (0.5 mg/kg). Mice were kept on 
heating plates until full recovery from anesthesia. For analgesia, drinking water was supplemented 
with 1.33 mg/ml metamizole two days before surgery, which was refreshed every third day until one 
week after operation. Three days after surgery, the pressure gradient over the aortic ligature (aortic 
stenosis) was measured by transthoracic echocardiography using a Vevo2100 system with a 30 MHz 
center frequency transducer. Therefore, animals were anesthetized with 3 % isoflurane, and 
respiration, temperature and ECG-controlled anesthesia was maintained with 1.5 % isoflurane, as 
described previously (Toischer et al., 2010). At additional points of time after operations (1 week,  
4 weeks, 8 weeks), echocardiography was performed to determine the maximal left ventricular length 
(L), thicknesses of the septum, the posterior myocardial wall, the inner diameter of the left ventricle 
(LVEDD) and the area of the left ventricular cavity (area). Fractional area shortening (FAS) and ejection 
fraction (EF) were calculated via the area length method. 
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3.2.5.5 Sacrification and tissue preparation 
Animals were generally sacrificed in a CO2 atmosphere, followed by cervical dislocation. Therefore, an 
animal was placed into a suitable chamber (e.g. IVC) which was initially filled with atmospheric air, 
followed by gradually filling with CO2 for some minutes until unconsciousness and death of the animal. 
Anesthetized animals were disinfected with 70% ethanol before dissection. 
 
3.2.5.5.1 Donor animals 
For the analysis and isolation of effector cells, murine lymph nodes or/and spleens of rat and mice 
were extracted with a sterile dissection set and cooled in DMEM falcons on ice until homogenization. 
Lymph nodes, used for isolation of OT-I and OT-II TCR-transgenic T cells, were collected from lateral 
flanks, cervical neck and from the large intestine and lower abdomen. 
 
3.2.5.5.1.1 Preparation of Concanavalin A supernatant from rat spleens 
Concanavalin (Con) A supernatant is used as supplement in stimulation-media for splenocytes. To 
generate the supernatant, several rat spleens were dissected and homogenized by a Tenbrook 
homogenizer, followed by an 4 hrs incubation in specific Con A stimulation medium (DMEM, 5 % FCS, 
200 µl Con A) at 37 °C. Afterwards, splenocytes were collected, washed with DMEM and further 
cultured in DMEM supplemented with 10 % FCS for 24 hrs in a cell incubator. The stimulated 
lymphocytes secret various cytokines during this incubation time, generating a cytokine conditioned 
supernatant which is collected after centrifugation (10 min; 1100 x g), aliquoted and stored at -20 °C. 
 
3.2.5.5.1.2 TCR-transgenic T cells from OT-I or OT-II mice  
OT-I and OT-II mice are T-cell receptor (TCR)-transgenic animals, whose T cells were designed to 
recognize specific chicken ovalbumin (OVA) residues. The CD8+ T cells of OT-I mice recognize the OVA 
residues 257-264 in the context of H2Kb (H2 class I) and the CD4+ T cells of OT-II mice the OVA residues 
323-339 in the context of I-A (H2 class II). Therefore, OT-I T cells were used to study the response of 
cytotoxic T cells to antigen, whereas the OT-II mice were generated to analyze T cell help for B cell 
responses towards OVA as model antigen. To isolate TCR-transgenic T cells, lymph nodes from OT-I or 
OT-II mice were homogenized with a Ten brook homogenizer and cells were passed through a cell 
strainer. Cells were counted and an appropriate amount was used for subsequent MACS separation. 
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The isolated cells were counted and stained with CFSE and subsequently used for adoptive transfer. 
Cell quality was assured via flow cytometry. 
 
3.2.5.5.2 Preparation of teratomas 
Subcutaneous teratomas were prepared from anesthetized animals, measured, weighted and cut into 
three parts. The first piece was immediately transferred to liquid nitrogen and stored at -80 °C for 
later gene expression analyses. Another part of the tumor sample was fixed in phosphate-buffered  
4 % formalin overnight at 4 °C, followed by paraffin embedding for histological analysis. The other 
piece was stored in DMEM on ice for subsequent flow cytometric analysis. The abdomen and thoracic 
cavity were examined systematically for the presence of metastases, which, if present, were also 
treated as s.c. teratoma samples. After autopsy, tumor size was measured by calipers and its volume 
was calculated with the following formula: 
 
V= 
π × a × b × c 
2 
 
a, b, c = orthogonal diameters 
 
3.2.5.5.2.1 Teratoma digestion for flow cytometric analysis 
For flow cytometric analysis of teratomas, tumors were digested with Liberase, which is composed of 
highly purified collagenase I and collagenase II. First, tumors were cut into small pieces and transferred 
to round bottomed falcons in which small magnetic stirring bars were placed. A small volume of 
digestion medium (DMEM w/o FCS supplemented with 0.12 mg/ml Liberase) was added and the tubes 
were set into a 37 °C water bath onto a magnetic stirrer and incubated for 10 min. After the first 
incubation, the supernatant was transferred into a fresh tube with ice-cold medium with FCS and 
another volume of digestion medium was added to the remaining tumor parts. After additional  
10 min and merging of both supernatants, tubes were centrifuged at 1200 rpm for 10 min, followed 
by erythrocyte lysis for 3 min and an additional washing step with DMEM medium at 1200 rpm for  
10 min. The cell suspension was then passed through a 40 μm nylon mesh and centrifuged again for 








3.2.5.5.3 Blood and sera preparation 
After animals were sacrificed, blood was directly taken by cardiopuncture using a 1 ml syringe and 
transferred to 1.5 ml Eppendorf tubes for sera generation or in EDTA-containing plastic tubes if 
analysis using flow cytometry was required. Eppendorf tubes were initially stored at RT, followed by 
storage at 4 °C for 2-3 hrs. After centrifugation for 10 min at 1200 rpm, the upper phase was 
transferred into a new tube, the procedure was once repeated and pure sera were stored for 
subsequent analysis at -20 °C. For flow cytometry analysis, blood was directly transferred from EDTA-
containing tubes into FACS tubes and stained with antibodies. After incubation, erythrocytes were 
lysed with FACS™ lysis solution according to manufacturer’s instructions, followed by washing with 
PBS and subsequent measurement via flow cytometry. 
 
3.2.5.5.4 Preparation of TAC- and sham-operated animals 
After anesthesia and heart punctuation for blood isolation, hearts were excised, weighted and 
perfused with saline solution to eliminate residing blood in the tissue. The atria were cut off and the 
ventricles were weighted and dissected into three parts of which all were immediately transferred to 
liquid nitrogen. Samples were stored at -150 °C until usage for gene expression or histological analysis. 
Additionally, the length of tibia was measured for later calculations of the normalized heart weight 
(heart weight / tibia length). Spleens were collected in DMEM medium for later processing. 
 
3.2.6 Statistical analysis 
Statistical analysis was performed using WinStat software. For statistical evaluation of 51Cr release 
assays, mainly the two-way-ANOVA was used to analyze the lysis of different target cell lines by 
cytotoxic effector cells. Otherwise, if data were not normally distributed, the non-parametric Kruskal-
Wallis (H) test was used for comparison of multiple groups, or the Mann-Whitney U-test for 
comparison of two groups. In single cases, the chi-squared test or student’s t-test was used. Applied 
tests are indicated in figure legends. Data are depicted as mean + standard deviation (SD) or standard 






4.1 Investigation of immune response contributing to the pathogenesis of load-induced 
heart failure 
Due to the high prevalence of heart failure (HF), it is important to understand the underlying 
mechanisms to prevent or treat this disease. One new concept of treatment could be the 
transplantation of stem cell-derived grafts. For this, it is important to examine the immunological 
milieu of the diseased heart, which would presumably influence the outcome of transplantations. 
Moreover, autoimmunity can contribute to the development of HF and new results suggest that even 
purely load-induced HF might be associated with the development of autoimmune reactions. 
Therefore, we used cMy-mOVA mice, which express ovalbumin (OVA) as model antigen in 
cardiomyocytes to examine whether HF induced by increased afterload elicits OVA-specific 
autoimmunity. For this, animals underwent transverse aortic constriction (TAC) surgery to increase 
the afterload of the heart. Previous experiments in our research group had revealed that cMy-mOVA 
mice show a small but statistically significant increase of OVA-specific CTL activity after TAC operation 
as tested in 51chromium (51Cr) release assays but with considerable individual variations. The level of 
OVA-specific antibodies was not increased after TAC operation and generally the heart function was 
not altered compared to wildtype mice as determined by echocardiography (Röhrborn et al., 
unpublished data). These findings indicate that clinically relevant autoimmunity against OVA as a 
model of a cardiac autoantigen was not a frequent outcome of TAC operations in our experimental 
setting. Therefore, animals were now further challenged by adoptive transfer of OVA-specific T cells 
to increase the number of naïve autoreactive T cells and to examine the progression of HF in animals 




4.1.1 Adoptive transfer of TCR-transgenic T cells into cMy-mOVA mice 
OVA-specific TCR-transgenic T cells of OT-I (CD8+) and OT-II (CD4+) mice were isolated by MACS 
technology and stained with CFSE before being adoptively transferred intravenously (107 cells in total 
/mouse) into cMy-mOVA mice. Experiments were performed in which both OT-I and OT-II T cells were 
transferred together because autoantigen-specific CD4+ and CD8+ T cells might need to cooperate to 
accelerate HF. In addition, transfers of only OT-I T cells were performed, because we had previously 
observed a significant activation of OVA-specific CTLs in cMy-mOVA mice after TAC. Transfers of OT-II 
T cells are on the way but currently not sufficient in numbers to be presented here. Animals underwent 
TAC or sham operation (day 3 post transfer) and functional parameters of the heart were regularly 
monitored via echocardiography. Usually at day 3 after the operations, the stenosis of the aorta was 
determined by echocardiography in millimeters of mercury (mmHg). Generally, TAC-operated animals 
showed stenosis of > 50 mmHg, whereas sham-operated control animals showed values about  
2-5 mmHg (data not shown).  
To identify the transferred CFSE+ T cells, blood was taken at day 6 post transfer. Flow cytometric 
analysis showed that CFSE+ T cells constituted only a minor proportion of PBMCs in the blood (Figure 
7A). In single animals up to 1.2 % CFSE+ T cells (CD8+CFSE+) of total PBMCs were found in the blood at 
that time point. Notably, much less CD4+CFSE+ T cells were found than CD8+CFSE+ T cells. Generally, 
TAC-operated animals showed lower numbers of CFSE+ cells in the blood than sham-operated animals. 
This might indicate recruitment to lymphoid organs or the heart, or loss of the CFSE signal due to 
proliferation. Animals were monitored up to 10 weeks after surgery, depending on the health 
condition of mice. At the end point they were sacrificed and tissue samples, including blood, spleen 
and heart were collected for analysis. Blood analysis of animals, which had received a mixture of OT-I 
and OT-II T cells showed a minimal amount of CFSE+ cells in the lymphocyte population in flow 
cytometry (Figure 7B). The low numbers of CFSE+ cells at this late time point could indicate loss of 






Analysis of the spleen for CFSE-stained cells at the end of the experiments showed that up to 0.89 % 
of splenocytes in a single animal (TAC, OT-I T cell transfer, CD3+CFSE+) were positive for CFSE. In 
general, only very few CFSE+ T cells were identified (Figure 8A). TCR-transgenic T cells of OT-I and  
OT-II mice can be identified by an anti-TCR Vβ 5.1/5.2 mAb, which is specific for the Vβ chain that was 
used for the transgenic TCR of OT-I and OT-II mice. Between 2.0 % to 2.6 % of splenocytes were 
positive for TCR Vβ 5.1/5.2, indicating a normal range of T cells with usage of these Vβ chains. Thus, 
the transferred CD8+ T cells did not undergo a massive expansion at least not within the splenocyte 
population (Figure 8B). The OT-II mice were CD45.1+, whereas the OT-I and cMy-mOVA mice expressed 
the CD45.2 allotype. This enabled a tracking of the transferred OT-II cells by a stable genetic marker. 
CD45.1+ cells originating from OT-II mice constituted on average 0.06 % (sham) to 0.21 % (TAC) of the 
splenocyte population of cMy-mOVA mice after transfer of OT-I and OT-II T cells. Thus, also the 
transferred CD4+ T cells did not undergo a massive expansion at least not within the splenocyte 
population.  
 
Figure 7 Flow cytometric analysis of transferred T cells in blood samples of cMy-mOVA mice which received 
TCR-specific OT-I T cells (107 cells /mouse) or a mixture of OT-I and OT-II T cells (5 x 106 each /mouse).  
Shown is the proportion of CFSE-stained cells of total lymphocyte numbers + SEM. (A) Proportion of CFSE+       
T cells of total PBMC numbers in blood samples taken 6 days post transfer. Animal numbers of CD3, CD8  and 
CD4 measurements respectively: OT-I sham: CFSE/CD3 (n = 9), CFSE/CD8 (n = 9), CFSE/CD4 (n = 0); OT-I TAC: 
CFSE/CD3 (n = 9), CFSE/CD8 (n = 9), CFSE/CD4 (n = 0); OT-I/OT-II sham: CFSE/CD3 (n = 7), CFSE/CD8 (n = 7), 
CFSE/CD4 (n = 3); OT-I /OT-II TAC: CFSE/CD3 (n = 8), CFSE/CD8 (n = 9), CFSE/CD4 (n = 5) (B) Proportion of CFSE+ 
T cells of total PBMC numbers after OT-I/OT-II transfer in blood samples taken after experimental endings (67 
days). Animal numbers of performed CD3, CD8 and CD4 measurements respectively: sham: CFSE/CD3 (n = 9), 
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4.1.1.1 Immunohistochemical analysis of leukocyte infiltration into the myocardium 
Lymphocyte infiltration into of the myocardium was determined on paraffin-embedded cross sections 
of the heart by immunohistochemistry (IHC). Example pictures in Figure 9 show an infiltration of CD3+ 
and CD45R+ cells into the myocardium of cMy-mOVA mice, which received OVA-specific T cells by 
adoptive transfer. Additionally, the type of infiltrating T cells was determined by staining for CD4+ and 
CD8+ cells (not shown). Stained tissue slides were scanned and analyzed via cellSens dimension 
software, determining cell counts per scanned tissue section area.  
 
Figure 8 Flow cytometric analysis of transferred T cells in spleens of cMy-mOVA mice which 
received OT-I T cells (107 / mouse) or a mixture of OT-I and OT-II T cells (5 x 106 each /mouse). 
Shown is the percentage of positive cells of total splenocytes + SEM (A) Proportion of CFSE+ and 
TCR Vβ 5.1/5.2+ T cells of total splenocytes of animals which received OT-I T cells at the end of 
experiments. CFSE/CD3 and CFSE/CD8: sham (n = 7), TAC (n= 8); TCR Vβ 5.1/5.2 /CD3 and TCR Vβ 
5.1/5.2 /CD8: sham (n= 7), TAC (n= 7) (B) Proportion of CFSE+ and CD45.1+ T cells of total 
splenocytes after experimental ending of animals which received OT-I and OT-II T cells. Animal 
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Due to variations in size of myocardial sections, cell counts per mm2 myocardium were computed, 
shown in Figure 10. The most abundant lymphocytes were CD8+ (i.e. cytotoxic T cells) and CD45R+ (i.e. 
B cells) (Figure 10A). CD3+ and CD4+ cells were only found in lower numbers in the myocardium of 
cMy-mOVA mice, ranging from 3.3 x 10-3 to 0.01 cells per mm2 myocard. Generally, more lymphocytes 
were detected in TAC-operated animals than in sham-operated animals and the amount of infiltrating 
T cells in the myocardium was always increased in animals which received adoptive transfers of T cells 
when summarizing transfer experiments of OT-I and OT-I/OT-II T cells. The higher frequency of CD8+ 
than CD3+ T cells could indicate differences in the quality of the mAbs or the presence of CD8+CD3- 
cells, e.g. some NK cells or DCs. 
 
Figure 9 IHC analysis of lymphocyte 
infiltration into myocardia of cMy-
mOVA mice, which received either 
OT-I T cells or OT-I and OT-II T cells. 
Shown are histological example 
tissue slides of TAC- and sham-
operated animals stained for CD3 or 
CD45R. Arrows indicate positive 
stained cells. Scale bars in each 
picture (bottom right corner) 





Figure 10 Immunohistochemical analysis of the myocardium of control cMy-mOVA mice and cMy-mOVA 
mice which received TCR-transgenic T cells. 
Shown are the mean of n-experiments (n numbers depicted below the columns in (B)) + SEM. (A) Summary 
of IHC analysis of infiltrated lymphocytes in the myocardium of operated (TAC, sham) cMy-mOVA mice 
which received no T cells (/) and cMy-mOVA mice which received T cells (OT-I and OT-I/OT-II) (+). (B) 
Diagrams of lymphocyte numbers in the myocardium of different animal groups (control, OT-I transfer,     
OT-I/OT-II transfer) which underwent sham or TAC surgery. Significant differences between groups of TAC-
operated animals are depicted in the diagram: * < 0.05, ** < 0.01. Differences between TAC-operated cMy-
mOVA and cMy-mOVA + OT-I T cells: CD3+ (p = 9.3 x 10-3), CD4+ (p = 8.5 x 10-3), CD8+ (p = 4.4 x 10-3), CD45R+ 
(p = 0.99), between TAC-operated cMy-mOVA and cMy-mOVA + OT-I/OT-II T cells: CD3+ (p = 0.75), CD4+ (p 
= 0.29), CD8+ (p = 0.09), CD45R+ (p = 2.9 x 10-3), and between TAC-operated cMy-mOVA + OT-I T cells and 
cMy-mOVA + OT-I/OT-II T cells: CD3+ (p = 5.4 x 10-3), CD4+ (p = 0.03), CD8+ (p = 0.11), CD45R+ (p = 0.73); 
Mann-Whitney U-Test. 
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In Figure 10B, the separated analysis for animals which received only OT-I T cells and those that 
received a mixture of OT-I and OT-II T cells is shown. Notably, the myocardium of animals that received 
only OT-I T cells showed significantly more infiltrated T cells (CD3+, CD4+, CD8+) after TAC operation 
compared to cMy-mOVA animals without transfer and those which received both T cell types. Hereby, 
up to 0.04 CD3+ and CD4+ and 0.4 CD8+ cells per mm2 myocardium were detected. Average numbers 
of T cell infiltrates in hearts after OT-I/OT-II transfer were similar to control cMy-mOVA mice. B cell 
infiltration was similar in TAC-operated cMy-mOVA and those which additionally received OT-I T cells 
(on average 0.19 and 0.22 cells per mm2), whereas after the transfer of OT-I and OT-II T cells, a lower 
number of B cells was detected in the tissue (in the mean 0.07 cells per mm2). 
Additionally, leukocyte composition in the spleen and heart of cMy-mOVA mice which received 
adoptive transfer of OT-I and OT-II T cells was analyzed but revealed no major differences in overall 
leukocyte proportion in these mice after TAC operation compared to controls (Supplement, Ch. 7.1.1). 
Moreover, adhesion molecules expression on endothelial cells in the heart was not altered after TAC 
operation and consequently did not enhance leukocyte infiltration by this mechanisms (Supplement, 
Ch. 7.1.2). 
 
4.1.1.2 Activation of OVA-specific cytotoxic T lymphocytes 
The splenocytes of the mice were used as effector cells in cytotoxicity assays to determine the lysis 
rate of OVA-expressing (RMA OVA-eGFP) or control RMA (RMA eGFP) cells. For this, splenocytes were 
restimulated in vitro for 4 days with OVA protein and IL-2. In Figure 11, the specific lysis of the target 
cells by restimulated splenocytes isolated of cMy-mOVA which received either OT-I T cells or OT-I and 
OT-II T cell is shown. The lysis of OVA-expressing RMA targets ranged on average from 12.1 % (TAC) 
to 13 % (sham) at the highest effector to target (E:T) ratio by splenocytes of animals, which received 
OT-I T cells. Splenocytes of animals that received OT-I and OT-II T cells showed a mean specific lysis of 
OVA-expressing targets up to 35.6 % (TAC) and 39.4 % (sham). Splenocytes of TAC-operated cMy-
mOVA mice, which did not receive adoptive transfer showed a slightly lower lysis rate of 9 % on the 
highest E:T ratio (Röhrborn et al., unpublished data; data not shown). Killing of the OVA-expressing 
RMA cell line, in contrast to the RMA control showed that OVA-specific CTLs were present in spleens 
of TAC- and sham-operated animals 10 weeks after transfer. Here, the additional transfer of OT-I  
T cells increased the capability of CTLs to kill the OVA-expressing target line compared to cMy-mOVA 




cytotoxic response of CTLs towards OVA. However, no major differences in the target lysis rates 
occurred between splenocytes obtained from sham- and TAC-operated animals, showing that even 
without increased afterload, OVA-specific CTLs became activated and were able to lyse OVA-
expressing cells.  
 
 
4.1.1.3 Anti-OVA antibody generation  
Whether OVA-specific antibodies were generated after adoptive transfer of OT-I or a mixture of  
OT-I/OT-II TCR-transgenic T cells was analyzed by ELISAs. For this analysis, pre-sera obtained before 
operation (7 days pre operation) of cMy-mOVA mice and sera, obtained after animals were sacrificed 
(normally after 10 weeks), were used in serial dilutions to determine the OVA-specific antibody titer 
compared to serum of control animals which had been immunized with recombinant OVA protein. 
The OD value of the reference serum was set to 100 % for the lowest dilution (1:30) to calculate the 
relative anti-OVA antibody level of other sera. As seen in Figure 18, no OVA-specific antibodies arose 
after the transfer of OVA-specific T cells into cMy-mOVA mice undergoing surgery. The slightly higher 
anti-OVA titer at the end point of experiments in those animals can be caused by increased age of 











































Figure 11 Cytotoxicity assays performed with splenocytes of TAC- or sham-operated mice which received 
adoptive transfer of either (A) OT-I T cells or (B) a mixture of OT-I/OT-II T cells. 
Splenocytes were obtained 10 weeks after transfer of TCR-transgenic T cells into cMy-mOVA mice and were 
restimulated in vitro with OVA protein and IL-2 for 4 days before used as effector cells in 51Cr release assays. 
Control RMA (RMA-eGFP) and RMA OVA (RMA eGFP-OVA) served as targets in the test. Shown is the mean 
of specific lysis + SEM at different E:T ratios. OT-I T cell transfer: sham/TAC (n= 10, each); OT-I/OT-II T cell 





transfer, animals displayed a similar OVA-titer independent of the type of surgery (TAC/sham). These 
results were similar to anti-OVA titers of cMy-mOVA mice, which did not received adoptive transfers 
(Röhrborn et al., unpublished data; data not shown). Thus, the transfer of TCR-transgenic T cells had 
no influence on the anti-OVA antibody generation. 
 
 
4.1.1.4 Cardiac fibrosis 
The pathology of HF includes cardiac fibrosis. After TAC operations of cMy-mOVA mice, increased 
fibrosis was detected by histological evaluation of Sirius Red-stained tissue slides. To determine 
whether the transfer of T cells specific for a cardiac antigen increases fibrosis, myocardia of animals 
which received adoptive transfers were analyzed. In Figure 13A, histological example pictures of Sirius 
Red-stained myocardia are depicted which show that the collagen staining is more intense in tissues 
after TAC operation. The proportion of collagen-stained area to total myocardia area was calculated, 
showing that the TAC operation and the additional transfer of OT-I and OT-II T cells led to increased 
fibrosis (18.3 %) compared to TAC-operated cMy-mOVA mice, which did not received T cells (12.5 %), 
although this reached not statistical significance (Figure 13B). In contrast, the transfer of only OT-I  
T cells resulted in a comparable level of fibrosis in TAC-operated mice (12.2 %) to cMy-mOVA mice, 
 
Figure 12 Anti-OVA-antibody titer in cMy-mOVA mice which received (A) OT-I and OT-II or (B) only OT-I     
T cells before sham and TAC operation.  
Sera were taken 1 week prior to surgery (pre) and at the end point of experiments (†). Shown are relative 
anti-OVA titers + SEM compared to control sera, which were obtained from prior OVA-immunized 129/Sv 
animals. 
Sera dilution Sera dilution 
1:30 1:60 1:120 1:240
OT-I T cells
† sham (n = 9)
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undergoing the same surgery. Fibrosis in sham-operated animals ranged from 7.1 % (cMy-mOVA +  
OT-I T cells) to 9.3 % (cMy-mOVA + OT-I/OT-II T cells) and showed no major differences between the 
animal groups. The only significant changes in fibrosis were detected when TAC- and sham-operated 
animals were compared. Overall, there might be a trend towards increased fibrosis after TAC, if 







(p = 9.3 x 10-4); cMy-mOVA + OT-I/OT-II 



























Figure 13 Fibrosis in the myocardia of 
cMy-mOVA and cMy-mOVA mice which 
received adoptive transfer of either OT-I 
or OT-I and OT-II T cells.  
(A) Sirius Red staining of cMy-mOVA 
myocardia of sham- and TAC-operated 
mice to visualize fibrosis. Scale bars in 
each picture (bottom right corner) 
represent 50 µm each. (B) Proportion of 
fibrotic area per myocardium calculated 
by cellSens dimension software. CMy-
mOVA: sham (n= 22), TAC (n= 15); cMy-
mOVA + OT-I T cells: sham (n= 8), TAC (n= 
11); cMy-mOVA + OT-I/OT-II T cells: sham 
(n= 10), TAC (n= 14). Differences between 
cMy-mOVA vs. cMy-mOVA + OT-I T cells: 
sham (p = 0.61), TAC (p = 0.34); cMy-
mOVA vs. cMy-mOVA + OT-I/OT-II T cells: 
sham (p = 0.07), TAC (p = 0.21); differences 
between sham- and TAC-operated 




4.1.1.5 Hypertrophy and heart function 
After TAC operation, eliciting pressure overload-induced HF, hearts size and weight were increased in 
cMy-mOVA mice due to cardiac hypertrophy. To analyze heart weight, which can differ between 
animals due to their overall phenotype (size, weight, sex of mice), ventricular weight (vw) is generally 
normalized to the tibia length of animals (Yin et al., 1982). Effects of the transfer of T cells specific for 
OVA into cMy-mOVA mice on the phenotype of the heart are summarized in Figure 14. The heart 
weight was not significantly affected by the adoptive transfer of OVA-specific T cells, showing similar 
heart weight after TAC operations for each animal group, ranging from ratios of 10.3 (+ OT-I T cells) to 
12.1 (+ OT-I/OT-II T cells). Compared to sham-operated animals, all groups showed a significant higher 
heart weight after TAC operation.  
 
 
Major parameters to assess heart function were measured by echocardiography and include ejection 
fraction (EF), which measures the fraction of blood pumped out of the heart with each heartbeat and 
the left ventricular fractional area shortening (FAS), which estimates the cardiac contractility. 
Additionally, hypertrophy parameters including diastolic and systolic anterior wall thickness (AWThd, 
AWThs) were analyzed and evaluated. After TAC operation, hypertrophy increased in all groups 
compared to sham-operated animals, whereas the overall function of the heart decreased compared 
to animals without aortic banding. Comparison of all parameters showed that neither the cardiac 
hypertrophy (wall thickness) nor functional parameters of the heart were significantly affected by the 
additional transfer of OVA-specific T cells into cMy-mOVA mice (Figure 21). 
 
Figure 14 Heart weight of cMy-mOVA mice and 
mice which received OVA-specific T cells.  
Shown are the mean of ventricular weight (vw) 
[mg] to tibia length [mm] ratios after experimental 
ending (10 weeks post operation) + SEM. Animal 
numbers w/o transfer: sham (n= 21), TAC (n= 17); 
+ OT-I T cells: sham (n= 8), TAC (n= 11); + OT-I/OT-
II T cells: sham (n= 8), TAC (n= 14). Differences 
between sham- and TAC-operated animals:       
cMy-mOVA (p = 3.6 x 10-3), OT-I T cell transfer         
(p = 5.2 x 10-7), OT-I/OT-II T cell transfer (p = 5.6 x 
10-7). CMy-mOVA w/o transfer vs. cMy-mOVA + 
OT-I T cells: sham (p = 0.36), TAC (p = 0.49); cMy-
mOVA w/o transfer vs. cMy-mOVA + OT-I/OT-II T 






























Figure 15 Analysis of hypertrophy and heart function of cMy-mOVA mice by echocardiography.  
Mice underwent TAC or sham surgery and received TCR-transgenic OT-I or a mixture of OT-I and OT-II      
T cells. Over the time of experiments, heart functionality was monitored via echocardiography, including 
measurements/calculation of ejection fraction (EF), left ventricular area shortening (FAS), diastolic 
anterior wall thickness (AWThd) and systolic anterior wall thickness (AWThs). Animal numbers: w/o 
transfer: sham (n= 21), TAC (n= 17); + OT-I T cells: sham (n= 8), TAC (n= 11); + OT-I/OT-II T cells: sham (n= 
8), TAC (n= 14). Differences between TAC-operated cMy-mOVA and cMy-mOVA + OT-I T cells at 8 weeks 
post operation: AWThd (p = 0.86), AWThs (p = 0.25), FAS (p = 0.25), EF (p = 0.23) and between cMy-mOVA 
and cMy-mOVA + OT-I/OT-II T cells at 8 weeks post surgery: AWThd (p = 0.72), AWThs (p = 0.70), FAS (p 
= 0.63), EF (p = 0.56), student’s t-test. 










































4.1.2 Analysis of immune reactions in cMy-mOVA/OT-II 
To further increase the proportion of autoreactive T cells and to ensure their presence at all time 
points during the development of HF after TAC, cMy-mOVA mice were bred with OT-I and OT-II mice 
to create double-transgenic mice, which express OVA exclusively on cardiomyocytes and whose T cells 
were specific for this cardiac antigen. The attempt to create cMy-mOVA/OT-I mice failed because of 
early mortality between days 1 to 5 after birth due to unknown reasons. Analysis of the hearts showed 
no pronounced T cell infiltration, however impairment of heart function by only low numbers of 
autoreactive CTLs at this time point cannot be excluded.  
In contrast, cMy-mOVA/OT-II mice were successfully bred and were therefore available for further 
analysis. Mice were TAC- and sham-operated and monitored for up to 10 weeks. After experimental 
ending 10 weeks post operation, splenocytes of cMy-mOVA/OT-II mice were used for flow cytometric 
analysis to determine proportions of lymphocyte populations and the expression of activation 
markers, including CD25 and CD69 which can be found on activated T cells (Figure 16). Half of the 
splenocyte population consisted of B cells (CD45R+: 53.9 % (TAC) to 54.1 % (sham)), followed by  
T helper cells (CD3+CD4+: 20.6 % (TAC) to 23.0 % (sham)). Significantly smaller numbers of cytotoxic  
T cells (CD3+CD8+: 4.8 % (TAC) to 6.0 % (sham); p = 0.04) than in wildtype mice were found whereas 
the proportion of γδ T cells was in the normal range. Numbers of NK cells were significantly higher 
after TAC operation (DX5+CD3-: 4.3 % (sham) to 5.3 % (TAC); p = 2.1 x 10-3) compared to controls. 
Additionally, the numbers of TCR Vβ 5.1/5.2 positive CD3+ and CD8+ cells were determined, showing 
a significantly lower number of those cells after TAC operation (p = 6.2 x 10-3). Importantly, these data 
demonstrated that the majority of T cells carried the transgenic TCR. Further analysis of activation 
marker on CD3+ cells revealed that after TAC operation, significantly higher numbers of CD4+CD25+ 
cells were present in the splenocyte population (p = 7.5 x 10-3). However, examination of CD69+ cells 
showed no major differences in the activation status of T helper and cytotoxic T cells between sham- 





Furthermore, intracellular cytokine staining (ICS), that detect cytokine production by immune cells in 
combination with cell surface makers, was performed by flow cytometry to monitor whether the CD4+ 
T cells exhibit a polarization towards a certain cytokine profile. Here, the proportion of T helper cells 
expressing cytokines, including various interleukins (IL-2, IL-4, IL-6, IL-10, IL-17A, IL-17B), interferon 
gamma (IFNγ), tumor necrosis factor α (TNFα), transforming growth factor β (TGFβ) and additionally 
the amount of regulatory T cells (Tregs) was determined in splenocytes 10 weeks post operations 
(Figure 17). Tregs, which are known to be important for immune modulation and tolerance to self-
antigens, made up only 7.8 % of total CD4+ cells in TAC-operated and 10.9 % of CD4+ cells in sham-
operated animals. CD4+ T cells expressing TNFα and TGFβ were most abundant. The proportion of 
TNFα+CD4+ T cells was significantly higher in TAC-operated animals (8.34 %) than sham-operated  
(4.1 %) cMy-mOVA/OT-II mice. In contrast, a greater proportion of TGFβ+CD4+ cells was found after 
sham operation (8.9 %), however the difference to TAC-operated animals (5.4 %) was not significant. 
A significantly higher proportion of IL-17A+CD4+ T cells (4.1 %) was found in TAC-operated than sham-
operated animals. IL-2+CD4+ and IL-10+CD4+ T cells were equal for both animal groups (IL-2+: 1.7 % TAC, 
1.9 % sham; IL-10+: both 1 %), while IL-4+ and IL-6+ T helper cells were significantly more abundant 
after TAC operation (IL-4+: 0.4 %, IL-6+: 1.1 %) although at low level. Additionally, a significantly higher 
 
 
Figure 16 Analysis of surface markers on splenocytes, isolated after experimental ending of cMy-
mOVA/OT-II mice which underwent TAC or sham surgery.  
Shown is the cell proportion of (A) total splenocytes or (B) CD3+ cells + SEM. Animal numbers: sham (n = 10), 
TAC (n= 17). TAC (n = 17), sham (n = 10), mean duration of experiments: TAC (67 days), sham (69 days). 
*<0.05; ** < 0.01; student’s t-test. (A) Staining for various cell types including T helper cells (CD3+CD4+), 
cytotoxic T cells (CD3+CD8+), B cells (CD45R+), NK cells (DX5+CD3-), and for TCRs on CD3+ and CD8+ cells.              

















































































amount of IFNγ+CD4+ cells were found after TAC operation (sham: 0.1 %; TAC: 2.7 %). Generally the 
proportion of T helper cells with an inflammatory Th1 and a Th17 cytokine profile was increased at  
10 weeks post TAC operation compared to sham-operated cMy-mOVA/OT-II mice. 
 
 
4.1.2.1 Anti-OVA antibody generation 
To test whether OVA-specific antibodies arose in cMy-mOVA/OT-II mice, sera of various time points 
over the course of experiments (pre, 1 week, 4 weeks, 8 weeks) and after experimental ending (†) 
were collected and analyzed via ELISA tests. The reactivity of sera from sham- and TAC-operated mice 
against OVA were determined at several dilutions compared to control sera of mice immunized against 
OVA. As seen in Figure 18, the level of OVA-specific antibodies in cMy-mOVA/OT-II mice was not 
increased after TAC operation, showing similar levels of anti-OVA titers compared to cMy-mOVA mice 
(Röhrborn et al., unpublished data) and to cMy-mOVA mice which additionally received T cell transfer 




































Figure 17 Proportion of CD4+ T cells of cMy-mOVA/OT-II mice expressing intracellular cytokines after TAC 
and sham operations.  
Splenocytes were analyzed 10 weeks post operations via flow cytometry. Shown is the mean proportion 
for various intracellular cytokines of CD4+ T cells + SEM. Sham (n = 10), TAC (n = 17). Significant differences 
of cytokines levels between sham- and TAC-operated animals are marked with asterisks, showing an 
increased proportion of Th1- and Th17-polarized T helper cells: IL-2 (p = 0.67), IL-4 (p = 0.045), IL-6 (p = 7.6 
x 10-3), IL-10 (p = 0.84), IL-17A (p = 0.017), IL-17F (p = 0.51), TNFα (p =0.016), IFNγ (p = 1.6 x 10-3), TGFβ (p 






4.1.2.2 Infiltration of lymphocytes into heart tissue 
To analyze the infiltration of immune cells into myocardia of cMy-mOVA/OT-II mice, sections of 
paraffin embedded specimens were used for histological analysis. Representative IHC stainings in 
Figure 19A show the presence of CD3+, CD4+, CD8+ and CD45R+ cells in the myocardium of TAC-
operated cMy-mOVA/OT-II mice. Number of infiltrating cells were calculated via cellSens dimension 
software and are depicted in Figure 19B. The most abundant cells found in the myocardia of cMy-
mOVA/OT-II were CD45R+ cells (0.03 (sham) to 0.05 (TAC) cells /mm2) and CD8+ T cells (0.01 cells /mm2) 
in TAC-operated animals, but generally lower numbers of these cells were found than in myocardia of 
cMy-mOVA mice. The amount of CD3+ cells in cMy-mOVA/OT-II mice was higher after sham operation 
(0.01 cells /mm2) than in TAC-operated animals (7.1 x 10-3 cells /mm2), and overall more CD3+ cells 
were found in cMy-mOVA/OT-II mice than in cMy-mOVA mice. The amount of CD4+ cells in myocardia 
of cMy-mOVA/OT-II mice was significantly higher than in cMy-mOVA mice. In summary, cMy-
mOVA/OT-II animals show lower numbers of infiltrated CD8+ and CD45R+ cells, but higher CD4+ and 

















































Figure 18 Anti-OVA 
antibody titers in sera 
of cMy-mOVA/OT-II 
mice obtained at 
different time point 
pre and post sham and 
TAC operation. 
 Shown are relative 
anti-OVA titers 
compared to sera of 
OVA-immunized 129/Sv 
mice + SEM. Sham (n = 




















Figure 19 IHC analysis of infiltrating cells into the myocardia of cMy-mOVA/OT-II animals.  
(A) Example pictures of IHC stained tissue slides of myocardia from cMy-mOVA/OT-II mice after TAC 
operation. Positive stained cells indicate infiltrating lymphocytes and are marked with asterisk. Scale bars 
in each picture (bottom right corner) represent 20 µm each. (B) Calculated lymphocyte numbers per 
defined area in myocardia of cMy-mOVA/OT-II mice compared to control cMy-mOVA, all of which 
underwent TAC or sham surgery. Shown are the mean cell numbers per mm2 + SEM; Animal numbers are 
depicted below each column. Differences between TAC-operated cMy-mOVA and cMy-mOVA/OT-II: CD3+ 






































4.1.2.3 Cardiac fibrosis 
Analysis of fibrosis showed that after TAC operation the amount of collagen in the myocardium 
detected by Sirius Red staining on histological tissue slides was significantly increased in all animal 
groups compared to sham-operated mice (Figure 20A). In comparison to cMy-mOVA mice, proportion 
of fibrosis in cMy-mOVA/OT-II mice was slightly lower (6.5 % (sham) to 10.5 % (TAC)), but was not 









surgery. Calculations were performed via cellSens dimension software. CMy-mOVA: sham (n = 
22), TAC (n = 15); cMy-mOVA/OT-II: sham (n = 15), TAC (n = 19); cMy-mOVA vs cMy-mOVA/OT-
II: TAC (p = 0.07), sham: (p = 0.27); Mann-Whitney U-test, *** < 0.001. 
Figure 20 Fibrosis in the myocardia of 
cMy-mOVA/OT-II mice after TAC and 
sham operations.  
(A) Sirius Red stainings of cMy-
mOVA/OT-II myocardia of sham- and 
TAC-operated mice to visualize fibrosis. 
Scale bars in each picture (bottom right 
corner) represent 50 µm each. (B) 
Proportion of fibrotic area per 
myocardium of cMy-mOVA/OT-II mice 
compared to control cMy-mOVA mice all 
































4.1.2.4 Hypertrophy and heart function 
The hypertrophy of hearts of cMy-mOVA/OT-II mice after TAC operation was analyzed to detect 
potential differences to cMy-mOVA mice and those, which additionally received adoptive transfer. In 
Figure 21, heart weight of TAC- and sham-operated animals after experimental ending is shown. 
Noticeable, TAC-operated mice of all groups showed a higher heart weight ratio, ranging between 11 
to 12 compared to sham animals (6 to 7). CMy-mOVA/OT-II mice displayed a slightly higher heart 
weight (12.2) compared cMy-mOVA (11.2) or those which received adoptive transfer (11.0) but these 
changes were not significant. Consequently, a high numbers of CD4+ T cells specific for a cardiac 





Next, functional parameters of hearts of cMy-mOVA/OT-II mice after sham and TAC operation were 
analyzed to clarify whether animals with high frequency of T cells specific for a cardiac antigen are at 
higher risk for rapid progression into HF after TAC operation compared to cMy-mOVA mice. As seen 
in Figure 22, the anterior wall thickness in diastole and systole were increased after TAC operation, 
but was not differing between cMy-mOVA and cMy-mOVA/OT-II mice. In contrast, EF and FAS showed 
a significantly reduction in cMy-mOVA mice, showing that high numbers of transgenic T cells have 





Figure 21 Hypertrophy of TAC- and sham-
operated cMy-mOVA and cMy-mOVA/OT-II. 
Shown are mean ratios of ventricular weight 
(vw) [mg] to tibia length [mm] + SEM after 
experimental ending. Animal numbers:   
cMy-mOVA: sham (n = 15), TAC (n = 19);   
cMy-mOVA/OT-II: sham (n = 15), TAC (n = 
22). Heart weight was significantly affected 
by TAC operation: cMy-mOVA (p = 3.6 x 10-
3), cMy-mOVA/OT-II (p = 7.4 x 10-7). No 
significant differences were monitored 
between cMy-mOVA and cMy-mOVA/OT-II 





























The transfer of OVA-specific T cells did not significantly affect cardiac hypertrophy and did not led to 
deterioration of functional parameters determined by echocardiography. Thus, the transfer of T cells 
with a specificity for an antigen in cardiomyocytes alone was not sufficient to accelerate the 
progression to HF. In contrast, the presence of CD4+ T cells, specific for a cardiomyocyte antigen, in 
high frequency as in cMy-mOVA/OT-II mice was associated with a systemic inflammatory T cell 
response and a faster progression to HF at 10 weeks after TAC, indicating that autoreactive T helper 
cells can promote progression from hypertrophy to HF and this independent of an antibody response.
 
Figure 22 Analysis of functional parameters assessing heart function of cMy-mOVA/OT-II after TAC and 
sham operations compared to control cMy-mOVA mice.  
Shown are mean of AWThd, AWThs, FAS and EF + SEM determined by echocardiography over the course 
of experiments. CMy-mOVA: sham (n = 15), TAC (n = 19); cMy-mOVA/OT-II: sham (n = 15), TAC (n = 22). 
Differences at 8 weeks post operation between TAC-operated cMy-mOVA and cMy-mOVA/OT-II animals: 
AWThd (p = 0.14), AWThs (p = 0.79), FAS (p = 0.03), EF (p = 0.04); student’s t-test.  




































4.2 Immunogenicity of pluripotent stem cells 
Pluripotent stem cells (PSCs) are seen as important tool for future medical therapies and are therefore 
an important topic of research. Previous work in our group focused on the in vitro immunogenicity of 
murine PSC lines including ESCs, iPSCs and maGSCs. It was shown that PSCs exhibit an 
immunosuppressive phenotype in vitro, because they were able to inhibit antigen-dependent T cell 
proliferation of CD4+ and CD8+ T cells in direct co-culture experiments. They were also 
immunoprivileged because they failed to process and present antigens on MHC class I molecules. 
However, important for future transplantation therapies is the clarification of the immunogenicity of 
stem cells and stem cell-derived grafts in vivo. Specifically, the role of minor histocompatibility (miHC) 
antigens need to be clarified since they cannot be matched in allogeneic transplantations. For this, 
OVA as a model of a miHC antigen was introduced into several stem cells lines and these were 
examined in comparison to their wildtype counterparts in otherwise syngeneic recipients. One newly 
generated iPSC (129/Sv TD11.1; XY) and one new ESC line (BTL1; XY) from 129/Sv mice were used for 
these experiments and a well-established ESC line (MPI-II; XY) from the same mouse line was included 
for comparison. The PSCs were transfected to express an OVA-EGFP fusion protein. Four or five of the 
new cell lines and two clones of the MPI-II cells were selected for further experiments. All stem cells 
lines and clones that were used for in vivo analysis had been previously analyzed in vitro for their 
pluripotency in terms of OCT4, NANOG, and SSEA-4 expression, expression of the transgene and 
absence of microbial contaminations via quantitative real-time PCR (qPCR), western blot and flow 




4.2.1 Tumor formation in immunodeficient hosts 
To determine their pluripotency in vivo, the cell lines and clones were injected into immunodeficient 
mice. Stem cells were subcutaneously injected in numbers of 1.5 x 106 cells per animal into various 
immunodeficient hosts, including RAG2-/-c-/-, RAG2-/-, SCID/beige and SCID mice, mainly depending 
on availability of the mice. All of these animals are mutant mice, lacking B and T cells, however  
RAG2-/-c-/- and SCID/beige mice are additionally deficient for NK cells or are impaired in their NK cell 
function, respectively. Initially, two ES wildtype stem cell lines (ESC BTL1, ESC MPI-II), seven OVA-
expressing ES cell lines (BTL1 OVA#1, BTL1 OVA#4; BTL1 OVA#9, BTL1 OVA#14, BTL1 OVA#20, MPI-II 
OVA#1, MPI-II OVA#4), one iPSC wildtype cell line (iPSC 129/Sv TD11.1) and four OVA-expressing iPS 
cell lines (iPSC 129/Sv OVA#6, iPSC 129/Sv OVA#13, iPSC 129/Sv OVA#18, iPSC 129/Sv OVA#24) were 
used for inoculation into immunodeficient mice. In Table 13, the tumor frequency of the various stem 
cell lines is shown, which ranged from 0 to 100 %. The ESC BTL1 OVA cell clones #9 and #14 and ESC 
MPI-II OVA clone #1 were excluded from most further experiments due to the lack of tumor formation 
(0 % each, Table 13). Additionally, some cell lines, like ESC BTL1 OVA#1 and #20 show only a minor 
rate of tumor formation (< 30 %) and were also excluded or are reported separately. The failure of 
some OVA-expressing clones to form teratomas is most likely a random clonal effect and not result of 
OVA expression. Thus, one OVA-expressing cell clone for each wildtype ESC stem cell line was used for 
further analysis.  
Table 13 Tumor formation in immunodeficient hosts. Cell lines which were further analyzed are marked bold. 
Stem cell line tumor frequency [%] n 
ESC BTL1 wt 75 12 
ESC BTL1 OVA#1 22 9 
ESC BTL1 OVA#4 64 11 
ESC BTL1 OVA#9 0 3 
ESC BTL1 OVA#14 0 4 
ESC BTL1 OVA#20 29 7 
ESC MPI-II wt 90 30 
ESC MPI-II OVA#1 0 11 
ESC MPI-II OVA#4 88 8 
iPSCs 129 SV TD 11.1 100 17 
iPSCs 129 SV TD11.1 OVA#6 100 29 
iPSCs 129 SV TD11.1 OVA#13 100 4 
iPSCs 129 SV TD11.1 OVA#18 64 11 
iPSCs 129 SV TD11.1 OVA#24 89 9 




The stem cell lines which showed a high proportion of tumor formation in the immunodeficient hosts, 
thereby demonstrating proliferation and differentiation capacity in vivo, were used for further 
analysis. In Figure 23, a summary of wildtype and OVA-expressing stem cells is depicted, which shows 
that all types of cells, comprising ES and iPS and wildtype and OVA-expressing cells lines, were able to 
form tumors in vivo. Therefore, the expression of OVA appears to have no principal effect on the 
tumor formation in immunodeficient hosts. 
 
 
4.2.1.1 Effects of OVA expression on tumor formation, size and weight in immunodeficient 
hosts 
The following data were statistically analyzed with respect to tumor formation rate, tumor size, tumor 
weight and influences of the presence of NK cells, sex of the recipients and type of stem cells on these 
parameters. Moreover, the duration until experiments were terminated, either due to tumor growth 
or due to achievement of the end point of experiments (usually 3 month) were compared. Comparison 
of tumor formation between wildtype and OVA-expressing stem cells showed that the expression of 
OVA does not lead to an altered tumor formation rate compared to wildtype stem cells (ESC wt vs. 
ESC OVA: p = 0.19; iPSC wt vs. iPSC OVA: p = 0.29; PSC wt vs. PSC OVA: p = 0.21; Mann-Whitney U-test; 
Figure 24A). Statistical analysis of teratoma formation between ESC- and iPSC-derived tumors showed 





















w tumor w/o tumor
Figure 23 Tumor formation in immunodeficient hosts.  
Stem cell lines which were generally not able to give rise to 
tumors in vivo were already excluded from this summary. 
Numbers of performed experiments are depicted in the 




expressing stem cells (ESC wt vs. iPSC wt: p = 0.36; ESC OVA vs. iPSC OVA: p = 0.4, Mann-Whitney U-
test; Figure 24A). Further analysis showed that the presence of NK cells in RAG2-/- and SCID mice had 
no influence on the tumor formation rate (data not shown) and that tumor formation also showed no 
statistical differences between the various hosts (RAG2-/-c-/-, RAG2-/-, SCID/beige, SCID, data not 
shown). The different sex of host animals (m vs. f) had also no impact on the tumor formation rate 
(data not shown). Tumor size and weight were also not influenced by the different type of stem cells 






(B) Depicted is the mean tumor size + SEM. ESC OVA (n = 14), iPSC OVA (n = 18), ESC 
wt (n = 34) iPSC wt (n = 6). ESC OVA vs. ESC wt (p= 0.05), iPSC OVA vs. iPSC wt (p = 
0.79), differences between stem cell type: iPSC wt vs. ESC wt  (p = 0.46), iPSC OVA 
vs. ESC OVA (p = 0.36); Mann-Whitney U-test (C) Shown is the mean tumor weight 
+ SEM. ESC OVA (n = 13), iPSC OVA (n = 18), ESC wt (n = 35), iPSC wt (n = 5). ESC OVA 
vs. ESC wt (p= 0.05), iPSC OVA vs. iPSC wt (p= 0.68); differences between stem cell 
types: iPSC wt vs. ESC wt (p = 0.28); iPSC OVA vs. ESC OVA (p = 0.20); Mann-Whitney 
U-test. 
Figure 24 Analysis of (A) tumor 
formation, (B, tumor size and (C) tumor 
weight after injections of OVA-
expressing and wildtype iPSC and ESCs 
into immunodeficient hosts. 
(A) Shown is the percentage of tumor 
formation of tumors which were further 
analyzed concerning size and weight. ESC 
OVA (n = 19), iPSC OVA (n = 25), ESC wt (n 









































In Table 14, tumor formation rates, tumor size, tumor weight and duration of experiments for each 
analyzed stem cell clone is depicted. Examination of these parameters for each clone showed that the 
tumor formation rate was not statistically differing between the various cell clones. In contrast, 
analysis of tumor size, weight and experimental duration showed significant differences between 
wildtype cell clones, whereas OVA-expressing cell clones significantly varied in duration, while 
showing similar tumor size and weight (Table 14, lower rows). This indicates that each clone has its 
distinct growth rate, leading to varying size and weight of forming tumors. The differing duration of 
experiments for single clones is promoting this hypothesis, revealing the time differences until tumors 
reached a certain size and experiments had to be ended. Apart from that, the varying duration of 
experiments could not be associated with a type of stem cells (ESC, iPSC) or the expression of OVA 
(data not shown). 
 
Table 14 Analysis of tumor formation, mean tumor size, weight and experimental duration for each stem cell 
clone after injection into immunodeficient hosts. Significant differences between wildtype or OVA-expressing 
stem cell clones are depicted in lower rows; Kruskal-Wallis H-test. *<0.05; **<0.01; ***<0.001. 
Immunodeficient hosts 
 tumor duration 
clone formation size weight  
 [n of total] [mm3] [mg] [days) 
ESC BTL1 9 / 12 272.6 0.36 40 
ESC BTL1 OVA#4 7 / 11 467.6 0.96 64 
ESC MPI-II 27 / 30 858.9 1.61 50 
ESC MPI-II OVA#4 7 / 8 488.3 0.87 66 
iPSC 129/Sv 17 / 17 838.98 1.19 27 
iPSC 129/Sv OVA#6 29 / 29 267.9 0.41 26 
iPSC 129/Sv OVA#13 4 / 4 1005.9 1.20 27 
iPSC 129/Sv OVA#18 7 / 11 412.5 1.37 47 
iPSC 129/Sv OVA#24 8 / 9 344.88 0.46 26 
Differences between 
OVA clones: p =  
     *** 
Differences between 
wt clones: p = 




4.2.1.2 Histological analysis of teratomas 
All emerging tumors were histologically analyzed for the development of structures of all three germ 
layers and if present confirmed as teratomas. In Figure 25, examples are depicted of mesodermal, 
ectodermal and endodermal structures, which formed after injections of stem cells. All clones that 
were able to form tumors at high frequency were able to form teratomas and can be considered 
therefore as pluripotent. Additionally, qPCR analysis was performed to determine the expression of 




Figure 25 Histological example pictures of teratomas formed after injection of iPSC 129/Sv TD11.1 into 
immunodeficient RAG2-/-c-/- mice.  
Teratomas were fixed with formalin and embedded with paraffin for cutting, sections were stained with 
hematoxylin and eosin (H&E). The tumor contains derivatives of all germ layers, indicated by colored arrows: 
yellow: neural-like tissue (ectoderm); light blue: rivulet of muscles/ myocytes (mesoderm); dark blue: cartilage 




4.2.2 Adoptive transfer of OVA-specific T cells into immunodeficient hosts 
Next, adoptive T cell transfer experiments were done in immunodeficient (RAG2-/-c-/-) animals to 
examine whether PSCs are immunosuppressive in vivo as they are in vitro. For these experiments a 
wildtype iPSC line (iPSC 129/Sv) and two OVA-expressing iPSC clones (iPSC 129/Sv OVA#6, OVA#24) 
were used. It was analyzed whether OVA-specific CD4+ and/or CD8+ T cells become activated after 
transfer and have an effect on tumor formation of injected stem cells. In Figure 26, a schematic 
overview over the adoptive transfer experiment is depicted.  
 
 
OVA-specific T cells were isolated from spleen and lymph nodes of OT-I and OT-II mice via MACS 
technology and quantified by flow cytometry for expression of the OVA-specific TCR (data not shown). 
Furthermore, the capacity of T cells to become activated after in vitro stimulation with the respective 
OVA peptide was monitored. Over 80 % of isolated T cells expressed the transgenic TCRs specific for 
OVA (TCR Vβ 5.1/5.2+) and showed proliferation after in vitro activation and were therefore 
considered as suitable for adoptive transfer experiments (data not shown). 
Freshly isolated T cells were stained with CFSE and intravenously injected in varying combinations  
(OT-I T cells, OT-II T cells or a mixture of OT-I/OT-II T cells; 5 x 106 cells /animal) into tail veins of  
RAG2-/-c-/- mice four days after injections with wildtype and OVA-expressing stem cells (1.5 x 106 cells 
/animal). Blood was taken on day 5 after adoptive transfer to monitor whether CFSE-stained T cells 
could be detected via flow cytometry. Due to missing native T cells in the immunodeficient hosts, all 
T cells found in this experiment derived from the previously transferred cells. In Figure 27A, it is shown 
that after transfer of OT-I T cells, up to 23.2 % of total PBMCs were cytotoxic T cells in the 
          
 
Figure 26 Schematic overview over adoptive transfer experiments performed in immunodeficient 
RAG2-/-c-/- mice.  
Wildtype or OVA-expressing stem cells were subcutaneously injected followed by an adoptive transfer 
(day 4) of transgenic OT-II CD4+ cells, OT-I CD8+ cells or a mixture of both into the tail vein of the animals 








immunodeficient hosts, which also had received stem cells. In contrast, in mice that had received  
OT-II T cells, T helper cells constituted 0.5 to 2.8 % of total PBMCs. Analysis of the CFSE staining 
indicated that cytotoxic T cells (CD3+CD8+) had proliferated since they showed a reduced CFSE staining 
(Figure 27B). Distinct peaks in flow cytometric histograms indicate the cell divisions. T helper cells 
(CD3+CD4+), in contrast, did hardly proliferate after adoptive transfer. Notably, the OVA-specific 
CD3+CD8+ T cells proliferated in recipients which had received OVA-expressing iPSCs as well as in 
recipients with a wildtype stem cell line or control mice without iPSCs. This indicates a high antigen-
independent proliferative capacity of OT-I T cells in lymphocyte-depleted hosts. 
 
Figure 27 Flow cytometric blood analysis of transferred T cells of RAG2-/-c-/- mice which previously received 
different stem cell injections. 
Blood samples were taken on day 5 after adoptive transfer of OT-I and OT-II T cells. (A) Shown is the mean 
proportion + SD of total PBMCs. Animal numbers are indicated directly below the bars. (B) Exemplary 
measurements of CFSE staining of gated CD3+CD8+ and CD3+CD4+ cell populations. Animals received OVA-
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4.2.2.1 Effect of TCR-transgenic T cells on tumor formation  
To analyze which influence the adoptive transfer of the TCR-transgenic T cells in various combinations 
had on the injected wildtype or OVA-expressing stem cells, the formation and characteristics of the 
tumors in the immunodeficient mice were evaluated. This showed that the adoptive T cell transfer 
had no influence on the tumor formation rate in those animals (p = 0.36), displaying tumor formation 
in almost every performed experiment (Figure 28). Moreover, the size and weight of formed tumors 
were not significantly altered after T cell transfer (Supplement, Ch. 7.2.2). 
 
 
However, additional histological analysis of tumors showed that teratomas derived from OVA-
expressing stem cells were highly infiltrated by CD3+ cells as depicted in example pictures in Figure 29. 
























Figure 28 Tumor formation in immunodeficient hosts, which 
either additionally received adoptive transfer of OVA-specific 
T cells (OT-I T cells, OT-II T cells, OT-I/OT-II T cells) or no T cells 
(w/o transfer).  
Numbers of performed experiments are depicted in the 





After experimental ending, blood and spleen were collected for further analysis of T cell activation. 
Even after 40 days post transfer, CFSE-stained cells were still found in blood and spleen of the hosts 
(around 2-4 %; data not shown). However, most T cells had lost CFSE staining likely due to 
proliferation. Splenocytes were directly used in 51Cr release assays to determine the cytotoxic activity 
of CTLs, shown in Figure 30A for animals which received iPSC 129/Sv OVA#6 stem cells and adoptive 
transfer of OT-I T cells. For this, OVA-expressing RMA (eGFP-OVA) and control RMA (eGFP) cells were 
used as target cell lines. At this, RMA OVA target cells were killed by all splenocytes of animals that 
previously had received OVA-expressing stem cells and OT-I or OT-I/OT-II T cells (data not shown), 
showing that OVA-specific CTLs became activated in those animals. In mice carrying teratomas derived 
from wildtype iPSCs, the CTLs were much less active against the OVA-expressing target cells, indicating 




Figure 29 Histological analysis of T cell infiltration into teratomas derived from iPSC 129/Sv OVA#6 
stem cells in RAG2-/-c-/- mice which additionally received OVA-specific OT-I T cells.  
Shown is an immunohistochemical staining of CD3+ cells in three different teratomas in 100 x 






Further analysis of survival of animals showed that animals, which received OT-I T cells and displayed 
high proliferating CD3+CD8+ T cell in blood analysis (day 5 post transfer) showed a longer survival 
(Figure 31C). This indicates that the OVA-specific CTLs could inhibit tumor growth of injected stem 
cells to a certain extent and thereby led to a longer survival in some animals due to delayed tumor 
growth. Nevertheless, the injected OVA-specific T cells were not sufficient to prevent the growth of 






Figure 30 Analysis of OVA-specific CTL activation examined via 51Cr release assays.  
Shown is the mean specific lysis of the target cells RMA (eGFP) as control and RMA OVA (eGFP-OVA) by 
splenocytes of animals which received (A) OVA-expressing or (B) wt 129/Sv iPSCs and OT-I T cells + SEM. 









































Figure 31 Kaplan-Meier survival curve of 
immunodeficient animals after inoculation of 
iPSC 129/Sv OVA#6 and adoptive transfer of 
OT-I T cells.  
T cells showed various patterns of activation, 
defined at day 5 post OT-I T cell transfer: rapid 
proliferating T cells: CD3+CD8+: 20-30 % cell 
count in blood analysis (n = 3), w T cells: all 
other animals which received T cell injections (n 




4.2.3 Effect of OVA expression in stem cells on tumor formation in immunocompetent 
hosts 
Next, stem cells were injected subcutaneously into immunocompetent mice (129/Sv) to monitor 
whether immune reactions against OVA developed, which represents a single miHC antigen in 
otherwise syngeneic hosts. Only clones that regularly had formed tumors in the immunodeficient 
hosts were included in this analysis. After stem cell injections, tumor formation was monitored and 
differences in the tumor frequency of OVA-expressing and wildtype stem cells were detected (Figure 
32). Injections of wildtype stem cells into immunocompetent mice led to a tumor growth in 83 or  
85 % of the recipients for ESCs and iPSCs, respectively, which is similar to the tumor rates observed in 
immunodeficient hosts (Figure 23). In contrast, OVA-expressing stem cells failed to engraft and to 
form tumors in 62 % of the recipients for iPSC OVA clones and 73 % for ESC OVA clones (Figure 32).  
 
 
In contrast to wildtype iPSCs and its OVA-expressing clones which derived from one iPS cell line 
(129/Sv TD11.1), tested ESC clones consisted of different stem cell lines. Besides the previously widely 
used ESC line MPI-II, the newly generated ESC BTL1 and their OVA-expressing clones were 
investigated. Analysis of tumor formation of the wildtype ES cell lines and their OVA-expressing clones 
showed that tumor formation rate of wildtype ESCs were similar, ranging from 81 % (MPI-II) or 86 % 





















w tumor w/o tumor
Figure 32 Tumor formation of wildtype and OVA-expressing 
stem cells in immunocompetent 129/Sv mice.  









4.2.3.1.1 Effect of OVA expression in stem cells on various parameters in immunocompetent hosts 
Tumors derived from OVA-expressing and wildtype ESCs or iPSCs in immunocompetent 129/Sv mice 
were confirmed to be teratomas by histology (data not shown) and qPCR analysis (Supplement,  
Ch. 7.2.1). They were also analyzed for differences in tumor formation rate, size and weight and the 
influence of recipient gender, stem cell type or expression of OVA. Additionally, the duration until 
experiments were terminated, due to animal condition and tumor size, were considered for analysis. 
In contrast to tumor formation in immunodeficient mice, the expression of OVA led to a significantly 
reduced tumor formation rate in immunocompetent hosts (ESC wt vs. ESC OVA: p = 3.6 x 10-9; iPSC wt 
vs. iPSC OVA: p = 2.4 x 10-4; PSC wt vs. PSC OVA: p = 2.9 x 10-12; Mann-Whitney U-test; Figure 34A). 
However, no differences in engraftment of iPSC- or ESC-derived tumors were observed when 
comparing either wildtype or OVA-expressing stem cell tumors (ESC wt vs. iPSC wt: p = 0.86; ESC OVA 
vs. iPSC OVA: p = 0.26; Mann-Whitney U-test; Figure 34A). Further analysis showed that size and 
weight significantly varied between tumors derived from OVA-expressing or wildtype stem cells and 
additionally between wildtype tumors derived from iPSCs and ESCs. In Figure 34B/C, it is displayed 





















w tumor w/o tumor
Figure 33 Tumor frequency after ESC injections into 
immunocompetent 129/Sv host summarized for groups of 
wildtype ESC BTL1, ESC MPI-II and their derived OVA-expressing 
clones.  





tumors derived from their wildtype counterparts. Tumors derived from OVA-expressing ESCs were 
also slightly smaller although not lighter than wildtype tumors. These results suggest that the 
expression of OVA as a single antigen is sufficient to prohibit engraftment or to lead to a reduction of 
the size of the stem cell-derived tumors. Nevertheless, significant variation in tumor size and weight 
were monitored between tumors derived by wildtype iPSCs and ESCs (ESC wt vs. iPSC wt: size (p = 2.9 
x 10-4), weight (p = 8.7 x 10-5); Mann-Whitney U-test). Tumors originated from OVA-expressing stem 
cell displayed variations concerning tumor size (ESC OVA vs. iPSC OVA, p = 0.03; Mann-Whitney U-
test). This might indicate that immune reactions against other differentially expressed antigens 
between iPSCs and ESCs influence tumor growth. However, these seem to have no major effects on 
the overall engraftment frequency since only sizee of tumors was affected. Consequently, it is more 




is depicted. ESC OVA (n = 9), iPSC OVA (n = 22), ESC wt (n = 53), iPSC wt (n = 15). 
ESC OVA vs. ESC wt (p= 0.03), iPSC OVA vs. iPSC wt (p = 6.5 x 10-5), Mann-Whitney 
U-test. (C) The mean tumor weight + SEM is shown. ESC OVA (n = 12), iPSC OVA 
(n =23), ESC wt (n = 51), iPSC wt (n = 17). ESC OVA vs. ESC wt (p= 0.23), iPSC OVA 
vs. iPSC wt (p= 3.6 x 10-5), ESC OVA vs. iPSC OVA (p = 0.48), Mann-Whitney U-
test. 
Figure 34 Analysis of (A) tumor 
formation, (B) tumor size and (C) 
tumor weight after injections of 
OVA-expressing and wildtype iPSCs 
and ESCs into immunocompetent 
129/Sv hosts.  
(A) The frequency of tumor formation 
is shown. ESC OVA (n = 34), iPSC OVA 
(n = 61), ESC wt (n = 66), iPSC wt (n = 


















































The analyzed parameters for single stem cell clones are shown in Table 15, revealing variations in 
tumor formation frequency for OVA clones (ESC BTL1 OVA#4; ESC MPI-II OVA#4; iPSC 129/Sv OVA#6, 
#13, #18, #24), but not for wildtype stem cells (ESC BTL1, ESC MPI-II, iPSC 129/Sv) (OVA: p = 3.2 x  
10-3; wt: p = 0.84; Chi-squared test). However, for wildtype stem cell lines significant differences 
concerning tumor size, tumor weight and duration of the experiments were monitored (size:  
p = 5.8 x 10-5; weight: p = 6.5 x 10-5, duration: p = 8.1 x 10-3; Kruskal-Wallis H-test). Tumors derived 
from the OVA-expressing clones showed similar phenotypic characteristics, i.e. tumor size and tumor 
weight, and similar growth rates, indicated by the duration of experiments (size: p = 0.09, weight:  
p = 0.46, duration: p = 0.07, Kruskal-Wallis H-test).  
 
Table 15 Analysis of tumor formation, tumor size, tumor weight and experimental duration for each stem cell 
clone after injection into syngeneic immunocompetent 129/Sv host. Significant differences between wildtype 
or OVA-expressing clones are depicted in lower rows. **< 0.01, ***< 0.001. 
Immunocompetent hosts 
 tumor duration 
clone formation size weight  
 [n of total] [mm3] [mg] [days] 
ESC BTL1 30 / 35 234.48 0.78 30 
ESC BTL1 OVA#4 4 / 27 633.0 0.65 67 
ESC MPI-II 25 / 31 488.81 0.68 64 
ESC MPI-II OVA#4 8 / 17 92.1 1.08 42 
iPSC 129/Sv 17 / 20 941.61 1.79 17 
iPSC 129/Sv OVA#6 10 / 19 280.9 0.81 51 
iPSC 129/Sv OVA#13 1 / 6 879.6 1.39 63 
iPSC 129/Sv OVA#18 1 / 15 58.6 0,09 35 
iPSC 129/Sv OVA#24 11 / 21 227.6 0,34 36 
Differences between 
OVA clones 
 **     
Differences between  
wt clones  
   *** *** ** 
 
Additionally, it was analyzed whether a distinct sex of injected stem cells and hosts led to a reduced 
tumor formation in 129/Sv mice after stem cell inoculations. Injections of male stem cells bearing a Y-
chromosome into female hosts could possibly result in immune reactions against HY antigens besides 
the model antigen OVA. Therefore, the tumor formation in male and female hosts was examined. The 
frequency of teratoma engraftment of wildtype stem cells was similar in male and female recipients 




female mice (8%) compared to male hosts (46 %) (Analysis for single cell clones: Supplement,  
Ch. 1.1.1). These data suggest, an additional effect of further miHC antigens such as HY antigens 
derived from the Y-chromosome of male stem cells on the rejection of OVA-expressing stem cells or 
their derivates. However, alternatively stronger immune responses in female than male hosts against 
OVA could explain this result.  
 
 
4.2.4 Comparative analysis of tumor formation and characteristics in immunodeficient 
and immunocompetent hosts 
Comparison of tumor formation in immunodeficient (summarized as SCID) and immunocompetent 
hosts (129/Sv) revealed that the OVA expression led to a significant reduced engraftment as well as 
teratoma size and weight in 129/Sv mice compared to immunodeficient hosts (Figure 36), also 
indicating an effect of OVA expression on the tumor formation. Generally, OVA expression significantly 
affected tumor frequency and tumor weight only in immunocompetent but not in immunodeficient 
mice (OVA vs. wt in 129/Sv: formation (p = 2.9 x 10-12), weight (p = 0.01); OVA vs. wt in SCID: formation 
(p = 0.29), weight (p = 0.08); formation: chi-squared test, weight: Mann-Whitney U-test). The size of 
wildtype and OVA-expressing tumors was reduced in 129/Sv mice (129/Sv wt vs. 129/Sv OVA:  
p = 5.6 x 10-3; SCID wt vs SCID OVA: p = 0.03; Mann-Whitney U-test). This observation is in agreement 
with previous observations that NK cells can delay the growth of teratomas (Dressel et al., 2008, 2010). 
 
Figure 35 Percentage of tumor 
formation and rejection in male 
and female immunocompetent 
129/Sv mice after injections of 
OVA-expressing or wildtype 
stem cells.  
Numbers of performed 
experiments are depicted in 


























However, the size differences between wildtype and OVA-expressing stem cell-derived tumors in 
immunodeficient mice (SCID wt vs. 129/Sv wt: p = 0.01; Mann-Whitney U-test) suggest clonal 
differences in the in vivo proliferation rate as a further explanation. The tumor weight showed a similar 
pattern in the different hosts. The duration of experiments before termination due to tumor size was 
not significantly altered by immune status of the hosts (immunocompetent or immunodeficient) or 
OVA expression (SCID wt vs SCID OVA: p = 0.72; 129/Sv wt vs. 129/Sv OVA: p = 0.73; SCID wt vs. 129/Sv 
wt: p = 0.52; SCID OVA vs. 129/Sv OVA: p = 0.68, Mann-Whitney U-test; data not shown). 
 
 
4.2.5 Analysis of teratomas  
Next, teratomas were further analyzed via qPCR for expression of pluripotency and proliferation 
markers, transgene expression and additional markers, which were previously suggested to be 
involved in stem cell immunogenicity or immune escape mechanisms, respectively.  
 
 
OVA SCID vs. OVA 129/Sv (p = 2.5 x 10-7), wt SCID vs. wt 129/Sv (p = 0.39), SCID 
OVA vs. SCID wt (p = 0.29), Mann-Whitney U-test. (B) Depicted is the mean 
tumor size + SEM. SCID OVA (n = 32), SCID wt (n = 40), 129/Sv OVA (n = 31), 
129/Sv wt (n = 68). SCID vs. OVA 129/Sv (p = 0.016), wt SCID vs. wt 129/Sv (p = 
0.01), Mann-Whitney U-test (C) Shown is the mean weight of tumors + SEM. 
SCID OVA (n = 32), SCID wt (n = 40), 129/Sv OVA (n = 31), 129/Sv wt (n = 68).OVA 
SCID vs. OVA 129/Sv (p = 0.05), wt SCID vs. wt 129/Sv (p = 0.08), Mann-Whitney 
U-test. 
Figure 36 Analysis of formation, size 
and weight of tumors derived from 
wildtype or OVA-expressing stem 
cells in immunodeficient and 
immunocompetent 129/Sv animals. 
(A) Shown is the mean percentage of 
tumor formation. SCID OVA (n = 44), 
SCID wt (n = 46), 129/Sv OVA (n = 

















































4.2.5.1 Characterization of pluripotency of tumor cells 
Expression of marker genes for the three germ layers was found in the tumors (Supplement; Ch. 7.2.4). 
Thus they were confirmed to be teratoma cells also at the molecular level, it was then analyzed 
whether teratomas still express markers of pluripotent cells. For this, Nanog and Oct4, two 
pluripotency markers were examined for their expression levels in teratomas. The relative expression 
of Nanog and Oct4 in teratomas was calculated compared to the corresponding PSC line, which was 
set to 1. As shown in Figure 37, the relative expression of both markers varied in teratomas but 
generally they showed a lower expression level (<1) in teratomas than pluripotent control cell lines 
(set as 1). The expression of Nanog was usually higher than Oct4. In summary, after injection of stem 
cells into hosts, cells start to differentiate into more mature cell types expressing markers of specific 




Additionally, teratomas were examined by IHC, revealing frequently areas positive for the 
pluripotency marker OCT4 and the proliferation marker KI67 as seen Figure 38. Thus even after several 
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Figure 37 QPCR analysis of pluripotency and transgene markers in teratomas derived from various 
injected stem cells into immunodeficient (RAG2-/-c-/-) and immunocompetent (129/Sv) syngeneic 
hosts.  
Shown is the relative expression of pluripotency marker Oct4 and Nanog + SD in teratomas formed after 
injections of wildtype (ESC BTL1, iPSC 129/Sv) and OVA-expressing (iPSC 129/Sv OVA#6 and #24) stem 
cells compared to the PSC lines (set as 1). Numbers of analyzed teratomas are depicted directly below 






4.2.5.2 Transgene expression in teratomas 
Because the effects of the miHC antigen OVA expressed in various stem cells is the basis for this study, 
it was examined whether the transgene OVA-eGFP was expressed after differentiation in teratomas 
as in the PSC lines. In Figure 39, it is shown that the relative expression of the transgene was 
dramatically reduced in many teratomas down to 0.01 fold of the expression in PSCs. Variations 
occurred between different injected clones, e.g. teratomas derived from iPSC 129/Sv OVA#24 showed 
 
Figure 38 Analysis of 
cell proliferation and 
pluripotency via IHC 
stainings of teratoma 
tissue derived from 
wildtype and OVA-
expressing stem cell 
injections into 129/Sv 
hosts.  
Shown are IHC 
stainings with 
antibodies against the 
pluripotency marker 
OCT4 and the 
proliferation marker 
KI67 for exemplary 
teratomas. iPSC wt: 
iPSC 129/Sv, iPSC OVA: 
iPSC 129/Sv OVA#6, 
ESC wt: ESC BTL1, ESC 
OVA: ESC BTL1 OVA#4. 
Scale bars in pictures 
(bottom right corner) 




a minor reduction (0.73 to 0.34 fold) in transgene expression compared to other teratomas (0.01 to 
0.1 fold). However, the loss of transgene in tumors derived from iPSC OVA#24 was higher in 
immunocompetent animals, which indicates that immune cells might have caused this reduction due 
to elimination of OVA-expressing cells. In contrast, expression in teratomas derived from iPSC OVA#6 
showed similar levels of low transgene expression, leading to the assumption that epigenetic changes 
while differentiation silenced the transgene locus and consequently expression was lost. In summary, 
it was shown that transgene expression can get lost after differentiation, which has to be considered 
in the evaluation of immune reactions against OVA. 
 
4.2.5.3 Expression of amino acid-depleting enzymes in teratomas 
To analyze whether teratomas display an immune escape mechanism that was described for stem 
cells, i.e. T cell suppression by expression of special amino acid depleting enzymes, the expression of 
the respective genes was examined. This included expression analysis of Arg1, which leads to 
depletion of L-arginine if highly expressed and results in T cell suppression and Ido, which is reported 
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Figure 39 QPCR analysis of transgene markers in teratomas derived from injections of various 
stem cells into immunodeficient (RAG2-/-c-/-) and immunocompetent (129/Sv) syngeneic hosts.  
Shown is the relative expression of transgene marker Ova and eGFP + SD in teratomas derived 
from OVA-expressing stem cell lines (iPSC 129/Sv OVA#6, #24; ESC BTL1 OVA#4) compared to 
pluripotent precursors (set as 1). Numbers of analyzed teratomas are depicted directly below the 




2010). Figure 40 shows the relative expression of both genes compared to liver tissue as positive 
control for Arg1 (set as 1) and to placenta as control for Ido (set as 1). Both genes were expressed in 
all PSCs on a minimal level compared to positive controls (Ido: 6.8 x 10-8 to 5 x 10-3 fold, Arg1: 4.6 x  
10-4 to 4 x 10-3 fold). Expression increased with differentiation and teratomas showed a constant 
expression of Arg1 at a low level between 0.02 to 0.08 fold of control, whereas Ido was also low in 
PSCs but became increased in teratomas (0.02 to 0.53 fold). However, in single teratomas derived 
from wildtype ESC BTL1, levels higher than control levels of placenta were reached (1.9 to 22.7 fold). 
Thus, the overexpression of Ido could be responsible for a failing immune recognition of teratomas in 































































Figure 40 QPCR analysis of Ido and Arg1 gene expression in teratomas derived from various stem cell clones 
into immunocompetent (129/Sv) or immunodeficient (RAG2-/-c-/-) hosts and their PSC lines.  
Shown is the mean relative expression of Arg1 compared to liver tissue (129/Sv) and Ido expression compared 
to placenta tissue (129/Sv) expression + SD. Numbers of analyzed teratomas are depicted below each column. 
Hprt was used as housekeeper for Ido expression normalization, for Arg1 the geometric mean of Gapdh and 




4.2.5.4 Expression of immunogenicity-causing genes 
In the literature it was reported that transplanted stem cells show an overexpression of so-called 
‘immunogenicity-causing’ genes namely Cyp3a11, Zg16 and Hormad1 (Zhao et al., 2011). To test 
whether the PSCs analyzed here as well as the teratomas derived from them express these genes, 
qPCR analysis was performed. In Figure 41, the relative expression of these genes in wildtype stem 
cells and teratomas is depicted, showing an overall low expression of each gene. Expression of 
Cyp3a11 ranged from 6.7 x 10-3 to 0.01 in PSCs and from 4.4 x 10-3 to 0.07 in teratomas compared to 
liver tissue. Hormad1 showed even lower expression than Cyp3a11 ranging on minimal levels of  
2.1 x 10-3 to 8.1 x 10-3 in PSCs and from 5.6 x 10-4 to 9.2 x 10-3 in teratomas compared to testis tissue 
expression. Relative Zg16 expression showed the lowest expression of 9.5 x 10-9 to 8.1 x 10-3 fold for 
PSCs and 1.5 x 10-6 to 1.6 x 10-4 in teratomas compared to lung tissue expression. Generally, these 
genes were only expressed on a minimal level and it appears to be unlikely that these genes have 
major impacts on the immunogenicity of stem cells and derived teratomas.  
 
In summary, general analysis of teratomas showed that stem cells differentiated into more mature 
cell types, thereby partly losing their transgene expression. However, residuals of pluripotent cells and 
proliferating cells were still found in certain areas in the teratomas. On gene expression level, tumors 
neither showed strong activation of immune escape mechanisms based on depletion of amino acids 






4.2.5.5 Infiltration into teratomas 
To further characterize the effects that the expression of OVA as miHC antigen might have on the 
inoculated stem cells, leukocyte infiltration into teratomas derived from OVA-expressing and wildtype 
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Figure 41 QPCR analysis of ‘immunogenicity-causing’ gene expression in teratomas derived from injections 
of various stem cell clones into immunocompetent (129/Sv) or immunodeficient (RAG2-/-c-/-) hosts and 
their PSC lines.  
Shown is the mean relative expression of Cyp3a11 compared to liver tissue (129/Sv), Hormad1 expression 
compared to testis (129/Sv) and Zg16 expression compared to lung tissue (129/Sv) expression + SD. Numbers 







Figure 42 IHC stainings of teratoma tissue derived from wildtype and OVA-expressing stem cell injections 
into 129/Sv hosts, analyzed for infiltrating leukocytes.  
IPSC wt: iPSC 129/Sv, iPSC OVA: iPSC 129/Sv OVA#6, ESC wt: ESC BTL1, ESC OVA: ESC BTL1 OVA#4; Scale bars 




Analysis showed that tumors were infiltrated to a distinct extend by various leukocyte populations 
including T cells (CD3+), macrophages (F4/80+) and B cells (CD45R+) (Figure 42). Granzyme B (GrB) was 
included as a marker of cytotoxic cells such as activated CTLs and NK cells, and single cells positive for 
this marker were found in the teratomas.  
The leukocyte infiltration into teratomas derived from OVA-expressing stem cells and wildtype stem 
cells were further quantified by a semi-quantitative histological analysis and flow cytometry. IHC 
analysis showed that CD3+, CD45R+, F4/80+ and CD8+ cells were found in teratomas derived from 
wildtype and OVA-expressing stem cells (Figure 43). However, if signals were classified in groups of  
(1) single positive cells, (2) groups of positive cells and (3) confluent groups of positive cells, tumors 
derived from OVA-expressing stem cells showed higher infiltration of these immune cell populations 
than tumors derived from wildtype stem cells. Additionally, leukocyte infiltration was examined in 
single teratomas by flow cytometry, confirming the infiltration of several leukocyte populations by 







Figure 43 Analysis of leukocyte infiltration into teratomas analyzed by IHC.  
Proportion of leukocyte marker-positive cells for classified groups. Histological tissue slides of tumors were 
stained with antibodies against various leukocyte markers and positive signals were grouped by manual 
analysis. Visible positive stained cells were classified in either 0 = no staining, 1 = single positive cells,                  
2 = groups of positive cells or 3 = confluent groups of positive cells. Teratomas derived from wildtype stem 
cells: CD3 (n= 42), CD45R (n=22), F4/80 (n= 28), CD8 (n=4); teratomas derived from OVA-expressing stem 
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0 = no pos. cells 
1 = single pos. cells 
2 = groups of pos. cells 





4.2.6 Generation of OVA-specific CTLs in syngeneic hosts 
Next, it was clarified whether OVA-specific T cells arose in animals which received OVA-expressing 
stem cells in contrast to animals which received wildtype stem cells. Cytotoxicity tests were performed 
using splenocytes obtained from 129/Sv hosts which previously received injections of wildtype and 
OVA-expressing stem cells. The experiments were performed at the experimental end points, after  
90 days or when animals had to be sacrificed due to tumor growth (long term experiments), or after 
1 week (short-term experiments). The splenocytes were restimulated in vitro for 4 days with OVA 
protein before the 51Cr release assays. Analysis of splenocyte composition, including T helper cells, 
cytotoxic T cells, NK cells and specific TCR Vβ 5.1/5.2 T cells, showed no major differences between 
animals which received wildtype or OVA-expressing stem cells or which showed tumor formation or 
tumor rejection (Figure 44; Supplement, Ch. 7.2.5, unstimulated). The E:T ratio for effector cells in the 
cytotoxicity assays was adjusted to the proportion of CD3+CD8+ cells of the restimulated splenocyte 
population detected via flow cytometry on day 4. 
 
 
The restimulated splenocytes were used as effector cells in 51Cr release assays with two RMA target 

































Figure 44 Flow cytometric analysis of restimulated splenocytes on day 4 after in vitro 
stimulation with OVA protein and IL-2.  
Splenocytes were obtained from 129/Sv mice which previously received OVA-expressing (OVA) 
or wildtype (wt) stem cells, which led to tumor formation (w tumor) or tumor rejection (w/o 
tumor). Wt w/o tumor: CD3+CD8+ (n = 7), CD3+CD4+ (n = 7), DX5+CD3- (n = 7) CD3+TCRVß+ (n = 0), 
OVA w/o tumor: CD3+CD8+ (n = 126), CD3+CD4+ (n = 36), DX5+CD3- (n = 58), CD3+TCRVß+ (n = 15), 
wt w tumor: CD3+CD8+ (n = 22), CD3+CD4+ (n = 13), DX5+CD3- (n = 22), CD3+TCRVß+ (n = 6), OVA 




stem cells or wildtype stem cells. The RMA target cells comprised of an OVA-expressing RMA cell line 
(RMA eGFP-OVA, here referred as RMA OVA), which was transfected with the transgene for a OVA-
eGFP fusion protein (as OVA-expressing stem cell lines) and a control cell line (RMA eGFP; here 
referred as RMA control), lacking the OVA in the transfected construct. In Figure 45, the specific lysis 
of those RMA target cell lines by splenocytes isolated of two animals is shown, of which one received 
wildtype cells (iPSC 129/Sv) and the other OVA-expressing stem cells (iPSC OVA#13). The control RMA 
cell line was neither killed by splenocytes of the animal receiving OVA-expressing stem cells nor from 
splenocytes of the mouse that received wildtype stem cells. However, the OVA-expressing RMA target 
cell line was only lysed by splenocytes of recipients of OVA-expressing stem cells, indicating the 
presence of OVA-specific CTLs in this animal.  
 
 
In Figure 46A, a summary of the specific lysis of OVA-expressing RMA and control RMA by splenocytes 
of animals which previously received either wildtype or OVA-expressing iPSCs (iPSC 129/Sv) or ESCs 
(ESC BTL1, ESC MPI-II) is shown. On average, the specific lysis of RMA OVA targets by splenocytes of 
animals which received OVA-expressing stem cells was higher (16 % for ESC OVA and 20 % for iPSC 
OVA at the highest E:T ratio), than the lysis by splenocytes isolated of 129/Sv hosts which received 
 
of experimental triplicates.  
(A) Splenocytes were obtained 
on day 49 after injection of 
iPSC 129/Sv stem cells that led 
to tumor formation. (B) 
Splenocytes were obtained on 
day 82 after injection of iPSC 
129/Sv OVA#13 cells, that did 





















Figure 45 Analysis of OVA-
specific CTLs in 129/Sv 
animals which received stem 
cell inoculations.  
Shown is the specific lysis of 
control RMA (RMA eGFP) and 
RMA OVA (RMA eGFP-OVA) by 
in vitro restimulated 
splenocytes (day 4) isolated 
from animals, which received 
(A) wildtype or (B) OVA-























wildtype stem cells (6.4 % for ESC wt, 7.8 % for iPSC wt). In Figure 46B, the lysis of RMA OVA by 
splenocytes derived from animals, which received the individual stem cell clones is depicted 
separately. Despite the fact that the specific lysis of RMA OVA by the various splenocytes differed, all 
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Figure 46 Analysis of the presence of OVA-specific T cells after stem cell inoculation in syngeneic hosts by 
51Cr release assays at the end point of the experiment (long-term). 
(A) Shown is the mean specific lysis + SEM of RMA control cells (RMA eGFP) and RMA OVA (RMA eGFP-OVA) 
cells by splenocytes from syngeneic hosts inoculated with OVA-expressing or wildtype ESCs or iPSCs at 
different E:T ratios. IPSC OVA (n = 61), iPSC wt (n = 8), ESC OVA (n = 104), ESC wt (n = 28). Differences 
between the killing of control RMA and RMA OVA by various splenocytes of animals that received iPSC OVA 
(p = 6.7 x 10-22), iPSC wt (p = 0.39), ESC OVA (p = 3.5 x 10-25), ESC wt (p = 0.83); Mann-Whitney U-test. (B) 
Shown is the mean specific lysis + SEM of RMA OVA target cells by splenocytes of 129/Sv which received 
distinct ES and iPS cell clones. IPSC OVA#6 (n = 19), iPSC OVA#13 (n = 6), iPSC OVA#18 (n = 15), iPSC OVA#24 
(n = 21), iPSC wt (n = 8), ESC BTL1 wt (n = 17), ESC BLT1 OVA#4 (n = 27), ESC MPI-II wt (n = 3), ESC MPI-II 
OVA#4 (n = 17). Differences between the killing of  control RMA and RMA OVA by various splenocytes of 
animals that received iPSC OVA#6 (p = 7.5 x 10-9), iPSC OVA#13 (p = 3.5 x 10-3), iPSC OVA#18 (p = 1.5 x 10-5), 
iPSC OVA#24 (p = 3.9 x 10-9), iPSC wt (p = 0.39), ESC BTL1 wt (p = 0.47), ESC BLT1 OVA#4 (p = 1.1 x 10-9), ESC 





Comparative analysis revealed that the specific lysis of OVA-expressing targets was higher by 
splenocytes of animals which did not show tumor formation (23 %) after OVA-expressing stem cell 
inoculation compared to lysis by splenocytes of animals which received the same stem cells but 
displayed tumor formation (14.6 %, p = 9.1 x 10-6, Mann Whitney U-test) (Figure 47A). After inoculation 
of wildtype stem cells, these differences were not monitored. This suggests that increased OVA-

















Figure 47 Analysis of OVA-specific CTL responses dependent on (A) tumor formation or (B) gender of hosts.  
(A) Shown is the mean specific lysis of OVA-expressing RMA targets by splenocytes of animals which received 
OVA-expressing stem cells (left) or wildtype stem cells (right) and which showed tumor formation (w tumor) 
or no tumor formation (w/o tumor) + SEM determined by 51Cr release assays.  OVA-expressing stem cells: w 
tumor (n = 35), w/o tumor (n = 78), wildtype stem cells: w tumor (n = 22), w/o tumor (n = 6). Differences w/o 
tumor vs. w tumor: OVA-expressing stem cells (p = 9.1 x 10-6), wt stem cells (p =0.06).(B) Influence of gender 
of hosts which received stem cell inoculations on the lysis rate of RMA target cell lines. Shown is the mean 
specific lysis of control RMA and RMA OVA by splenocytes obtained from male and female mice which received 
OVA-expressing stem cells (left) or wildtype stem cells  (right) + SEM determined by 51Cr release assays. OVA-

















































Noticeable, after inoculation of OVA-expressing stem cells, the specific lysis of the OVA-expressing 
target cell line by splenocytes of female host was significantly higher than the lysis by splenocytes 
obtained from male hosts (RMA OVA m vs. f: p = 2.9 x 10-5; Mann-Whitney U-test; Figure 47B). 
Inoculation of wildtype stem cells did not led to any differences in killing of RMA OVA and control RMA 
by splenocytes obtained from male or female hosts (RMA control m vs. f: p = 0.97; RMA OVA  
m vs. f: p = 0.67; Mann-Whitney U-test). This indicates that that female recipients develop stronger 
immune responses against OVA. 
Next, the presence of an OVA-specific CTL activity was analyzed in animals receiving injections of OVA-
expressing stem cell clones, which were compromised in their pluripotency and did not form 
teratomas, or only in a minority of experiments, in immunodeficient hosts. As seen in Figure 48, the 
not fully pluripotent cell clones elicited a CTL response against OVA. The stem cell clones, which never 
gave rise to a teratoma in immunodeficient hosts, also induced OVA-specific CTLs but at a much lower 
level. This suggest that OVA-expressing cells derived from stem cells in vivo contribute to the CTL 
response. Injections of OVA-expressing stem cells, which lost the ability to substantially proliferate 
and differentiate in vivo elicited only a minor CTL response. 
 








































Figure 48 Analysis of the presence of OVA-specific T cells in syngeneic 129/Sv animals after stem cell 
inoculation.  
Splenocytes of 129/Sv were used as effector cells in 51Cr release assays with control RMA and RMA OVA as 
target cells. Animals received injections of stem cell clones, which were considered as not fully (left side) or 
not pluripotent (right side) due to reduced or lacking tumor formation in immunodeficient hosts. Shown is 
the mean specific lysis of RMA control (RMA-eGFP) and RMA OVA (eGFP-OVA) + SEM. Poor tumor 
formation: ESC BTL1 OVA#1, ESC BTL1 OVA#20 (n = 15); differences in the killing of RMA OVA and control 
RMA (p = 6.7 x 10-9), Mann-Whitney U-test; no tumor formation :ESC BTL1 OVA#9, ESC BTL1 OVA#14, ESC 





To determine when after inoculation of stem cells a CTL response was induced, short-term 
experiments were performed, in which animals were sacrificed one week after injections of wildtype 
or OVA-expressing stem cells. In Figure 49, the specific lysis of OVA-expressing RMA and control RMA 
by splenocytes of animals which previously received either iPSC 129/Sv or ESC BTL1 wildtype or OVA-
expressing stem cells or no cells as control animals is depicted.  
 
The splenocytes of animals, which were injected with OVA-expressing stem cells showed a higher lysis 































































iPSC wt (n = 8), control (n = 9). Comparison of RMA an RMA OVA killing: ESC wt (p = 0.58), ESC OVA 
(p = 2.6 x 10-6), iPSC wt (p = 0.08), iPSC OVA (p = 7.8 x 10-11); Mann-Whitney U-test. 
Figure 49 Analysis of the presence of OVA-
specific T cells after stem cell inoculation in 
syngeneic hosts after 1 week.  
Shown is the specific lysis of RMA control cells 
(RMA eGFP) and RMA OVA (eGFP-OVA) cells in 
51Cr release assays. Splenocytes from 
syngeneic hosts either inoculated with OVA-
expressing stem cells and wildtype stem cells 
or without stem cell inoculation (control), 
were used as effector cells. ESC OVA (n = 9), 




average, specific lysis of control RMA at the highest E:T ratio ranged between 5.4 % (ESC BTL1 wt),  
5.8 % (iPSC 129/Sv wt), 10.2 % (control), whereas up to 20.2 % (ESC BTL1 OVA) or 20.4 % (iPSC 129/Sv 
OVA) of the targets were killed when OVA-expressing stem cells had been inoculated. Thus, the lysis 
of both targets cell lines by splenocytes only significantly differed if animals previously received OVA-
expressing stem cells. This shows that the OVA-specific CTLs were present already one week after 
transplantation of the stem cells.  
 
4.2.7 Killing of wildtype and OVA-expressing iPSCs and ESCs by NK cells 
In parallel to several of the 51Cr release assays in which control RMA and RMA OVA were used as 
targets to determine CTL response against OVA in long term experiments, YAC-1, which is highly 
sensitive to NK cells, was used as target cell line. In this way the activation of NK cells in animals which 
either received OVA-expressing stem cells or wildtype stem cells or of animals which gave rise to 
teratomas versus those which did not show tumor formation was analyzed. The lysis of YAC-1 by 
splenocytes of animals which received OVA-expressing stem cells was higher than the killing by 
splenocytes of mice that had received wildtype stem cells (Figure 50, left panel). Moreover, the NK 
cell activity was higher in animals without tumors than in animals with tumors (Figure 50, right panel). 
These results indicate that in parallel to a CTL response against OVA, the NK cell activity increased in 
these mice. This might contribute to tumor rejection as suggested by the higher NK cell activity in the 





































Figure 50 Analysis of NK cell activity in animals which either received wildtype (wt) or OVA-expressing (OVA) 
stem cells, either leading to tumor formation (tumor) or tumor rejection (w/o tumor).  
Splenocytes were used in 51Cr release assays as effector cells against the target cell line YAC-1, which is known to 
be highly sensitive to NK cell lysis. Shown is the mean specific lysis of YAC-1 cells + SEM at different effector (CD3-
DX5+) to target ratios. OVA (n = 65), wt (n = 14), tumor (n = 14), w/o tumor (n = 65). OVA vs. wt (p = 8.1 x 10-4), 
tumor vs. w/o tumor (p = 2.4 x10-3); Mann-Whitney U-test. 
 




4.2.8 OVA-specific antibody generation in syngeneic hosts 
Whether the expression of OVA in stem cells elicited an antibody response in otherwise syngeneic 
hosts was analyzed via ELISA. For this, sera of animals which previously received injections with OVA-
expressing stem cells, wildtype cells or no cells were collected and analyzed to determine OVA-specific 
antibodies by measuring ODs at 405nm at several different serum dilutions (1:20 to 1:2560 for general 
anti-OVA titer, 1:30 to 1:240 for isotype subclasses). For the determination of the general OVA titer a 
secondary antibody reacting with IgG and IgM antibodies was used, for which a cross-reactivity to 
further antibody classes was not excluded. As positive control, four 129/Sv mice were immunized with 
OVA protein and TiterMax adjuvant and further boosting injections with OVA protein. These control 
sera were pooled, stored in aliquots and used as reference serum on each ELISA plate by setting ODs 
at the lowest dilution (1:20) to 100 % to calculate the relative OVA antibody titer of other sera. Sera 
were obtained from blood samples after animals were sacrificed at experimental end points. In the 
long-term setting, the duration of the experiments varied between single animals depending on tumor 
size and animal condition but ranged from 21 (w tumor) to 90 (w/o tumor) days. In Figure 51A it is 
shown that OVA-specific antibodies were found in the sera of animals which received OVA-expressing 
stem cells. Hereby, the average relative OVA titer (94 %) was similar to the OVA titer of the control 
immune serum (100%). In contrast, the average relative anti-OVA titer of animals which received 
wildtype stem cells (27 %) was on a similar level as of those animals which were not injected with any 
cells (34 %). Analysis of sera of animals which were either injected with ESCs or iPSCs showed that 
OVA expression in both ESCs and iPSCs led to significant higher relative anti-OVA titers (ESC wt vs. ESC 
OVA: p = 5.6 x 10-3; iPSC wt vs. iPSC OVA: p = 7.5 x 10-7, Mann-Whitney U-test) (Figure 51B). However, 
relative OVA titers were higher in mice that have received OVA-expressing iPSCs than ESCs (ESC OVA 
vs. iPSC OVA: p = 2.3 x 10-10; ESC wt vs. iPSC wt: p = 2.1 x 10-17, Mann-Whitney U-test). Significant 
variations in OVA titers occurred dependent on the injected clones as depicted in Figure 51C, e.g. 
showing anti-OVA antibody titers up to 153 % relative to control titers after injection of iPSC OVA 
clones #6 and #24. ESC OVA clone injections led to relative anti-OVA titers of 61 % (BTL OVA#4) to  
90 % (MPI OVA#4), whereas injections of iPSC OVA#13 caused anti-OVA titers similar to those found 
after wildtype iPSC injections. Moreover, it was analyzed whether animals which rejected tumors 
showed divergent anti-OVA titers compared to animals showing tumor formation. Anti-OVA 
antibodies showed significant higher titers in animals that formed teratomas compared to those 




of tumor formation or rejection (Figure 51D). Furthermore, it was analyzed whether gender of hosts 
had influence on the generation of OVA antibodies, but no dependency was found.  
 
 
Figure 51 Analysis of OVA-specific antibody titers in syngeneic 129/Sv mice after injections of wildtype or 
OVA- expressing stem cells via ELISA.  
 
 
Sera were obtained from blood samples at the experimental end points. Shown is the mean relative anti-OVA 
titer + SEM compared to a pool of positive controls, which were previously immunized with recombinant OVA 
protein. (A) Mean relative anti-OVA titer in animals which received either no cell injections (/) or wildtype (wt) 
or OVA-expressing stem cells (OVA), depicted in serial dilutions. Control (/) (n = 12); wt (n = 56); OVA (n = 105). 
(B) Comparison of mean relative anti-OVA titer for the smallest sera dilution (1:20) of animals which received 
either wildtype or transgenic ESCs or iPSCs: ESC OVA (n = 44), ESC wt (n = 38), iPSC OVA (n = 61), iPSC wt (n = 
18). **<0.01, ***<0.001; Mann-Whitney U-test. (C) Comparison of relative anti-OVA titers after injections of 
distinct stem cell clones in 129/Sv mice. ESC BTL1 wt (n = 35), ESC BTL1 OVA#4 (n = 27), ESC MPI-II wt(n = 3), 
ESC MPI-II OVA#4 (n = 17), iPSC 129/Sv wt (n = 18), iPSC 129/Sv OVA#6 (n = 19), iPSC 129/Sv OVA#13 (n = 6), 
iPSC 129/Sv OVA#18 (n = 15), iPSC 129/Sv OVA#24 (n = 21). (D) Anti-OVA antibody titers in animals which 
showed tumor formation or rejected tumors after stem cell inoculation of wildtype or OVA-expressing stem 
cells. Numbers of performed experiments are depicted below each bar. Differences in OVA titers between 
animals showing tumor formation or not: OVA (p = 2.8 x 10-31), wt (p = 0.1), Mann-Whitney U-test. 










wt #4 wt #4 wt #6 #13 #18 #24

















































































































If OVA-antibodies (relative anti-OVA titer > 60%) were found, the sera were additionally analyzed for 
the isotypes of OVA-specific antibodies using isotype-specific secondary antibodies in ELISAs. This 
showed that in animals which had received OVA-expressing stem cells, the OVA-specific IgG1 titer was 
increased compared to sera of animals which did not receive stem cell injections (Figure 52). 
Furthermore, OVA-specific antibodies of the IgG2a and IgG2b isotypes were found. No OVA-specific 
antibodies were found among the other isotypes. These findings indicate that the OVA-specific 
antibodies which arose after transplantation of OVA-expressing stem cells were of the IgG isotype. 




In short-term experiments, in which animals were sacrificed 1 week after stem cell inoculation, the 
antibody response against OVA was also examined. Comparison of anti-OVA antibody levels of animals 
which either received wildtype stem cells (ESC BTL1 wt and iPSC 129/Sv wt), OVA-expressing stem cells 
(ESC BTL1 OVA#4 and iPSC 129/Sv OVA#6) and control animals (no cell injections) showed no 
differences in OVA-specific antibody titers (p = 0.34, Kruskal-Wallis H-test) one week after injections 
(Figure 53A). Examination of an anti-OVA antibody isotype distribution as depicted in Figure 53B 
showed no major differences compared to controls. In general, no increased levels of OVA-specific 
antibodies were found 1 week after inoculation of OVA-expressing stem cells compared to control 



























Figure 52 Analysis of OVA 
antibody isotype distribution in 
sera of 129/Sv mice which 
received no stem cells (control) 
or OVA-expressing stem cells. 
(OVA).  
Shown is the mean proportion of 
various OVA-specific antibody 
isotypes in the sera (1:30) 
obtained after experimental 
endings + SEM. OVA (n = 79), 





4.2.9 Summary  
Analysis of OVA-expressing and wildtype stem cells in vivo showed that the expression of OVA as a 
model of a miHC antigen had effects on the engraftment of stem cells in immunocompetent syngeneic 
hosts, affecting tumor frequency, tumor size and weight. Additionally, it was shown that the injection 
of OVA-expressing stem cells elicited OVA-specific immune responses including CTL responses and 
induced OVA-specific IgG antibodies, demonstrating also class switching of OVA-specific B cells. CTL 
responses against OVA were already found early after stem cell injection (1 week), whereas antibody 
generation was monitored only later after injection, with higher OVA-specific titers in animals which 
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Figure 53 Analysis of OVA-specific antibody titer in syngeneic hosts 1 week after stem cell injections.  
(A) Mean of relative anti-OVA titer after various cell injections + SEM in serial dilutions from 1:20 to 
1:320 is depicted. As positive control for normalization sera of four 129/Sv mice immunized with 
recombinant OVA protein was used. Numbers of analyzed sera are depicted below columns. (B) Mean 
proportion of antibody isotypes of OVA antibodies at a dilution of 1:30 in various sera + SEM are shown. 






Adoptive transfer experiments revealed that OVA-specific T cells alone were able to delay tumor 
growth in immunodeficient hosts, but were not able to completely suppress tumor formation. 
Generally, all teratomas were infiltrated by various immune cells. The presence of immune escape 
mechanisms or immunogenicity marker expression on stem cells and their derivatives could not be 
confirmed in this study. In conclusion, the expression of a single antigen largely impaired engraftment 
of stem cells in immunocompetent recipients. 
 
4.3 The role of NKG2D in the killing of pluripotent stem cells 
In the previous experiments, not only an activation of CTLs but also of NK cells was observed. An 
activation of NK cells might be beneficial in the context of a transplantation of stem cell-derived grafts 
because PSC-derived grafts are at risk of giving rise to teratomas in the recipient, if residuals of 
undifferentiated cells remain in the grafts after in vitro differentiation. Our group previously showed 
that NK cells can kill allogeneic and autologous PSCs and reduce the risk of teratoma growth after 
transplantation of PSCs (Dressel et al., 2010; Kruse, Hamann et al., 2015). Inhibition studies indicated 
that NKG2D is an activating NK cell receptor which is involved in the killing of murine PSCs (Dressel et 
al., 2010), whereas for killing of human iPSCs DNAM-1 appeared to be more important (Kruse, Hamann 
et al., 2015). To further clarify the role of NKG2D in the murine system, the capability of NK cells from 
wild type C57BL/6 and NKG2D-deficient mice to kill various murine PSC lines was compared. 
 
4.3.1 Killing of murine stem cells by naïve C57BL/6 and NKG2D-deficient NK cells 
Six murine stem cell lines of different origin (iPSCs, ESCs, maGSCs) which were either syngeneic to the 
used NK cells (C57BL/6) or MHC-matched but otherwise allogeneic (129/Sv) were used as targets for 
freshly isolated wildtype C57BL/6 or NKG2D-deficient NK cells in 51Cr release assays. The NK cell-
sensitive cell line YAC-1 was always included in the experiments as reference target cell line. 
Comparative analysis showed that all tested stem cell lines were moderately killed by freshly isolated 
wildtype C57BL/6 NK cells. The specific lysis at the highest E:T ratio ranged between 12.5 % for iPSCs 
to 20.6 % for maGSCs (Figure 54A). In contrast, the stem cells were largely resistant to killing by naïve 
NKG2D-deficient NK cells, showing specific lysis on the highest E:T ratio only between 3.9 % for ESCs 
to 4.2 % for iPSCs (Figure 54B). The killing of the stem cell lines and the NK cell sensitive cell line YAC-




(ESCs: p = 3.4 x 10-8; iPSCs: p = 8.4 x 10-8; maGSCs: p = 7.7 x 10-7; YAC-1: p =5.2 x 10-14; 2-way-ANOVA 




The killing pattern of syngeneic (C57BL/6) or allogeneic but MHC-matched (129/Sv) target cells were 
similar. A significant lower killing off all six stem cell lines by NKG2D-deficient compared to the killing 
by wildtype C57BL/6 NK cells was observed (ESC BTL-1: p = 1 x 10-4; ESC MPI-II: p = 8.7 x 10-5, iPSC 
129/Sv: p = 3.1 x 10-7; iPSC C57BL/6: p = 0.01; maGSCs 129/Sv: p = 0.01; maGSCs C57BL/6:  







Figure 54 Killing of different 
stem cell lines and control 
YAC-1 cells by (A) naïve 
wildtype C57BL/6 NK cells or 
(B) NKG2D-deficient NK cells. 
Shown is the mean specific 
lysis of target cells + SEM. 
Differences between the killing 
efficiency of the two types of 
NK cells were significant for 
each type of cell. ESCs: ESC-
MPI-II and ESC BTL1; iPSCs: 
iPSC 129/Sv and iPSC C57BL/6; 
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4.3.2 Killing of murine stem cells by IL-2-activated wildtype C57BL/6 and NKG2D-deficient 
NK cells 
In the next experiments, the lysis of the different stem cell lines by in vitro IL-2-activated wildtype and 
NKG2D-deficient NK cells was compared. For this, isolated NK cells were in vitro stimulated for 4 days 
before they were used in cytotoxicity assays to determine their killing capacity of target cell lines. The 
specific lysis at the highest E:T ratio ranged between 22.8 % for iPSCs to 40.3 % for maGSCs, showing 
that the stimulation of the NK cells by IL-2 increased the killing of all tested stem cell lines (Figure 56). 
However, the NKG2D-deficiency was not fully compensated and wildtype NK cells were still more 
efficient than NKG2D-deficient NK cells, since the specific lysis on the highest E:T ratio by C57BL/6 NK 
cells ranged between 34.2 % for iPSCs to 55.6 % for maGSCs. This difference between the NK cell types 
was significant for iPSCs (p = 0.02) and maGSCs (p = 1.9 x 10-5) and at borderline for ESCs (p = 0.06). 
 
Figure 55 Killing of various stem cells lines by naïve wildtype C57BL/6 and NKG2D-deficient NK 
cells.  
Shown is the mean specific lysis of stem cells by NK cells + SEM. Number of performed experiments: 
maGSCs 129/Sv (n = 4), maGSC C57BL/6 (n = 4), iPSC 129/Sv (n= 4), iPSC C57BL/6 (n = 5), ESC BTL1      
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The lysis of the syngeneic (C57BL/6) or allogeneic but MHC-matched (129/Sv) stem cells is shown in 
Figure 57 for each stem cell line. Here, the difference between the lysis by wildtype and NKG2D -/- NK 
cells was significant for ESC BTL1 (p = 7.1 x 10-4) and both maGSC cell lines (maGSC 129/Sv: p = 0.01; 
maGSC C57BL/6: p = 5.9 x 10-4). The killing of the ESC MPI-II cell line by NKG2D-deficient NK cells after 
IL-2 stimulation was almost identical to the lysis rate by the wildtype NK cells (p = 0.64). Additionally, 
the susceptibility of both iPSC lines to stimulated NKG2D -/- NKs cell was not significantly lower than to 
stimulated NK cells (iPSC 129/Sv: p = 0.1;  iPSC C57BL/6: p = 0.23), but still not on the wildtype level. 
This shows that a stimulation with IL-2 increases the killing of stem cell lines by NKG2D-deficient NK 





Figure 56 Killing of various cell lines by IL-2 stimulated wildtype C57BL/6 and NKG2D-deficient NK cells. 
NK cells were in vitro stimulated for 4 days before they were used in cytotoxicity assays to determine 
their killing capacity of target cell lines. Shown is the mean specific lysis + SEM. ESCs (n= 6), maGSCs (n= 
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4.3.3 Expression of ligands of the NKG2D receptor on murine stem cells 
To determine the expression pattern of NKG2D ligands on the target cells flow cytometry analysis was 
performed using antibodies against RAE1, MULT1 and H60. All of the stem cell lines expressed these 
NKG2D ligands on their surface, but to a variable extent in number (cell positive for the ligands) and 
intensity (MFI) (Figure 58). The most abundant NKG2D receptor ligands was RAE1 which was detected 
in 40.2 % (iPSC C57BL/6) to 76.0 % (ESC BTL1) of the cells, except on maGSC C57BL/6, for which only 
6.4 % of the cells were positive. RAE1 expression analysis showed also the highest MFI values in the 
experiments, showing values from 4.9 (iPSC 129/Sv) up to 42.6 (maGSC 129/Sv). H60 was expressed 
on 2.7 % (maGSC C57BL/6) to 46.8 % (ESC BTL1) of the stem cells with similar MFI values of 1.4 (ESC 
MPI-II) to 3.4 (maGSC C57BL/6). The cell surface expression of MULT1 was the lowest of the NKG2D 
ligands, ranging from 2.8 % (maGSC C57BL/6) to 10.0 % (ESC-BTL1) with small MFI values of 0.1 (ESC 
MPI-II) to 3.1 (maGSC C57BL/6). YAC-1 was always included as NK cell target cell line and showed a 
 
 
Figure 57 Killing of various stem cells lines by in vitro IL-2 stimulated wildtype C57BL/6 and NKG2D-
deficient NK cells.  
Shown is the mean specific lysis + SEM; maGSCs 129/Sv (n= 3), maGSCs C57BL/6: (n= 3), iPSCs 129/Sv: (n= 
3), iPSC C57BL/6: (n= 3), ESC BTL1: (n= 3), ESC MPI-II: (n=3). 
 
n=3 





5:1 2,5:1 1,25:1 0,62:1 0,31:1















5:1 2,5:1 1,25:1 0,62:1 0,31:1















5:1 2,5:1 1,25:1 0,62:1 0,31:1















5:1 2.5:1 1.25:1 0.62:1 0.31:1















5:1 2.5:1 1.25:1 0.62:1 0.31:1















5:1 2,5:1 1,25:1 0,62:1 0,31:1











C57BL/6 NK cells 
NKG2D-/- NK cells 




high expression of all NKG2D ligands with 87.5 % RAE1+; 28.9 % MULT1+, 49.6% H60+ cells. Therefore, 
NKG2D expression on stem cell lines occasionally almost equals the expression on the control NK cell 




It was shown that the analyzed PSCs were largely resistant to killing by naïve NKG2D-deficient NK cells. 
In contrast, wildtype NK cells killed all targets with low or intermediate efficacy. The additional 
stimulation of wildtype and NKG2D-deficient NK cells by IL-2 increased the killing of all PSCs. 
Nevertheless, the NKG2D-deficiency was not fully compensated and wildtype NK cells were still more 
efficient. Furthermore, it was demonstrated that all PSC lines expressed NKG2D ligands although the 
expression pattern of RAE-1, MULT-1 and H60 molecules was variable. 
 
 
Figure 58 Expression of NKG2D ligands on stem cell lines and control (YAC-1) cell.  
(A) Mean percentage of NKG2D ligand positive cells + SEM (B) Mean MFI (mean fluorescence intensity) of 
ligands expression on the cells + SEM; YAC-1 (n = 13), iPSC 129/Sv (n = 5), iPSC C57BL/6 (n = 8), ESC BTL1 (n = 











































































5.1 Involvement of autoimmune responses on the pathogenesis of load-induced heart 
failure 
Previous results of our group have indicated that autoimmune reactions against OVA can occur in 
cMy-mOVA mice after TAC. These mice express OVA exclusively on the surface of cardiomyocytes and 
thus enable the investigation of immune responses against this specific cardiac antigen. The mice were 
generated and first analyzed by Grabie et al., who showed that the mice display tolerance to OVA. Our 
previous results indicated that OVA-specific CTL responses after TAC were weak and stronger 
reactions not frequent in young and otherwise healthy mice. To examine whether autoimmunity is a 
more frequent outcome after TAC operations in animals at higher risk to develop autoimmunity, 
transgenic T cells with specificity for OVA were transferred into the cMy-mOVA mice. Moreover, 
double-transgenic mice were analyzed, which expressed OVA on their cardiomyocytes and an OVA-
specific TCR on the majority of their CD4+ T cells. It was further investigated, whether autoreactive  
T cells, either endogenous or transferred, were sufficient to alter the cardiac remodeling after TAC 
operation or even accelerate the progression to HF. 
 
5.1.1 Increased leukocyte infiltration into the myocard after TAC 
Load-induced HF in C57BL/6 mice achieved by TAC surgery was accompanied with an increased 
leukocyte infiltration into the heart as analyzed by IHC (Toischer et al., 2010). Further analysis of this 
afterload model in our laboratory and by others revealed that TAC operations lead to infiltration of 
professional APCs and T cells into the myocardium (Laroumanie et al., 2014; Sasse et al., unpublished 
data). This was shown in our group for several time points from 1 day to 10 weeks post surgery by 
flow cytometric analysis. In this thesis, the infiltration of lymphocytes into the myocard was monitored 
at the experimental end point latest 10 weeks after surgery by IHC analysis of paraffin sections. At this 
time point a higher number of CD8+, CD4+, and CD45R+ cell were found after TAC than after sham 
operation for cMy-mOVA mice, cMy-mOVA mice which received either CD8+ OT-I T cells or a mixture 
of CD8+ OT-I and CD4+ OT-II T cells, and for cMy-mOVA/OT-II mice. The myocardia of animals that 
received OT-I T cells showed even higher infiltration of CD8+ but also CD4+ T lymphocytes than cMy-
mOVA or cMy-mOVA/OT-II animals, indicating the recruitment of further lymphocytes besides the 
TCR-transgenic CD8+ T cells into the myocardium. The examination of the leukocyte composition in 




populations including B cells (p = 0.01), T cells, and NK cells were slightly increased compared to sham-
operated animals. The general distribution of leukocyte populations in the heart resembled 
proportions of myeloid and lymphocyte cell proportions reported in a previous study (Bönner et al., 
2012). This study demonstrated that 2.3 x 103 resident leukocytes /mg tissue were present in the 
unstressed heart of C57BL/6 mice, including a large proportion of APCs as sentinel cells of the 
myocardium (Bönner et al., 2012). These residential APCs in the heart might also play an important 
role in the presentation of autoantigens to T lymphocytes.  
 
5.1.1.1 Controversial influence of endothelial surface adhesion molecules on immune cell 
infiltration 
Moreover, we have investigated whether the increased infiltration of lymphocytes after TAC 
correlates with altered surface expression of adhesion molecules on residential cells. It was previously 
reported that endothelial cells show an activation in chronic HF in terms of expression of adhesion 
molecules and chemokines (Colombo et al., 2005; Tousoulis et al., 2005). Thus, endothelial cells might 
be essential for inflammation in HF by facilitating transendothelial migration of leukocytes. In humans 
and mice with HF, it was reported that T cells showed a higher affinity towards the endothelium than 
controls (Nevers et al., 2015). Therefore, we examined whether an upregulation of the adhesion 
molecules VCAM-1 and ICAM-1 on endothelial cells in the heart occurs after TAC. However, no 
differences in the VCAM-1 and ICAM-1 surface expression in the myocard between sham- and TAC-
operated animals were found. This is in contrast to a study showing an upregulated protein expression 
of ICAM-1 on endothelial cells of left ventricular intramyocardial vessels after TAC (Nevers et al., 2015. 
Another recent study reported that ICAM-1-deficient mice displayed decreased T-cell and 
proinflammatory monocyte infiltration into the left ventricle after TAC surgery compared to controls, 
demonstrating the important role of ICAM-1 for immune cell infiltration (Salvador et al., 2016).  
 
5.1.2 Activation of adaptive immune responses towards cardiac antigens 
After the increase of lymphocytes infiltrating the myocardium in response to TAC operation and 
additional challenge by autoreactive T cells was demonstrated, it had to be clarified whether the OVA-
specific lymphocytes were activated. A first hint of CD8+ T cell activation was found after transfer of 




cells was found in animals, which underwent TAC surgery compared to sham-operated mice. However, 
this could indicate proliferation but also loss of cells or recruitment to other organs such as the heart.  
In cytotoxicity assays, the activation of OVA-specific CTLs was further proven in TAC- and sham-
operated animals. In TAC-operated cMy-mOVA mice that did not receive an adoptive transfer of  
T cells, a significant but low activation of CTLs against OVA was detected, albeit single animals showed 
specific lysis rate of RMA OVA targets up to 15 % (Röhrborn et al., unpublished data). In this thesis, 
the specific lysis rate of OVA-expressing target cells was higher for the animals that had received OT-I 
T cells. It was even further enhanced when OT-I and OT-II T cells were transferred, indicating an 
additional effect of OVA-specific CD4+ T cells on the activation of OVA-specific CTLs. However, this 
activation of T cells in cMy-mOVA mice that received OVA-specific T cells was largely independent of 
the type of surgery.  
In C57BL/6 mice, which underwent TAC surgery, it was previously shown that more CD4+ and CD8+  
T cells expressed activation markers such as CD25 and CD69 (Sasse et al., unpublished data). CD4+ cells 
of cMy-mOVA/OT-II mice also expressed more CD25 after TAC than sham surgery. The expression level 
of CD69 on CD4+ T cells was not affected. Laroumanie et al. showed that CD4+CD44high effector T cells 
numbers, in contrast to CD8+CD44high T cells were increased after TAC. These findings indicate a 
contribution of activated CD4+ cells on ongoing immune responses in the failing heart.  
Examination of the cytokine profile of T helper cells in cMy-mOVA/OT-II mice after TAC operation 
revealed a polarization mainly towards an inflammatory Th1 and Th17 response, showing an increased 
proportion of CD4+ T cells positive for IL-6, IL-17A, IFNγ and TNFα. This was also previously found in 
C57BL/6 mice, in which more CD4+ cells expressing IFNγ and IL-17A were present after TAC operation 
(Sasse et al., unpublished data). Nevers et al. (2015) reported an upregulation of TNFα, IL-1β, IL-6 and 
IFNγ after TAC operation compared to controls. A further study confirmed a significant increase of Th1 
cytokines, and a decrease of Th2 type cytokines in TAC-, compared to sham-operated animals 
(Laroumanie et al., 2014). While the Th1 response is triggering macrophage activation and cell-
mediated immunity, the Th17 response is involved in several autoimmune diseases in mice and human, 
including murine models of MS (EAE) (Komiyama et al., 2006), rheumatoid arthritis (Yen et al., 2006), 
psoriasis (Li et al., 2004a) and colitis (Littman and Rudensky, 2010). An upregulation ICAM-1 and the 
increased T cell infiltration after TAC was recently shown to be induced by cardiac cytokines IL-1β and 




Generally, due to the detection of autoantibodies in patients and animals models of various cardiac 
diseases (Kaya et al., 2012), it was further analyzed whether antibodies were induced by increased 
afterload in cMy-mOVA mice. Analysis of these animals showed that no OVA-specific IgG 
autoantibodies were induced after TAC (Röhrborn et al., unpublished data). Challenging the mice with 
additional T cells against OVA in this thesis showed that neither in cMy-mOVA mice that obtained 
OVA-specific T cells by adoptive transfer, nor in cMy-mOVA/OT-II mice antibody generation against 
OVA was induced. 
 
5.1.3 The role of adaptive immune responses in the progression to heart failure 
Increased numbers of infiltrating lymphocytes suggested an involvement of adaptive immune 
responses in the progression to HF in the murine afterload model of TAC (Yndestad et al., 2006) as 
well as in humans (Yndestad et al., 2003). When wildtype and immunodeficient RAG2-/-γc-/- mice were 
compared, it was found that lymphocytes promote cardiac hypertrophy in response to an increased 
afterload but are not required for the progression to HF (Sasse et al., unpublished data). However, 
analysis of RAG2-/- mice in another study revealed that the transition from hypertrophy to HF was 
attenuated at 6 weeks after TAC operation compared to immunocompetent animals (Laroumanie et 
al., 2014). This effect disappeared with reconstitution of T cells into the immunodeficient mice 
(Laroumanie et al., 2014), inferring an effect of T cells on cardiac function. Generally, an increased 
afterload in C57BL/6 mice reduced heart function as measured by FAS and EF compared to control 
mice (Patten and Hall-Porter, 2009; Sasse et al., unpublished data; Toischer et al., 2010). These effect 
were not observed after TAC in mice deficient for TCRα. These animals did not displayed hypertrophy 
or impaired cardiac function at 4 weeks after TAC surgery (Nevers et al., 2015), indicating an important 
role of T lymphocytes on the deterioration towards HF. Additionally, cardiac hypertrophy and fibrosis 
of the myocardium were not detectable in those mice, further suggesting T cells as regulators of these 
processes. The pharmacological depletion of T cells in the onset of HF by administration of an anti-
CD3 antibody into TAC-operated C57BL/6 mice led to improved cardiac function although mice 
displayed cardiac hypertrophy (Nevers et al., 2015). Laroumanie et al. (2014) examined the 
importance of CD4+ and CD8+ T lymphocytes on the adverse remodeling in HF by using either CD4-
deficient (MHC-II-/-) or CD8-deficient (CD8-/-) mice. In contrast to CD8-/- mice which developed cardiac 
failure, CD4-deficient mice showed attenuated cardiac remodeling and preserved cardiac function at 
6 weeks after TAC surgery compared to controls. Notably, OT-II mice, with transgenic CD4+ T cells 




These findings indicate an antigen-specific mechanism of CD4+ T cells that affects the progression to 
HF, which was further investigated in the cMy-mOVA model.  
 
5.1.4 Increased numbers of autoreactive T cells accelerate progression of load-induced 
heart failure 
Since various autoantibodies against cardiac antigens were found in patients with HF and other cardiac 
disease studies, autoimmunity was suggested to be associated with the progression to HF (Kaya et al., 
2012). Röhrborn et al. analyzed whether the expression of OVA as cardiac antigen accelerates the 
progression to HF after TAC operation in cMy-mOVA mice. However, heart function was in general not 
altered compared to C57BL/6 wildtype mice. Moreover, the additional transfer of autoreactive T cells 
against OVA into cMy-mOVA mice was not sufficient to affect fibrosis, heart weight or hypertrophy 
neither after OT-I nor after OT-I and OT-II T cell transfer as shown in this thesis. Higher numbers of 
autoreactive CD4+ T cells in cMy-mOVA/OT-II mice accelerated progression to HF after TAC operation 
compared to cMy-mOVA mice. Unfortunately, the breeding of cMy-mOVA/OT-I mice failed due to 
early mortality of mice after birth (day 1 to 5). In conclusion, these findings demonstrate that a 
pathological increase of cardiac afterload can be sufficient to break the immunological tolerance of 
CD4+ and CD8+ T cells, even in young and healthy mice. In a model for virus-induced myocarditis, it 
was found that inoculation of an OVA-expressing vesicular stomatitis virus into cMy-mOVA mice only 
affected heart function after the animals additionally received adoptive transfer of naïve CD8+ T cells 
of OT-I mice (Grabie et al., 2003), indicating that immunological tolerance can be broken by virus 
infection if enough autoreactive CTLs are present.  
The role of CD4+ cells was previously indicated to be important for the deterioration of cardiac function 
after TAC in C57BL/6 mice (Laroumanie et al., 2014), although our group could not prove their 
necessity for those processes (Sasse et al., unpublished data). In this thesis it was shown that high 
numbers of CD4+ T cells with specificity for a cardiac antigen are sufficient to induce autoimmune 
reactions after TAC and accelerate the progression to HF. Previous findings indicated an involvement 
of antibodies in immune responses responsible for the progression to HF due to detection of cardiac 
autoantibodies (Kaya et al., 2012). However, this thesis proved that heart function was affected by 




5.1.5 Immune mechanisms contributing to heart failure 
Generally, in response to tissue injury in the heart, resulting from pathogens or environmental injury 
such as hemodynamic overloading or ischemia, innate immune responses become activated. Cardiac 
innate immune responses are initiated by the detection of damage associated molecular patterns 
(DAMPs) or pathogen associated molecular patterns (PAMPs) by pattern recognition receptors (PRRs), 
which not only detect infiltrating pathogens, e.g. bacteria but were also shown to recognize molecular 
patterns of endogenous material released after heart injury by damaged or dying cells (Mann, 2015). 
Subsequently, neutrophils and monocytes in the damaged tissue area become activated through 
engagement of extracellular or intracellular PRRs, leading to short term adaptation of the heart to the 
abnormal conditions. In addition to many resident tissue macrophages in the heart, which were 
established during embryonic development and contribute to cardiac recovery, the infiltration of bone 
marrow-derived neutrophils and monocytes lead to a pro-inflammatory stress response within the 
myocardium. This has been shown to contribute to further tissue damage, progressive fibrosis and 
adverse cardiac remodeling (Epelman et al., 2015; Lavine et al., 2014). It is assumed that the 
myocardium adapts to environmental stress by synthesizing a variety of cytoprotective factors such 
as adenosine and nitric oxide (Bolli et al., 1997; Downey et al., 1993). It responds to various 
endogenous stress-induced factors including basic fibroblast growth factor (bFGF), TGFβ, vascular 
endothelial growth factor (VEGF) and angiotensin II (Eghbali, 1989; Hammond et al., 1984; Li et al., 
1997; Sadoshima et al., 1993; Weiner and Swain, 1989). This limits cell injury by upregulation of 
cytoprotective factors and facilitate subsequent tissue repair. If cardiac homeostasis cannot be 
restored, overexpression of these factors can lead to a chronic low grad inflammation, which 
contributes to further disease progression and infiltration of further immune cells. An increased 
afterload was shown to lead to a significant up-regulation of Toll-like receptor genes, such as Tlr2, 
apoptosis-related genes such as Casp3, genes encoding chemokines attracting myeloid cells including 
Ccl9, genes for adhesion molecules (Icam-1, Vcam-1, E-selectin), and chemokine receptor genes 
expressed on myeloid cells, such as Ccr1 as examined in hearts of C57BL/6 mice 1 week (Sasse et al., 
unpublished data) or 4 weeks after TAC (Nevers et al., 2015). Additionally, stress-inducible ligands 
including Rae1, Ulbp1 and H60 of the murine NK receptor NKG2D, which functions as costimulatory 
molecule on T cells were found to be significantly upregulated 1 week after TAC surgery (Sasse et al., 
unpublished data). Usually, these mouse ligands and their human counterparts (MICA, MICB,  
ULBP1-6), are constitutively expressed on only few cell types but become inducible by proteotoxic and 




but also in many autoimmune diseases (Ogasawara and Lanier, 2005; Ogasawara et al., 2004; Salih et 
al., 2003). The gene encoding NKG2D itself, Klrk1, was also significantly up-regulated at this time point 
suggesting the presence of cells, which can respond to the NKG2D ligands (Sasse et al., unpublished 
data). Due to the early upregulation of these ligands in the myocardium after TAC surgery, non-
professional APCs could co-stimulate and thereby activate naïve T cells, which were found to infiltrate 
the myocardium. Thus, T cells with specificity for cardiac autoantigens might become activated also 
by non-professional APCs including cardiomyocytes. Additionally, professional APCs, i.e. DCs, could 
take up antigens released from damaged cells in the myocardium, maturate in response to DAMPs 
and proinflammatory cytokines, and activate autoreactive T cells in regional lymph nodes that escaped 
central tolerance. Notably, it was found that not all cardiac antigens are expressed by thymic 
medullary epithelial cells as shown for α-MHC, revealing that α-MHC reactive CD4+ T cells were even 
found in the blood of healthy patients (Lv et al., 2011). After activation of T lymphocytes, autoreactive 
cells either directly affect the myocardium, as e.g. CTLs do, or enhance the inflammatory function of 
other cells e.g. by helping B cells produce pathogenic antibodies as shown for T helper cells. 
Additionally, the polarization of CD4+ T cells, into Th1 and Th17 cells, as shown in cMy-mOVA/OT-II mice 
seems to exert adverse effects on the myocardium. Significantly more CD4+ T cells expressing 
inflammatory (IL-6, TNF-), Th1 (IFN-), Th17 (IL-17A), and at very low level Th2 (IL-4) cytokines were 
present after TAC surgery compared to controls. IFN-γ, which is produced by CD4+ Th1, CD8+ CTL, NK 
and NKT cells, is known to have multiple proinflammatory effects (Lichtman, 2013). However, it also 
exhibits anti-inflammatory effects including feedback inhibition of effector T cells that produce the 
cytokine, thereby limiting T cell activation and T cell mediated inflammatory damage to the 
myocardium (Lichtman, 2013). Moreover, IL-6 seems to play a critical role in the pathogenesis of LV 
hypertrophy in response to pressure overload since genetic deletion led to alleviation of hypertrophy 
and cardiac dysfunction (Zhao et al., 2016). Th17 cells produce IL-17, a cytokine associated with 
neutrophilic inflammation, that was shown to affect cardiac fibroblasts, thereby promoting fibrosis, 
but not the severity of inflammation in autoimmune myocarditis (Baldeviano et al., 2010). Moreover, 
it has been shown that a blockade of IL-17A improves the LV function of the heart and lowers 
cardiomyocyte apoptosis and neutrophil recruitment (Liao et al., 2012). The fact that infiltrating T cells 
have influence on cardiac remodeling of the myocardium was additionally proven in a mouse model 
of T cell deficiency (TCRα-/-) since these mice displayed reduced fibrosis and hypertrophy, improved 




In conclusion, inflammatory CD4+ T cells and their cytokine products are involved in the progression 
to HF, leading to an increased damage of the myocardium. 
 
5.1.6 Summary and future perspectives 
These data show that CTLs as well as CD4+ T cells specific for OVA as cardiac antigen can become 
activated in a model of increased afterload and promote the progression from hypertrophy to HF. 
Interestingly, T helper cells seem to deteriorate heart function by a mechanism independent of 
antibody induction, since no OVA-specific antibodies were found neither in cMy-mOVA/OT-II nor in 
cMy-mOVA mice which received adoptive transfer of CD4+ and CD8+ T cells. Such direct effects on 
heart function might be of interest if those autoreactive T cells exist in subgroups of patients with HF 
either alone or in combination with cardiac autoantibodies, since autoimmune processes can be 
targeted by established or newly developed therapeutics. Thus, it could be possible to decrease or 
slow the risk of transition into manifest HF in those patients and prevent long term 
immunosuppression if the activation of these autoreactive T cells could be prevented by short-term 
intervention in time periods of increased risk, e.g., after acute cardiac ischemia. 
 
5.2 Stem cell immunogenicity 
Stem cells are important tools for future regenerative medicine since they can be differentiated to 
various cells types and therefore replacing or promoting damaged or diseased tissue. However, it is 
necessary to evaluate the immunogenicity of transplanted material to reduce the risk of graft 
rejection. The role of the highly polymorphic MHC was previously studied, whereas miHC antigens 
were so far mostly disregarded. However, clarification of the immunogenicity of those antigens is 
critical since they cannot be matched in allogenic transplantations, which are expected to be clinically 
most relevant. Therefore, OVA-expressing stem cells, i.e. iPSCs and ESCs, were analyzed regarding 
their engraftment and their effects on effector cell activation in otherwise syngeneic recipients. 
Additionally, expression of immune-evading or immunogenicity-causing genes in stem cells was 







5.2.1 Influence of minor histocompatibility antigen expression on stem cell immunity  
The expression of other antigens besides MHC and ABO antigens were reported to influence the 
outcome of transplantation, i.e. transplantations between MHC-matched individuals led to the 
development of GVHD or resulted in T cell-mediated graft failure (Ferrara et al., 2009; Opelz and 
Collaborative Transplant Study, 2005). These immune reactions are likely elicited by the expression of 
variant miHC antigens between donor and recipient, leading to activation of CD4+ and CD8+ T cell 
alloresponses. To study the effects of miHC antigen expression for transplantations of stem cell-
derived grafts, several murine stem cell lines were transfected with an OVA-eGFP fusion construct to 
express the model antigen OVA (Monecke, 2013). The analysis of OVA-expressing stem cell in vitro 
revealed that the antigen processing and consequently antigen presentation of murine stem cells was 
impaired (Monecke, 2013). The antigen processing and presentation via the MHC class I pathway leads 
to the cell surface expression of MHC class I molecules, which confers susceptibility of cells to the 
cytotoxicity of CTLs. As previously reported, murine PSCs lack surface expression of MHC class I 
molecules, which is also not inducible by IFNγ (Abdullah et al., 2007; Monecke, 2013; Nussbaum et al., 
2007; Tian et al., 1997). The stem cell lines transfected with OVA-eGFP were not killed by OVA-specific 
CTLs in vitro analyzed in cytotoxicity assays (Monecke, 2013). However, the supplement of processed 
OVA peptide SIINFEKL increased the lysis rate of all tested stem cells, including iPSCs, ESCs and 
maGSCs, demonstrating that PSCs were not generally protected against CTL cytotoxicity. In co-culture 
experiments with OVA-specific T cells, it was demonstrated that PSCs were able to actively suppress 
T cell activation in vitro, mediated by cell-cell contact of PSCs and T cells (Monecke, 2013). In addition 
to data describing immune-escape or tolerance-inducing mechanisms of stem cells, e.g. by expression 
of Arg1 and IDO, these findings suggest that PSC are at least in vitro resistant against immune 
responses. Nevertheless, T cell-mediated immune responses against murine PSCs were monitored in 
vivo (Boyd and Wood, 2009; Dressel et al., 2009; Robertson et al., 2007; Wu et al., 2008). To further 
characterize the effect of miHC antigens expressed by stem cells or stem cell-derived grafts on 
engraftment and stem cell immunogenicity, OVA-expressing stem cells were analyzed in vivo 
compared to their wildtype counterparts in this thesis. It was hypothesized that adaptive immune 
reactions against OVA as a single miHC antigen in otherwise syngeneic hosts might affect 
transplantations of stem cells and stem cell-derived grafts in vivo. For this, OVA-expressing ESCs and 
iPSCs and wildtype stem cells were injected into otherwise syngeneic mice to examine their 





5.2.1.1 Expression of OVA as miHC antigen affects engraftment of stem cells in 
immunocompetent syngeneic hosts 
To exclude clonal abnormalities due to OVA expression, OVA-expressing and wildtype stem cells were 
inoculated into immunodeficient mice to monitor teratoma growth and exclude potentially aberrant 
cell clones. The expression of OVA on iPSCs and ESCs showed no general effects on teratoma 
formation compared to wildtype stem cells. To examine whether OVA-specific T cells impair the 
engraftment of OVA-expressing PSCs, TCR-transgenic T cells, i.e. CD4+ and/or CD8+ T cells, specific for 
OVA, were transferred into the immunodeficient animals after stem cell inoculation. However, the 
presence of the OVA-specific T cells did not impair engraftment of OVA-expressing stem cells. In 
contrast, inoculation of OVA-expressing stem cells into immunocompetent but otherwise syngeneic 
animals revealed differences in the engraftment, i.e. tumor formation rate, compared to inoculated 
wildtype stem cells. Animals which were inoculated with OVA-expressing iPSCs or ESCs displayed a 
significant reduced tumor formation rate, suggesting OVA-specific immune responses towards the 
transplanted cells. Generally, tumors derived from OVA-expressing stem cells were significantly 
smaller and lighter compared to teratomas of wildtype stem cells and to those formed in 
immunodeficient mice, indicating an influence of immune cells on the formation of teratomas. The 
analysis whether Y-chromosome derived (HY) antigens might additionally influence the outcome of 
transplantation, tumor formation of male stem cells in female host was monitored. Noticeably, the 
expression of those antigens seem to have an additional effect on tumor formation since tumor rate 
was markedly reduced in female mice (8 %), compared to male hosts (46 %) but only for tumors 
derived from OVA-expressing stem cells. This indicates an enhancing effect of HY antigens on the 
rejection process of OVA-expressing stem cells. These data are in accord with a previous small scale 
study in our group (Monecke, 2013). Analysis of mouse embryogenesis revealed that HY antigens are 
already expressed at the eight cell stage of the embryo and might therefore affect stem cell 
immunogenicity (Krco and Goldberg, 1976). Infiltration of leukocytes was observed in all teratomas 
derived from wildtype and OVA-expressing stem cells. However, teratomas derived from OVA-
expressing stem cells showed increased numbers of infiltrating leukocytes. The infiltration of 
leukocytes into teratomas derived from PSCs in syngeneic hosts was previously shown in several 
studies (Dressel et al., 2008; Kofidis et al., 2005).  
Clonal differences in proliferation capacity and growth rate between cell clones resulted in slightly 
variable tumor formation rates, variable tumor size, weight and variations in the duration of 




expression like HY antigens and antigen independent effector mechanisms as NK cell killing possibly 
contributed to smaller differences in tumor size and weight. Monitored distinctions between tumors 
derived from OVA-expressing stem cell clones might be explained by the variant expression of OVA by 
single cell clones and its reduction with differentiation. QPCR analysis revealed that the transgene 
expression was distinctly reduced in teratomas compared to its expression in PSCs. The loss of 
transgene expression over differentiation might happen due to epigenetic changes during the 
differentiation process, resulting in silencing of the genomic loci in which the OVA-eGFP transgene 
had integrated. To overcome this problem, the transgene construct was inserted into the Rosa26 
locus, which was reported to be constitutively expressed with differentiation (Kisseberth et al., 1999). 
Investigations concerning the immunogenicity of those stem cells are still ongoing (Petrov et al., 
unpublished data). Transgene expression differed between iPSCs and ESCs but also displayed 
interclonal variations which affect the overall immunogenicity of each stem cell clone. An already low 
transgene expression in teratomas formed in immunodeficient mice can be explained by transgene 
loss due to differentiation. In contrast, a lower expression of OVA in immunocompetent than in 
immunodeficient animals was probably caused by immune effecter activation against OVA which 
eliminates OVA-expressing cells. Despite the loss of OVA expression with differentiation, it was 
demonstrated that inoculated OVA-expressing stem cells displayed a significantly reduced rate of 
engraftment in immunocompetent mice. This demonstrates that the expression of OVA was still 
sufficient to elicit an immune effector response. 
 
5.2.1.2 Expression of a miHC antigen led to OVA-specific cytotoxic T lymphocyte induction 
Already immunodeficient animals which were inoculated with OVA-expressing stem cells and 
additionally received transfer of OVA-specific T cells from OT-I and OT-II mice displayed altered 
immune responses compared to animals which received wildtype PSCs. Analysis of transferred T cells 
shortly after the transfer and after experimental ending revealed that CD8+ T cells became activated, 
showing proliferation in vivo and were able to directly kill OVA-expressing target cells when tested in 
vitro in cytotoxicity assays. Surprisingly, all OVA-expressing stem cell injections resulted in teratoma 
formation despite the proven activation of OVA-specific T cells and their infiltration into the 
teratomas. However, an influence of these cells on teratoma growth was shown in animals that 
displayed rapid proliferating CD8+ T cells, which was associated with a prolonged survival of the hosts. 




outranging small numbers of transferred T cells or the loss of transgene expression in stem cells over 
differentiation. In syngeneic immunocompetent host, the effect of OVA expression in the inoculated 
stem cells was investigated in an immunologically fully functional environment. To determine the 
activation status against OVA as miHC antigen, splenocytes were in vitro restimulated after 
experimental ending (up to 90 days) and used as effector cells in cytotoxicity assays. Noticeable, only 
splenocytes of animals which received injections of OVA-expressing stem cells were able to efficiently 
kill the OVA-expressing RMA target cell line, in contrast to splenocytes of animals, which received 
wildtype stem cells. This indicates that OVA-specific CTLs arose in the animals that obtained injections 
of OVA-expressing stem cells. Additionally, this could be already shown in animals 1 week after stem 
cell inoculation, revealing an early activation of CTLs after stem cell injection. Surprisingly, even the 
injection of not fully pluripotent stem cells whose injection did not led to tumor formation in 
immunodeficient mice, led to an induction of OVA-specific CTLs in immunocompetent hosts. 
Consequently, the inoculation of OVA-expressing stem cells, which were not able to proliferate, 
differentiate or form teratomas in vivo, was sufficient to activate immune effector responses against 
the expressed antigen. PSCs did not express MHC class I molecules but these are required for peptide 
presentation to activate CTLs. It is known that with differentiation of PSCs towards embryoid bodies 
(EBs), MHC class I molecule expression is upregulated (Petrov et al., unpublished data; Suárez-Alvarez 
et al., 2010). Additionally, current investigations in our group showed that components for the antigen 
processing machinery are also increased with differentiation to EBs (Petrov et al., unpublished data), 
leading to an augmented potential to present peptides and to become targets of peptide-specific CTLs. 
OVA-specific CTLs must have exerted an effect on the growth of OVA-expressing PSCs after 
differentiation, since the PSCs themselves were not able to process and present this antigen. However, 
some teratomas might have escaped rejection by down-regulation of OVA expressions. 
 
5.2.1.3 Expression of a miHC antigen resulted in OVA-specific antibody generation and CD4+ T 
cell activation 
To clarify whether the expression of OVA in stem cells led to B cell activation and antibody production, 
sera of animals were examined in ELISA assays to determine the anti-OVA antibody titer in animals, 
which received either wildtype or OVA-expressing stem cells. At the early point of time 1 week after 
stem cell inoculation, no induction of anti-OVA antibodies were detected in the sera of animals. 
However, after experimental ending (up to 90 days), anti-OVA antibodies were found in animals, 




animals. Strikingly, anti-OVA titers were significantly higher in animals, which received OVA-expressing 
stem cells and displayed teratoma formation in contrast to animals, which obtained the same stem 
cells but did not develop any tumors. This could be explained by the early activation of CTLs or NK cells 
in the host, leading to rapid rejection of the graft and elimination of the immunogenic antigen, i.e. 
OVA. In contrast, if those cells were not able to completely reject teratomas, OVA would be expressed 
in the forming tissue, enabling an increased immune response against this miHC antigen by CD4+ T 
and B cells.  
Whether CD4+ T cells specific for OVA were involved in the antibody generation of hosts was further 
determined by characterization of generated antibody isotype subclasses. Major proportion of OVA 
antibodies were of the IgG1 and IgG2b isotypes, indicating a class switch in OVA-specific B cells which 
requires the interaction with antigen-specific CD4+ T cells to induce the class switch since the OVA 
protein is a thymus-dependent antigen.  
Generally, the presumed time for humoral response after primary antibody exposure is up to 14 days 
(Ademokun and Dunn-Walters, 2010). Consequently, humoral response against OVA was not 
detectable early after transplantation but developed with tumor formation of inoculated stem cells, 
showing that expression of miHC antigens is sufficient to induce an antibody response of the host. At 
this, not only antigen-specific B lymphocytes but also antigen-specific CD4+ T lymphocytes became 
activated in syngeneic hosts after inoculation of stem cells expressing OVA as single miHC antigen. 
Due to the absent expression of MHC class II molecules, PSC itself unlikely function as professional 
APCs for CD4+ T cell activation. However, with differentiation to epithelial cells which serve as atypical 
APCs since they express MHC class II molecules, CD4+ T lymphocytes could be activated by direct 
allorecognition (Hershberg et al., 1998; Kreisel et al., 2002). More likely, OVA peptides derived from 
apoptotic PSCs or teratoma cells are taken up by host APCs and presented to CD4+ T lymphocytes via 
the indirect allorecognition pathway. Activated T helper cells then further activate and enhance CTL 
and B lymphocyte effector function. 
 
5.2.2 NK cells supported killing of stem cells 
Due to the rather low expression of MHC class I molecules, which served as ligands for inhibitory NK 
cell receptors, stem cells can also become targets for NK cells. The susceptibility of PSCs to NK cell 
killing was previously shown for murine and human cells, demonstrating that besides xenogeneic and 




Kruse, Hamann et al., 2015; Tian et al., 2006). Therefore, the contribution of NK cell killing in the 
rejection of inoculated stem cells was additionally examined by cytotoxicity assays in which a NK cell-
sensitive target cells line was used as target cell. The lysis of the target cell line by splenocytes obtained 
of animals that received OVA-expressing stem cells was distinctly higher compared to lysis by 
splenocytes of hosts, which were injected with wildtype stem cells. At this, a proinflammatory 
environment due to adaptive effector responses against OVA would increase the capability of NK cells 
to kill PSCs.  
 
5.2.3 Analysis of mechanisms potentially influencing the immunogenicity of stem cell and 
stem cell-derived grafts 
5.2.3.1 Negligible expression of immunogenic genes in stem cells and their derivates 
Initially, Zhao et al. reported that iPSCs were associated with the overexpression of so-called 
immunogenicity-causing genes, affecting the outcome of transplantion, i.e. teratoma formation, in a 
mouse model (Zhao et al., 2011). Since then, several investigations concerning the potential 
expression and impact of these genes, Cyp3a11, Hormad1 and Zg16, on the immunogenicity of iPSC 
compared to ESCs were implemented. Murine studies showed that in contrast to the initial study, 
neither differentiated cells nor undifferentiated iPSCs displayed variant expression of those genes 
compared to ESCs and their derivates (Araki et al., 2013; Guha et al., 2013). These findings were 
confirmed in this thesis since expression of Zg16, Hormad1 and Cyp3a11 in PSCs and derived 
teratomas was detected only on a minimal level and did not show noticeable variations between stem 
cell types or differentiation status. In accordance with these findings, examination of human ESCs and 
iPSCs via qPCR and flow cytometric analysis demonstrated similar gene and protein expression of 
Zg16, Hormad1 and Cyp3a11 regardless of their differentiation status (Maynard et al., 2014). 
Nevertheless, further analysis of ZG16 and HORMAD1 in human stem cells and their differentiation 
products evinced that HORMAD1 expression in hESCs and hiPSCs derivates was very low and 
heterogeneous, but ZG16 expression increased significantly on differentiation of hPSCs into clinically 
relevant cell derivates as hepatocytes, cardiomyocytes and oligodendrocytes (Awe et al., 2015). 
However, modified peripheral blood mononuclear cell (PBMC) co-culture assays in vitro revealed no 
acute immune response due to ZG16 expression, indicating no significant immunogenicity of this gene 





5.2.3.2 Expression of immune-mediating enzymes 
Immune privilege was previously reported for several stem cell types including ESCs and mesenchymal 
stem cells (MSCs) (Li et al., 2004b; Uccelli et al., 2008). It comprises cellular, molecular or anatomical 
mechanisms to prevent cells or tissue from immunological pursuit by the immune system (Figure 59). 
This includes passive forms of antigenic invisibility, e.g. achieved by the lack of antigen presentation, 
or active immune regulation to prevent antigen recognition. Evasion of antigen recognition due to 
immunological barriers, e.g. the blood brain barrier (BBB), can lead to immune activation if that 
isolation breaks down or is bypassed by primed immune cells, eventually causing autoimmunity. 
Therefore, most of the classical immune-privileged sites, e.g. the eye, exhibit additional active immune 
regulation, which locally suppress the adaptive immune response against a target antigen. ESC-
derived tissues as well as adult stem cells were reported to exhibit several of these features to evade 
immune recognition by the organism. 
 
Despite their restricted differentiation potential, adult stem cells are required for the homeostasis and 
regeneration of various tissues in the adult organism. They are located in specialized niches, kept 
quiescent and uncompromised by autoimmune or inflammatory responses until their proliferation 
and differentiation is needed (Liu et al., 2009; Uccelli et al., 2008; Zavazava, 2013). It is postulated that 
these niches serve as a protective microenvironment besides the own immune-privilege of the adult 
 
Figure 59 Strategies to 
achieve immune privilege, 
e.g. by cell recruitment, 




sites possess mechanisms of 
active or passive immune 
evasion, or both 
simultaneously. uNK: uterine 
NK cells; BBB: blood brain 
barrier; ag: antigen. Picture 





stem cells. However, it was highly debated whether ESCs, derived from the ICM of the early blastocyst, 
exhibit similar immune escape properties. Additionally, the immune regulatory capabilities of other 
stem cell types were investigated since it is important for future regenerative medicine to achieve 
tolerance to transplanted grafts by the recipient.  
A possibility to influence immune recognitions is the limitation of essential amino acids in a local 
environment. This can lead to interference of immune responses since lymphocytes require those fore 
rapid proliferation and effector function and are therefore especially sensitive to amino acid 
starvation (Calder, 2006; Chuang et al., 1990). Consequently, lowering the availability of essential 
amino acids in a tissue might lead to acquisition of immune privilege. It was previously shown that 
Indoleamine 2,3-dioxygenas (IDO), an intracellular enzyme that catabolized tryptophan, is not only an 
important factor for immune privilege during pregnancy but its expression was also found in DCs (Metz 
et al., 2007; Munn et al., 1998). Here, antigen presentation during tryptophan deprivation cause a 
polarization of CD4+ T cells towards the Treg phenotype (Fallarino et al., 2006). Additionally, the 
depletion of other essential amino acids, e.g. of arginine by Arginase 1, were found to modulate T cell 
responses (Bronte and Zanovello, 2005; Cobbold et al., 2009). It is assumed, that Ido expression on 
MSCs led to an immunosuppressive function in the human body (Su et al., 2014). In previous murine 
studies, only low amounts of Ido RNA and protein were found on ESCs and no contribution of IDO to 
immune suppressive activity of ESCs could be confirmed (Han et al., 2011; Monecke, 2013). In 
accordance with these studies, only very low RNA expression of Ido was discovered in PSCs in this 
thesis. After in vivo differentiation into teratomas, most tumors showed an increased level of Ido 
expression compared to PSCs but still lower than placenta tissue. However, in single animals, a 
tremendous amount of Ido, was expressed in teratomas derived from ES cells, outweighing the 
expression in the control. This indicates that undirected differentiation of stem cells can lead to an 
upregulation of Ido expression, which might influence the immunogenicity of the cells or tissue. In 
literature, this could be shown for several carcinomas, in which overexpression of Ido was associated 
with immune escape mechanisms of those tumors (Brandacher et al., 2006; Ozaki et al., 1988; Pan et 
al., 2008; Platten et al., 2012; Thaker et al., 2013). For Arg1 is was previously reported that its 
expression in tumor cell led to an ineffective anti-tumor immune response, but did not result in the 
complete inhibition of anti-tumor immune reactions (Korrer and Routes, 2014). However, other 
studies showed that the amino acid Arginine is important for tumor cells and suggested ARG1 as 
potential enzyme for anti-cancer therapy (Patil et al., 2016). In previous ES cell studies, it was 




of T cell activity (Yachimovich-Cohen et al., 2010). However, in vitro studies of murine ESCs revealed 
that Arg1 was not involved in the inhibition of co-cultured T cells since its expression was not 
detectable via qPCR analysis (Monecke, 2013). However, in this thesis a low expression of Arg1 was 
discovered in iPSC and ESC clones, which increased with differentiation during teratoma formation. 
However, whether this influences the immunogenicity of stem cell-derived tissues needs to be 
clarified. 
 
5.2.4 MiHC antigen expression affects engraftment by inducing an antigen dependent 
immune response – Summary and Outlook  
We could prove in this thesis that the expression of miHC antigens in PSCs led to adaptive immune 
effector activation in vivo. Thus, the in vivo immunogenicity of PSCs is highly different to its previously 
reported in vitro non-immunogenicity. In vitro, PSCs exhibited rather immunosuppressive features. 
However, with transplantation, the risk of indirect antigen presentation increases due to protein 
release from damaged or apoptotic cells. Additionally, the upregulation of MHC class I, as caused by 
differentiation of PSCs and/or an inflammatory environment, increases the risk of peptide-specific CTL 
responses towards miHC antigens. Consequently, variant miHC antigens have to be considered as 
immunogenic in PSCs in allogeneic transplantation settings even when MHC molecules are matched.  
MiHC antigens are generated by the intracellular degradation of polymorphic proteins which originate 
from polymorphisms in single nucleotide polymorphisms (SNPs), copy number variations (CNVs) or 
base-pair insertions or deletions (indels) (Hombrink et al., 2013). Since PSC-derived grafts are seen as 
new source for therapeutic transplantations, potential acquisition of neoantigens might occur due to 
incomplete or aberrant reprogramming of adult donor cells or the reprogramming itself, e.g. after 
integration of transcription factors into the genome (Takahashi and Yamanaka, 2006). Since the 
immune system has not encountered those antigens before, it is most likely that the tolerance 
towards these neoantigens is lacking. It was already reported that in more than 80 % of analyzed 
healthy patients OCT4-specific T cells, mainly CD4+ cells, were detected, indicating a feasible immune 
response against cells expressing this embryonic antigen like stem cells (Dhodapkar et al., 2010).  
Currently described miHC antigens include antigens encoded e.g. by sex chromosomes, derived from 
the Y chromosome, known as HY antigens. HY antigens are expressed among others on human 
hematopoietic progenitor cells which were already early assumed to affect hematopoietic stem cell 




organs, in which HY-mismatching was shown to correlate with clinical outcome and acute graft 
rejection (Gratwohl et al., 2008; Tan et al., 2008). Moreover, several miHC antigens are encoded by 
autosomal genes, as HA1 – HA8, which are even found in mitochondrial DNA, named maternally 
transmitted antigens (MTA) (López-Larrea, 2012). It was shown for SCNT-derived ESCs that 
mismatched mitochondria affected graft survival, however the group did not clarify by which 
mechanisms (Deuse et al., 2015). The tissue distribution of known miHC antigens ranged from 
exclusive expression on hematopoietic cells, i.e. HA1, HA2, to broader expression as for HY, HA3 and 
HA4 antigens (Goulmy, 1996; Warren et al., 1998).  
Initially, murine skin graft rejection models revealed that a mismatch of MHC molecules between 
donor and recipient led to rapid graft rejection (Rosenberg and Singer, 1992). The transfer of T cells 
from a sensitized donor to a naïve recipient accelerated the graft rejection, indicating that  
T lymphocytes caused this immune response. In experiments where donor and recipient were MHC-
matched but differed in miHC antigens, a slower graft rejection was monitored (Rosenberg and Singer, 
1992), initially revealing that miHC antigen can influence the success of transplantations. Most 
available clinical data concerning miHC antigen mismatch in humans were found in the field of 
hematopoietic stem cell transplantations (HSCT). Here, it was reported that the expression of 
disparate miHC antigens increased the risk to develop acute graft versus host disease (GvHD) 
(Dzierzak-Mietla et al., 2012; Goulmy et al., 1996; Santos et al., 2016; Tseng et al., 1999) and chronic 
GvHD (Dzierzak-Mietla et al., 2012; Markiewicz et al., 2009; Mutis, 2015; Nakasone et al., 2015). 
Studies about discrepancies in miHC antigen expression in solid organ transplantation are still rare and 
controversial. For instance patient studies on autosomal MHC class I-restricted miHC antigens in 
kidney transplantations revealed no effects of minor miHC antigen mismatching (Dierselhuis et al., 
2013; Heinold et al., 2008). However, other studies showed an influence of miHC antigen discrepancies 
on the outcome of transplantation as HY-mismatching affected the clinical outcome of kidney and 
cornea transplantations (Böhringer et al., 2006; Gratwohl et al., 2008; Tan et al., 2008). The 
involvement of CD4+ T lymphocytes against HY antigens was shown to result in plasma cell infiltration 
into biopsied kidneys and antibody development against miHC antigens, which was consistent with 
findings of other groups (Porcheray et al., 2011; Spierings et al., 2003). In a study of miHC antigen 
mismatched skin and hematopoietic cell grafts, the role of direct presentation by donor DCs was 
evaluated. It revealed that direct presentation of miHC antigens by donor DCs is needed for an 
efficient rejection of grafts by CTLs but that in the absence of donor DCs an immune response is caused 




In this thesis, it was confirmed that indeed expression of miHC antigens elicit antigen-dependent 
immune responses mediated by miHC antigen-specific CTLs, helper T and B cells. For this an in vivo 
murine model of miHC mismatch, due to OVA expression in the inoculated stem cells, was used in 
teratoma formation assays in otherwise syngeneic hosts. Since stem cells and stem cell-derived grafts 
are a potential source for cell replacement therapies, our findings showing their immunogenicity have 
to be considered for future replacement therapies. However, the intensity of the influence that miHC 
antigens have on immune responses might depend on the miHC antigen itself and on the conditions 
of transplantation. Additionally, the differentiation status and type of transplanted cells might alter 
the possibility to activate adaptive immune responses against miHC antigens. Nonetheless, the 
identification of potential immunogenic miHC antigens in PSCs and in PSC-derived grafts would allow 
screening for functionally relevant incompatibilities between donor and recipient and would be a start 
to evaluate the immunogenicity of miHC antigens in vivo. At this, potential recipients at risk of graft 
rejections could be treated by specific immunosuppressive strategies.  
 
5.3 Killing of murine pluripotent stem cells largely depends on the activating NK receptor 
NKG2D 
NK cells play an important role as cytotoxic effector cells scanning the organism for stressed, infected 
or malignant cells. Future strategies to treat diseases, such as HF or Parkinson’s disease might include 
the transplantation of PSC-derived grafts. However, those grafts are at risk of giving rise to teratomas 
in the recipient, if residuals of undifferentiated cells are still present in the grafts after in vitro 
differentiation. Previously, it was shown that NK cells are able to kill various human and murine PSCs 
in xenogeneic, allogeneic and syngeneic experimental set-ups (Dressel et al., 2008, 2010; Kruse, 
Hamann et al., 2015; Tian et al., 2006). The involvement of NKGD2 receptors on NK cells in killing of 
PSCs was assumed (Feng et al., 2009; Kim et al., 2007; Ogasawara et al., 2005) and then shown in an 
inhibition study in our group in which anti-NKG2D antibodies were used for analysis (Dressel et al., 
2008, 2010). To confirm the influence of NKG2D in the killing of various PSCs, a mouse model of NKG2D 
deficiency was used to test whether the susceptibility of PSCs to NK cells was altered in those animals. 
Here, the killing of PSCs by NK cells of NKG2D-deficient mice was compared to NK cells derived from 
wildtype C57BL/6 mice. All analyzed PSCs, including syngeneic and allogenic (but MHC-matched) 
maGSCs, ESCs and iPSCs, showed cell surface expression of NKG2D ligands which made them to 




clarified in in vitro cytotoxicity assays, in which it was shown that all PSCs were largely resistant to 
killing by naïve NKG2D-deficient NK cells. At this, wildtype NK cells showed a moderate level of killing 
even without previous in vitro stimulation of the NK cells. However, the stimulation of NK cells with 
IL-2 led to an increased killing of the target cell lines by NKG2D-deficient and wildtype NK cells. 
Nonetheless, IL-2-activated wildtype NK cells still showed higher lysis rates than NKG2D-deficient NK 
cells. This indicates that the moderate killing of PSCs largely depends on NKG2D receptors if NK cells 
are not stimulated. After stimulation of NK cells, obviously also other pathways than NKG2D are used, 
leading to an increased but not fully reconstituted killing of PSCs when compared to wildtype NK cell 
killing. Other ligand-receptor interactions that partially compensate the absent NKG2D receptor might 
include the activating NK cell receptor DNAM-1. The ligands for DNAM-1 that are CD112 and CD155 
were found to be expressed on human and murine stem cells (Dressel et al., 2010; Kruse, Hamann et 
al., 2015). Examination of human iPSC susceptibility to NK cells revealed that here DNAM-1 was the 
main mediator of stem cell killing by NK cells, albeit in a single donor-target combination also NKG2D 
was shown to influence PSC susceptibility (Kruse, Hamann et al., 2015). Since only one inbred mouse 
strain was analyzed in this thesis, it is possible that the NK cell receptor-ligand interactions are more 
diverse amongst different strains with different genetic background, which was already indicated for 
humans (Kruse, Hamann et al., 2015). 
In conclusion, it was demonstrated that NKG2D is an important activating receptor involved in killing 
of murine PSCs, which was lately also shown to concern other stem cell-like tumors (Rong et al., 2016; 
Wei et al., 2015; Zhang et al., 2016). Consequently, this knowledge can be used to develop strategies 
to deplete contaminating PSCs before grafting, thereby increasing the safety of transplantations. 
Moreover, immunosuppressive therapies not affecting NK cells might be favorable, if allogeneic PSC-
derived grafts are transplanted to allow a killing of residual PSCs by the NK cells of the recipient. 
Summary and Conclusions 
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6 Summary and Conclusions 
In this thesis, the effect of immune responses on the pathogenesis of load-induced HF and the 
rejection of stem cell and stem cell-derived grafts was analyzed. It was shown that an increased 
afterload in a murine model of HF was sufficient to activate T helper cells with a specificity for an 
antigen expressed on cardiomyocytes and to accelerate the progression to HF in TCR-transgenic 
animals at risk to develop autoimmunity. T helper cells exerted their effect on the heart function 
independently of autoantibody induction. Thus, autoimmunity may contribute to the transition from 
hypertrophy to HF even when caused by an increased afterload. Immune reactions against cardiac 
antigens might also affect the chances to treat HF by new PSC-based therapies. The expression of a 
single miHC antigen in PSCs affected the engraftment in otherwise syngeneic hosts due to activation 
of adaptive immune responses including antigen-specific CTLs, T helper and B cells. Additionally, it was 
demonstrated that various stem cells became targets for NK cells and that NKG2D was an important 
activating receptor involved in killing of murine PSCs. These findings are important for future 
therapeutic applications, e.g. to prevent activation of autoimmune T cells in heart failure patients. 
Moreover, variant miHC antigen expression in transplantations between donor and recipients have to 
be considered. Consequently, a suitable immunosuppressive or immunomodulatory therapy primarily 
targeting adaptive immune cells is needed. NK cells might be important to eliminate residual PSCs 





7.1 Investigation of immune response contributing to the pathogenesis of load-induced 
heart failure 
7.1.1 Leukocyte cell composition of spleen and heart 
The splenocytes of animals which received a mixture of OT-I and OT-II T cells were further analyzed via 
flow cytometry to determine the proportion of myeloid cells and lymphocytes in the population. In 
total, 81.6 % (sham) to 82.8 % (TAC) of splenocytes were positive for the leukocyte marker CD45. This 
population of CD45+ cells included B cells (CD19+CD45R+ ), T cells (CD3+CD4+, CD3+CD8+), macrophages 
(F4/80+), NKT cells (CD3+DX5+), dendritic cells (CD11c+MHCII+), NK cells (CD3-DX5+), neutrophils 
(CD11b+Ly6G+), and monocytes (CD115+C11b+Ly6C+) listed in decreasing order of cell numbers (Figure 
60A). Most abundant cells were B cells which made up almost half of the leukocyte population  
(41.6 % (TAC) to 44 % (sham)) followed by T helper cells (16.2 % (sham) to 19.2 % (TAC)), cytotoxic T 
cells (9.5 % (sham) to 10.7 % (TAC)) and macrophages (9.1 % (TAC) to 9.3 % (sham)). The cell 
populations with lower cell numbers included NK T cells (1.3 % (TAC) to 3.1 % (sham)), dendritic cells 
(2.2 % (sham) to 2.3 % (TAC)), NK cells (0.9 % (sham) to 1.6 % (TAC)), neutrophils (1.1 % (sham) to  
1.2 % (TAC)) and monocytes (0.4 %). Analysis of the proportion of CD4+CD45.1+ cells in the leukocyte 
population of cMy-mOVA mice was determined, showing that 0.4 % of CD45+ cells derived from OT-II 
mice (CD45.1+), transferred via adoptive transfer. However, no significant differences in the splenocyte 
composition between TAC- and sham-operated animals were found. 
Additionally, heart tissue was digested to single cells and analyzed via flow cytometry to clarify the 
proportion of lymphocytes and myeloid cells in the target tissue itself. In hearts of TAC-operated 
animals 6.5 % and in sham-operated animals 3.4 % of cells were positive for CD45. Most abundant 
leukocytes in the myocardium of cMy-mOVA mice were macrophages, whose cell proportions ranged 
from 35.6 % (TAC) to 53.2 % (sham) of the total leukocyte population (Figure 60B). B cells, which were 
found in significantly higher levels in the heart after TAC operation (13 % (sham) to 15 % (TAC);  
p = 0.01, student’s t-test) and monocytes (12.3 (TAC) to 19.2 % (sham)) were found in moderate 
numbers, followed by dendritic cell population (5.2 % (TAC) to 8.3 % (sham); p = 0.02, student’s t-test). 
T helper cells and neutrophils made up around 4 to 5 % of leukocyte population (T helper: 3.5 % (sham) 
to 5.5 % (TAC); neutrophils: 3.6 % (TAC) to 3.9 % (sham)). Populations of cytotoxic T cells, NK cells and 
NKT cells were detected in lower cell numbers ranging from 0.4 % (TAC) to 0.6 % (sham) for NKT cells, 




amount of CD45.1+CD4+ cells derived from transferred OT-II cells was monitored to be significantly 
higher in TAC -(3 %) than sham- (1%) operated animals (p = 0.02, student’s t-test). 
Generally, no major differences of the lymphocyte composition in the spleen and myocardium of TAC-
operated animals compared to sham mice were found after the animals received adoptive transfer of 
OT-I and OT-II T cells, besides an increase in B cell numbers in the myocard. However, TAC-operated 
animals displayed a higher amount of CD45+ positive cell in the heart tissue, suggesting activation of 






Figure 60 Proportion of lymphocytes and myeloid cells in the (A) spleen and (B) myocardium of 
cMy-mOVA mice which received OT-I and OT-II TCR-specific T cells.  
Shown is the mean proportion of B cells (CD19+B22O+), T cells (CD3+,CD4+/CD8+)), NK cells (CD3-
DX5+), neutrophils (CD11b+Ly6G+), patrolling monocytes (CD115+C11b+Ly6Clow), inflammatory 
monocytes (CD115+C11b+Ly6Chigh), macrophages (F4/80+) and dendritic cells (CD11c+I-Ab) of the 
CD45+ population + SEM. TAC (n = 7), sham (n = 6) except for T and NK cells: TAC (n= 6), sham (n = 














































































7.1.2 Endothelial cells in the myocard 
Moreover, the amount of endothelial cells (CD144+CD31+) in the population of CD45- cells in the spleen 
(as control) and myocardium of the analyzed cMy-mOVA mice was determined to examine the 
proportion of vascular cell adhesion protein 1 (VCAM-1) and intercellular adhesion molecule 1  
(ICAM-1) positive cells. These proteins are known to be important in inflammation and immune 
responses and could be responsible for an increased infiltration into the heart, if upregulated on 
cardiac endothelial cells. In the analyzed splenocyte population, 7.4 % (TAC) to 16.7 % (sham) were 
negative for the CD45 marker whereas in the myocardium 90.5 % (TAC) to 96.3 % (sham) of cells were 
not expressing this leukocyte marker. Epithelial cells positive for CD144 and CD31 in the CD45- 
population ranged from 0.3 % (TAC) to 0.6 % (sham) in the spleen and from 9.3 % (sham) to 9.8 % (TAC) 
in heart tissue (Figure 61) Further analysis of CD144+CD31+ cells showed that most of the cells in the 
spleen were double positive for VCAM-1 and ICAM-1 (39.5 % (TAC) to 45.2 % (sham)), and around 5 to 
10 % positive for single proteins. In contrast, in heart tissue around 50 % of the CD144+CD31+ cells were 
single positive for ICAM-1. Only 22.1 % (TAC) to 22.7 % (sham) of CD144+CD31+ cells were double 
positive for ICAM-1 and VCAM-1. VCAM-1 expression was found only on 1.9 % (TAC) to 2.5 % (sham) 
in this cell population.  
Overall, adoptive transfer and TAC operation was not associated with an altered expression in VCAM-









































Figure 61 Flow cytometric 
analysis of intercellular 
adhesion molecules ICAM-1 
and VCAM-1 on endothelial 
cells (CD144+CD31+) in 
spleen and heart of cMy-
mOVA mice which received 
a mixture of OT-I and OT-II T 
cells.  
Shown is the mean 
proportion + SEM. TAC (n = 




7.2 Stem cell immunogenicity 
7.2.1 Germ layer marker expression in tumors derived from wildtype and OVA-expressing 
stem cells in immunodeficient and immunocompetent host 
Besides the characterization of tumors as teratomas by histology, qPCR analysis was performed to 
examine germ layer marker gene expression in various tumors, confirming the formation of teratomas 
after the inoculation of various stem cell clones into immunodeficient (summarized as RAG2-/-γc-/-) and 
immunocompetent (129/Sv) mice. As germ layer markers for the analysis served Th and Syn as marker 
for ectodermal structures, Afp and Alb for endodermal tissues and Ctnt and αMhc for mesodermal 
tissues in the tumor. These markers are not expressed on stem cell lines (data not shown) and 
therefore tissues of syngeneic mice (129/Sv) known to be positive for the specific germ layer markers 
were used as reference cells including hippocampal tissue for ectodermal, spleen and liver for 
endodermal and lung tissue for mesodermal germ layer markers. In this analysis, Hprt and Gapdh were 
used as housekeeper genes. In Figure 62, the mRNA expression of germ layer markers are summarized 
for tumors derived from wildtype or OVA-expressing stem cells in immunocompetent or 
immunodeficient mice. The OVA-expressing stem cells consisted of iPSC 129/Sv clone OVA#6 and 
OVA#24, whereas ESC BTL1 and iPSC 129/Sv TD11.1 were injected as wildtype cell lines. The analyzed 
tumors showed a variable expression of the tested germ layer markers of which at least one out of two 
for every germ layer was clearly detectable. Consequently, the tumors could be characterized as 
teratomas. Expression of markers showed a high standard derivation due to variations in different 
teratomas, indicating that the differentiation is random. Each teratoma showed a variable stage of 
differentiation with different amounts of cells of each germ layer. Overall, Th and Afp were the most 
abundant expressed markers in teratomas derived from OVA-expressing stem cells and wildtype stem 
cells in RAG2-/-γc-/- and 129/Sv mice, with even higher expression than in the control tissues. Ctnt was 
rather expressed in teratomas formed in immunodeficient animals (1.4 and 2.1 fold of reference tissue) 
than in immunocompetent hosts (0.05 to 0.08 fold). Syn and αMHC were only expressed at low levels 



























Figure 62 Germ layer marker expression in teratomas.  
Shown is the mean relative expression of germ layer marker to their reference tissues known to be 
positive for each gene: ectoderm (Th, Syn), endoderm (Afp, Alb), mesoderm (Ctnt, αMhc) of 129/Sv 
mice + SD. Mean of Hprt and Gapdh was used as housekeeper reference. OVA: iPSC 129Sv #6, #24; 





7.2.2 Influence of adoptive transfer on tumor characteristics in RAG2-/-γc-/- mice 
The adoptive transfer of TCR-transgenic T cells had no significant effects on the size or weight of tumors 
derived by wildtype or OVA-expressing stem cells in immunodeficient mice. In Figure 63, it is shown 
that those parameters varied between tumors, independent of OVA expression and type of T cell 
transfer.  
 
Figure 63 Analysis of (A) tumor size and (B) tumor weight after injections of OVA-expressing and wildtype stem 
cells into immunodeficient hosts which received either TCR-transgenic T cells (OT-I T cells, OT-II T cells, OT-
I/OT-II T cells) or no T cells (w/o transfer). 
(A) Depicted is the mean tumor size + SEM. W/o transfer: OVA (n = 23), wt (n = 6); OT-I: OVA (n = 10), wt (n = 3); 
OT-I/OT-II: OVA (n = 12), wt (n = 5); OT-II: OVA (n = 3), wt (n = 2). Differences in tumor size between tumors 
derived from OVA-expressing stem cells (p = 0.32), between tumors derived from wildtype stem cells (p = 0.71), 
Kruskal-Wallis H-test. (B) Shown is the mean tumor weight + SEM. W/o transfer: OVA (n = 23), wt (n = 5); OT-I: 
OVA (n = 11), wt (n = 3); OT-I/OT-II: OVA (n = 14), wt (n = 5); OT-II: OVA (n = 3), wt (n = 3). Differences in tumor 
weight between OVA-expressing stem cell derived tumors (p = 0.36), between wildtype stem cell derived tumors 





























7.2.3 Influence of HY antigens on tumor formation in immunocompetent mice 
Further analysis of tumor formation for each stem cell clone in hosts of different gender revealed that 
almost all male stem cell lines showed tumor formation in male recipients but did not engraft in female 
hosts. Only injections of ESC BTL1 OVA#4 led to tumor formation in female hosts (Figure 64). However, 
tumor formation rate was only significantly altered for two male iPS cell clones (iPSC OVA#6, #24) 
which showed a high tumor formation rate in male host, but in contrast, no tumor formation in female 
hosts. Therefore, an additional influence of other miHC antigens derived from the Y-chromosome of 




Figure 64 Tumor formation after 
injection of OVA-expressing stem cells 
into immunocompetent 129/Sv mice 
of different sex.  
IPSC OVA#13 were not injected into 
female hosts, and are consequently 
not depicted in the graph. Numbers of 
experiments are depicted in each 
diagram. Significant differences in 
tumor formations between male and 
female hosts are marked with asterisk. 
**<0.01; ***<0.001. IPSC OVA#6 (p = 6 
x 10-3), iPSC OVA#18 (p = 0.68), iPSC 
OVA#24 (p = 3.2 x 10-5), ESC BTL1 
OVA#4 (p = 0.59), ESC MPI-II OVA#4 (p 
= 0.07); chi-squared test.  
 






7.2.4 Leukocyte infiltration into teratomas analyzed by flow cytometry 
For flow cytometry, tumors were digested to single cells and analyzed for several leukocyte 
populations. As seen in Figure 65, tumors derived from wildtype and OVA-expressing stem cells were 
positive for T cells (CD3+,CD4+,CD8+), B cells (CD45R+), macrophages (F4/80+), dendritic cells (CD11c+) 
and NK cells (NKp46+, DX5+). Numbers of cytotoxic T cells, dendritic cells and macrophages appeared 
to be higher in OVA-derived tumors compared to wildtype tumors, ranging from 10 to 30 % of CD45+ 
cells. In contrast, wildtype stem cell-derived teratomas showed higher numbers of T helper cells  
(22.6 %), B cells (10 %), NKp46+ (26.7 %) and DX5+ (11.2 %) NK cells compared to OVA-expressing tumors 
(CD3+CD4+: 14.2 %, CD45R+: 8 %, NKp46+: 20.8 %, DX5+: 6.8 %). Additionally, cells positive for the TCR 
Vβ 5.1/5.2 were found, but in significantly higher numbers in teratomas derived from OVA-expressing 
stem cells (16.6 %) compared to tumors formed by wildtype stem cells (3 %; p = 0.047). T cells using 
this receptor can be OVA-specific T cells as demonstrated by the OT-I and OT-II TCR. However, whether 





        
 
Figure 65 Analysis of leukocyte infiltration into teratomas analyzed by flow cytometry.  
Leukocyte population of CD45+ cells in tumor tissue derived from wildtype and OVA-expressing stem 
cells in syngeneic hosts (129/Sv) +SEM. ESC BTL1 wt (n = 6), iPSC OVA (n = 2). Differences between 
teratomas derived from wt and OVA-expressing stem cells: CD3+CD4+ (p = 0.5), CD3+CD8+ (p = 0.36), 
CD11c+ (p = 0.45), CD45R+ (p = 0.58), NKp46+ (p = 0.71), DX5+ (p = 0.71), F4/80+ (p = 0.39), TCR Vβ 





































7.2.5 Cellular composition of lymphocytes of host splenocytes after stem cell injections 
Splenocytes obtained from 129/Sv hosts which previously received injections of wildtype and OVA-
expressing stem cells were further analyzed to determine their cellular composition via flow 
cytometry. For this, freshly isolated (day 0) splenocytes of animals which showed tumor growth or 
failed to form teratomas were used. As seen in Figure 66, most abundant cell types were T helper cells 
(CD3+CD4+: around 25 %) and B cells (CD45R+: around 35%), followed by cytotoxic T cells (CD3+CD8+: 
around 10 %). Additionally, a minor extent of these T cells was positive for the TCR Vβ 5.1/5.2 which 
recognizes OVA, and some NK cells (DX5+CD3-, NKp46+) were found. In summary, no differences in the 
lymphocyte composition of animals that received OVA-expressing stem cells compared to wildtype 
stem cells could be monitored. Additionally, the lymphocyte composition of animals which rejected 






































Figure 66 Naïve splenocyte composition of animals which received either OVA-expressing (OVA) or 
wildtype (wt) stem cells and which showed tumor formation (w tumor) or tumor rejection (w/o 
tumor).  
Shown is the mean proportion of splenocytes + SEM. Wt w/o tumors: CD3+CD8+ (n = 5), CD3+CD4+ (n 
= 5), CD45R+ (n = 5), DX5+CD3- (n = 5), CD3+TCR Vβ 5.1/5.2+ (n = 0), NKp46+ (n = 0); OVA w/o tumor 
CD3+CD8+ (n = 59), CD3+CD4+ (n = 59), CD45R+ (n = 59), DX5+CD3- (n = 59), CD3+TCR Vβ 5.1/5.2+ (n = 
15), NKp46+ (n = 15); wt w tumor: CD3+CD8+ (n = 12), CD3+CD4+ (n = 12), CD45R+ (n = 12), DX5+CD3- (n 
= 12), CD3+TCR Vβ 5.1/5.2+ (n = 6), NKp46+ (n = 6); OVA w tumor CD3+CD8+ (n = 5), CD3+CD4+ (n = 5), 
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